Case number 1:21-cv-01015
Nippon Shinyaku.,Ltd. v. Sarepta Therapeutics, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 21, 2025 | 755 | NOTICE of Supplemental Authority by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd. (Attachments: # 1 Attachment)(Dudash, Amy) (Entered: 11/21/2025) (0) |
| May 23, 2025 | 754 | NOTICE of Withdrawal of Counsel by Sarepta Therapeutics, Inc., The University of Western Australia (Dellinger, Megan) (Entered: 05/23/2025) (4) |
| May 20, 2025 | 753 | NOTICE requesting Clerk to remove Charles E. Lipsey as co-counsel.. (Dellinger, Megan) (Entered: 05/20/2025) (4) |
| Apr 22, 2025 | 750 | REDACTED VERSION of 745 Reply Brief by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 04/22/2025) (20) |
| Apr 22, 2025 | 751 | REDACTED VERSION of 746 Declaration by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Tabs 1-6)(Dellinger, Megan) (Entered: 04/22/2025) (0) |
| Apr 22, 2025 | 752 | REDACTED VERSION of 749 Reply Brief Regarding Inequitable Conduct by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A)(Dudash, Amy) (Entered: 04/22/2025) (0) |
| Apr 15, 2025 | 745 | [SEALED] REPLY BRIEF re 734 MOTION for Supplemental Damages and Pre- and Post Judgment Interest filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 04/15/2025) (0) |
| Apr 15, 2025 | 746 | [SEALED] DECLARATION of John C. Jarosz re 745 Reply Brief by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Tabs 1-6)(Dellinger, Megan) (Entered: 04/15/2025) (0) |
| Apr 15, 2025 | 748 | REPLY BRIEF re 730 MOTION for Judgment as a Matter of Law or, In the Alternative, a New Trial on the Invalidity Issues filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 04/15/2025) (21) |
| Apr 15, 2025 | 749 | [SEALED] REPLY BRIEF Regarding Inequitable Conduct filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A)(Dudash, Amy) (Entered: 04/15/2025) (0) |
| Apr 8, 2025 | 744 | REDACTED VERSION of 741 Answering Brief in Opposition, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Dudash, Amy) (Entered: 04/08/2025) (0) |
| Apr 1, 2025 | 739 | Official Transcript of Pretrial Conference held on 12-09-24 before Judge Hall. Court Reporter Stacy Ingram,Email: stacy_ingram@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/22/2025. Redacted Transcript Deadline set for 5/2/2025. Release of Transcript Restriction set for 6/30/2025. (Ingram, Stacy) (Entered: 04/01/2025) (133) |
| Apr 1, 2025 | 740 | Official Transcript of Teleconference held on 12-12-24 before Judge Hall. Court Reporter Stacy Ingram,Email: stacy_ingram@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/22/2025. Redacted Transcript Deadline set for 5/2/2025. Release of Transcript Restriction set for 6/30/2025. (Ingram, Stacy) (Entered: 04/01/2025) (23) |
| Apr 1, 2025 | 741 | [SEALED] ANSWERING BRIEF in Opposition re 734 MOTION for Supplemental Damages and Pre- and Post Judgment Interest, filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd. Reply Brief due date per 716 Stipulation is 4/15/2025. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Dudash, Amy) Modified on 4/2/2025 (ceg). (Entered: 04/01/2025) (0) |
| Apr 1, 2025 | 742 | ANSWERING BRIEF in Opposition re 730 MOTION for Judgment as a Matter of Law or, In the Alternative, a New Trial on the Invalidity Issues filed by Sarepta Therapeutics, Inc., The University of Western Australia.Reply Brief due date per 716 Stipulation is 4/15/2025. (Attachments: # 1 Exhibits 1-4)(Dellinger, Megan) Modified on 4/2/2025 (ceg). (Entered: 04/01/2025) (0) |
| Apr 1, 2025 | 743 | Proposed Findings of Fact by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 04/01/2025) (28) |
| Feb 24, 2025 | 738 | REDACTED VERSION of 736 Declaration by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 02/24/2025) (30) |
| Feb 21, 2025 | 737 | STIPULATION TO EXTEND TIME to file a public version of the Declaration of John Jarosz (D.I. 736) to February 24, 2025 - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 02/21/2025) (2) |
| Feb 14, 2025 | 730 | MOTION for Judgment as a Matter of Law or, In the Alternative, a New Trial on the Invalidity Issues - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Text of Proposed Order)(Dudash, Amy) (Entered: 02/14/2025) (0) |
| Feb 14, 2025 | 731 | OPENING BRIEF in Support re 730 MOTION for Judgment as a Matter of Law or, In the Alternative, a New Trial on the Invalidity Issues filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Answering Brief/Response due date per Local Rules is 2/28/2025. (Dudash, Amy) (Entered: 02/14/2025) (30) |
| Feb 14, 2025 | 732 | Proposed Findings of Fact by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4)(Dudash, Amy) (Entered: 02/14/2025) (0) |
| Feb 14, 2025 | 734 | MOTION for Supplemental Damages and Pre- and Post Judgment Interest - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 02/14/2025) (8) |
| Feb 14, 2025 | 735 | OPENING BRIEF in Support re 734 MOTION for Supplemental Damages and Pre- and Post Judgment Interest filed by Sarepta Therapeutics, Inc., The University of Western Australia.Answering Brief/Response due date per Local Rules is 2/28/2025. (Dellinger, Megan) (Entered: 02/14/2025) (16) |
| Feb 14, 2025 | 736 | [SEALED] DECLARATION of John C. Jarosz re 734 MOTION for Supplemental Damages and Pre- and Post Judgment Interest by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 02/14/2025) (0) |
| Jan 15, 2025 | 722 | Official Transcript of Jury Trial Day 1 held on 12/13/2024 before Judge Jennifer L. Hall. Court Reporter/Transcriber Bonnie Archer, Email: Bonnie_Archer@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 2/5/2025. Redacted Transcript Deadline set for 2/18/2025. Release of Transcript Restriction set for 4/15/2025. (mpb) (Entered: 01/15/2025) (271) |
| Jan 15, 2025 | 723 | Official Transcript of Jury Trial Day 2 held on 12/16/2024 before Judge Jennifer L. Hall. Court Reporter/Transcriber Jennifer Guy, Email: jenniferguyrpr@gmail.com. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 2/5/2025. Redacted Transcript Deadline set for 2/18/2025. Release of Transcript Restriction set for 4/15/2025. (mpb) (Entered: 01/15/2025) (365) |
| Jan 15, 2025 | 724 | Official Transcript of Jury Trial Day 3 held on 12/17/2024 before Judge Jennifer L. Hall. Court Reporter/Transcriber Jennifer Guy, Email: jenniferguyrpr@gmail.com. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 2/5/2025. Redacted Transcript Deadline set for 2/18/2025. Release of Transcript Restriction set for 4/15/2025. (mpb) (Entered: 01/15/2025) (346) |
| Jan 15, 2025 | 725 | Official Transcript of Jury Trial Day 4 held on 12/18/2024 before Judge Jennifer L. Hall. Court Reporter/Transcriber Brian Gaffigan, Email: gaffigan.b@outlook.com. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 2/5/2025. Redacted Transcript Deadline set for 2/18/2025. Release of Transcript Restriction set for 4/15/2025. (mpb) (Entered: 01/15/2025) (335) |
| Jan 15, 2025 | 726 | Official Transcript of Jury Trial Day 5 held on 12/19/2024 before Judge Jennifer L. Hall. Court Reporter/Transcriber Kimberly Bursner, Email: kbursner@verizon.net. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 2/5/2025. Redacted Transcript Deadline set for 2/18/2025. Release of Transcript Restriction set for 4/15/2025. (mpb) (Entered: 01/15/2025) (276) |
| Jan 15, 2025 | 727 | Official Transcript of Jury Trial Day 6 held on 12/20/2024 before Judge Jennifer L. Hall. Court Reporter/Transcriber Brian Gaffigan, Email: gaffigan.b@outlook.com. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 2/5/2025. Redacted Transcript Deadline set for 2/18/2025. Release of Transcript Restriction set for 4/15/2025. (mpb) (Entered: 01/15/2025) (168) |
| Jan 15, 2025 | 728 | Official Transcript of Bench Trial Day 1 held on 12/16/2024 before Judge Jennifer L. Hall. Court Reporter/Transcriber Jennifer Guy, Email: jenniferguyrpr@gmail.com. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 2/5/2025. Redacted Transcript Deadline set for 2/18/2025. Release of Transcript Restriction set for 4/15/2025. (mpb) (Entered: 01/15/2025) (118) |
| Jan 15, 2025 | 729 | Official Transcript of Bench Trial held on 12/17/2025 before Judge Jennifer L. Hall. Court Reporter/Transcriber Jennifer Guy, Email: jenniferguyrpr@gmail.com. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 2/5/2025. Redacted Transcript Deadline set for 2/18/2025. Release of Transcript Restriction set for 4/15/2025. (mpb) (Entered: 01/15/2025) (346) |
| Jan 13, 2025 | 721 | SO ORDERED, re 719 Stipulation and Order to Extend Time to make any requests pursuant to FRCP 37(c)(1)(A) to January 15, 2025. Signed by Judge Jennifer L. Hall on 1/13/2025. (ceg) (Entered: 01/13/2025) (2) |
| Jan 9, 2025 | 720 | NOTICE requesting Clerk to remove Bornali Rashmi Borah as co-counsel. Reason for request: No longer with firm. (Dellinger, Megan) (Entered: 01/09/2025) (5) |
| Jan 8, 2025 | 719 | STIPULATION TO EXTEND TIME to make any request pursuant to FRCP 37(c)(1)(A) to January 15, 2025 - filed by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc.. (Dudash, Amy) (Entered: 01/08/2025) (2) |
| Jan 7, 2025 | 714 | SO ORDERED, re 708 Stipulation and Order regarding Damages Pertaining to Ex-US Sales. Signed by Judge Jennifer L. Hall on 1/7/2025. (ceg) (Entered: 01/07/2025) (2) |
| Jan 7, 2025 | 715 | SO ORDERED, re 709 Stipulation and Order to Extend Time to make any requests pursuant to FRCP 37(c)(1)(A) to January 8, 2025. Signed by Judge Jennifer L. Hall on 1/7/2025. (ceg) (Entered: 01/07/2025) (2) |
| Jan 7, 2025 | 716 | SO ORDERED, re 711 Stipulation and Order regarding Post-Trial Briefing. (*Setting Post-Trial Briefing Deadlines: Opening Briefs due 2/14/2025; Responsive Briefs due 4/1/2025; Reply Briefs due 4/15/2025). Signed by Judge Jennifer L. Hall on 1/7/2025. (ceg) (Entered: 01/07/2025) (2) |
| Jan 7, 2025 | 717 | SO ORDERED, re 712 Stipulation and Order of Partial Dismissal. (*See Order for details). Signed by Judge Jennifer L. Hall on 1/7/2025. (ceg) (Entered: 01/07/2025) (4) |
| Jan 7, 2025 | 718 | JUDGMENT FOLLOWING JURY VERDICT. Signed by Judge Jennifer L. Hall on 1/7/2025. (ceg) (Entered: 01/07/2025) (3) |
| Jan 3, 2025 | 708 | STIPULATION regarding Damages Pertaining to Ex-US Sales by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc.. (Dudash, Amy) (Entered: 01/03/2025) (2) |
| Jan 3, 2025 | 709 | STIPULATION TO EXTEND TIME to make any requests pursuant to FRCP 37(c)(1)(A) to January 8, 2025 - filed by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc.. (Dudash, Amy) (Entered: 01/03/2025) (2) |
| Jan 3, 2025 | 710 | REDACTED VERSION of 646 Proposed Pretrial Order,, [Amended] by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc.. (Attachments: # 1 Exhibit A - Table of Abbreviations, # 2 Exhibit 1 - Jt Asserted Claims, # 3 Exhibit 2 - Jt Undisputed Facts, # 4 Exhibit 3 - NS Contested Facts, # 5 Exhibit 4 - Sarepta-UWA Contested Facts, # 6 Exhibit 5 - NS Issues of Law, # 7 Exhibit 6 - Sarepta Issues of Law, # 8 Exhibit 7 - NS Exhibit List REDACTED, # 9 Exhibit 8 - Sarepta Exhibit List REDACTED, # 10 Exhibit 9 - Jt Exhibit List, # 11 Exhibit 10 - NS Witness List, # 12 Exhibit 11 - Sarepta-UWA Witness List, # 13 Exhibit 12 - NS Depo Designations, # 14 Exhibit 13 - Sarepta-UWA Depo Designations)(Dudash, Amy) (Entered: 01/03/2025) (0) |
| Jan 3, 2025 | 711 | STIPULATION regarding Post-Trial Briefing by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc.. (Dudash, Amy) (Entered: 01/03/2025) (2) |
| Jan 3, 2025 | 712 | STIPULATION of Partial Dismissal by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc.. (Dudash, Amy) (Entered: 01/03/2025) (4) |
| Jan 3, 2025 | 713 | PROPOSED Judgment Following Jury Verdict, by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc. (Dudash, Amy) Modified on 1/6/2025 (ceg). (Main Document 713 replaced on 1/6/2025) (ceg). (Entered: 01/03/2025) (3) |
| Dec 26, 2024 | 707 | ORAL ORDER: IT IS HEREBY ORDERED that, on or before January 3, 2025, the parties shall meet and confer and file on the docket (1) a proposed judgment and (2) a stipulated schedule for post-trial briefing. The parties shall also meet and confer within 14 days to discuss whether it would be appropriate to engage in further alternative dispute resolution. Ordered by Judge Jennifer L. Hall on 12/26/2024. (twk) (Entered: 12/26/2024) (0) |
| Dec 23, 2024 | 706 | Exhibit List for Jury Trial held December 16, 2024 - December 20, 2024. (twk) (Entered: 12/23/2024) (14) |
| Dec 20, 2024 | 702 | FINAL Phase II Jury Instructions read to jury panel on 12/20/2024. (twk) (Entered: 12/20/2024) (17) |
| Dec 20, 2024 | 703 | [SEALED] Phase II JURY VERDICT. (twk) (Entered: 12/20/2024) (0) |
| Dec 20, 2024 | 704 | REDACTED VERSION of 703 Phase II Jury Verdict. (twk) (Entered: 12/20/2024) (4) |
| Dec 20, 2024 | 705 | [SEALED] Jury Notes. (twk) (Entered: 12/20/2024) (0) |
| Dec 19, 2024 | 695 | FINAL Phase I Jury Instructions read to jury panel on 12/19/2024.(twk) (Entered: 12/19/2024) (30) |
| Dec 19, 2024 | 696 | The Court's Preliminary Jury Instructions (Phase II). (ceg) (Entered: 12/19/2024) (7) |
| Dec 19, 2024 | 697 | PRELIMINARY Phase II Jury Instructions read to jury panel on 12/19/2024.(twk) (Entered: 12/19/2024) (7) |
| Dec 19, 2024 | 698 | [SEALED] Phase I JURY VERDICT. (twk) (Entered: 12/19/2024) (0) |
| Dec 19, 2024 | 699 | REDACTED VERSION of 698 Phase I Jury Verdict. (twk) (Entered: 12/19/2024) (7) |
| Dec 19, 2024 | 700 | Proposed Jury Instructions by Sarepta Therapeutics, Inc., The University of Western Australia // Final Jury Instructions (Phase II). (Dellinger, Megan) (Entered: 12/19/2024) (17) |
| Dec 19, 2024 | 701 | VERDICT SHEET by Sarepta Therapeutics, Inc., The University of Western Australia // Verdict Form (Phase II). (Dellinger, Megan) (Entered: 12/19/2024) (4) |
| Dec 17, 2024 | 686 | Proposed Jury Instructions by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc. [Phase One Proposed Final Jury Instructions]. (Dudash, Amy) (Entered: 12/17/2024) (30) |
| Dec 17, 2024 | 687 | VERDICT SHEET by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc. [Phase One Proposed Verdict Form]. (Dudash, Amy) (Entered: 12/17/2024) (7) |
| Dec 17, 2024 | 688 | Proposed Jury Instructions by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc. [Phase Two Proposed Final Jury Instructions]. (Dudash, Amy) (Entered: 12/17/2024) (26) |
| Dec 17, 2024 | 689 | VERDICT SHEET by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc. [NS Phase Two Proposed Verdict Form for both parties]. (Dudash, Amy) (Entered: 12/17/2024) (5) |
| Dec 17, 2024 | 690 | VERDICT SHEET by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc. [NS Phase Two Proposed Verdict Form for NS only]. (Dudash, Amy) (Entered: 12/17/2024) (4) |
| Dec 17, 2024 | 691 | VERDICT SHEET by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc. [NS Phase Two Proposed Verdict Form for Sarepta only]. (Dudash, Amy) (Entered: 12/17/2024) (4) |
| Dec 17, 2024 | 692 | VERDICT SHEET by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc. [Sarepta Phase Two Proposed Verdict Form for both parties]. (Dudash, Amy) (Entered: 12/17/2024) (5) |
| Dec 17, 2024 | 693 | VERDICT SHEET by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc. [Sarepta Phase Two Proposed Verdict Form for NS only]. (Dudash, Amy) (Entered: 12/17/2024) (4) |
| Dec 17, 2024 | 694 | VERDICT SHEET by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc. [Sarepta Phase Two Proposed Verdict Form for Sarepta only]. (Dudash, Amy) (Entered: 12/17/2024) (4) |
| Dec 13, 2024 | 680 | STIPULATION and [Proposed] Order Regarding Admissibility by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 12/13/2024) (6) |
| Dec 13, 2024 | 681 | VOIR DIRE QUESTIONS propounded to jury pool on 12/13/2024(twk) (Entered: 12/13/2024) (5) |
| Dec 13, 2024 | 682 | PRELIMINARY Phase I Jury Instructions read to jury panel on 12/13/2024.(twk) (Additional attachment(s) added on 12/16/2024: # 1 Additional Instruction) (twk). (Entered: 12/13/2024) (0) |
| Dec 13, 2024 | 683 | ORDER: NS's Motion to Strike (D.I. 640 ) is GRANTED-IN-PART and DENIED-IN-PART, as discussed at the Pretrial Conference. (*See Order for details). Signed by Judge Jennifer L. Hall on 12/13/2024. (twk) (Entered: 12/13/2024) (3) |
| Dec 13, 2024 | 684 | SO ORDERED, re 666 STIPULATION and Order Regarding Admissibility by Sarepta Therapeutics, Inc., The University of Western Australia. Signed by Judge Jennifer L. Hall on 12/13/2024. (twk) (Entered: 12/13/2024) (7) |
| Dec 13, 2024 | 685 | SO ORDERED, re 680 STIPULATION and Order Regarding Admissibility by Sarepta Therapeutics, Inc., The University of Western Australia. Signed by Judge Jennifer L. Hall on 12/13/2024. (twk) (Entered: 12/13/2024) (6) |
| Dec 12, 2024 | 670 | Letter to The Honorable Jennifer L. Hall from Rodger D. Smith II regarding Response to Court's Order - re 669 Order,. (Smith, Rodger) (Entered: 12/12/2024) (2) |
| Dec 12, 2024 | 671 | Letter to the Honorable Jennifer L. Hall from Amy M. Dudash regarding bifurcation. (Dudash, Amy) (Entered: 12/12/2024) (2) |
| Dec 12, 2024 | 672 | Letter to the Honorable Jennifer L. Hall from Amy M. Dudash regarding the Court's Proposed Voir Dire. (Attachments: # 1 Exhibit A)(Dudash, Amy) (Entered: 12/12/2024) (0) |
| Dec 12, 2024 | 673 | Letter to the Honorable Jennifer L. Hall from Amy M. Dudash regarding list of potential witness names and glossary of technical terms. (Dudash, Amy) (Entered: 12/12/2024) (3) |
| Dec 12, 2024 | 674 | Letter to the Honorable Jennifer L. Hall from Amy M. Dudash regarding Preliminary Jury Instructions - re 668 Order,. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Dudash, Amy) (Entered: 12/12/2024) (0) |
| Dec 12, 2024 | 675 | ORAL ORDER: The parties' proposed changes to The Court's Proposed Voir Dire (D.I. 672 ) are ADOPTED. NS should change the caption of the document to "VOIR DIRE" and supply copies and pens at the jury selection, as directed at the Pretrial Conference. Ordered by Judge Jennifer L. Hall on 12/12/2024. (ceg) (Entered: 12/12/2024) (0) |
| Dec 12, 2024 | 676 | ORAL ORDER: The parties' proposed change to The Court's Proposed Preliminary Jury Instructions (D.I. 674 ) is ADOPTED. The parties shall meet and confer and confirm for the Court their agreement on the appropriate disposition of each side's patent claims that are not being tried. In order to conserve time, the Court still intends to read the Preliminary Jury Instructions following jury selection on December 13, 2024. However, as the Court is still assessing the parties' positions regarding trial phasing (set forth in their letters of this morning (D.I. 670 , 671 )), the Court has determined that the most prudent course of action is to wait to read instruction "XV. Course of the Trial" until immediately before opening statements on December 16, 2024. Accordingly, NS shall (1) change the caption of the document to "PRELIMINARY JURY INSTRUCTIONS"; (2) remove instruction XV. from the copy that will be provided to jurors on December 13, 2024; (3) make conforming edits to instruction XVI. consisting of (i) removing "As I mentioned previously" from the second paragraph and (ii) changing the last sentence of the sixth paragraph to "This allows me to expect that the presentation of evidence will be completed by Friday, December 20, 2024, although your deliberations could extend into the following week."; and (4) bring copies for the Court. Ordered by Judge Jennifer L. Hall on 12/12/2024. (ceg) (Entered: 12/12/2024) (0) |
| Dec 12, 2024 | 677 | ORAL ORDER: The parties shall provide the list of witness names and technical terms (D.I. 673 ) to the translators attending the trial. Ordered by Judge Jennifer L. Hall on 12/12/2024. (ceg) (Entered: 12/12/2024) (0) |
| Dec 12, 2024 | 678 | ORAL ORDER Setting Teleconference: A status teleconference is scheduled for December 12, 2024, at 4:30 PM. The parties shall dial the Court's conference line at (855) 244-8681, access code: 2302 219 8024. Ordered by Judge Jennifer L. Hall on 12/12/2024. (twk) (Entered: 12/12/2024) (0) |
| Dec 12, 2024 | 679 | ORAL ORDER: The Pretrial Order (D.I. 646 ) has been modified in accordance with the Court's rulings during the status call today, December 12, 2024. As discussed, the jury trial will proceed in two phases. Each side shall have 10.5 hours for phase I and 1.5 hours for phase II. Each side must reserve at least 40 minutes of its 10.5 hours for its phase I closing arguments. As soon as possible, but no later than 7:00 P.M. on December 16, 2024, the parties shall file updated proposed final jury instructions and verdict forms. Absent agreement of the parties, the bench trial shall proceed as discussed during the status call. Ordered by Judge Jennifer L. Hall on 12/12/2024. (JLH) (Entered: 12/12/2024) (0) |
| Dec 11, 2024 | 663 | The Court's Proposed Voir Dire. (ceg) (Entered: 12/11/2024) (6) |
| Dec 11, 2024 | 664 | ORAL ORDER re 663 The Court's Proposed Voir Dire: IT IS HEREBY ORDERED that the parties shall file a joint letter by 12 p.m. on December 12, 2024, setting forth any corrections or objections to the Court's Proposed Voir Dire. Ordered by Judge Jennifer L. Hall on 12/11/2024. (ceg) (Entered: 12/11/2024) (0) |
| Dec 11, 2024 | 665 | Letter to the Honorable Jennifer L. Hall from Amy M. Dudash regarding Pretrial Conference Issues. (Dudash, Amy) (Entered: 12/11/2024) (16) |
| Dec 11, 2024 | 666 | STIPULATION and [Proposed] Order Regarding Admissibility by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 12/11/2024) (7) |
| Dec 11, 2024 | 667 | The Court's Proposed Preliminary Jury Instructions.(ceg) (Entered: 12/11/2024) (24) |
| Dec 11, 2024 | 668 | ORAL ORDER re 667 The Court's Proposed Preliminary Jury Instructions: IT IS HEREBY ORDERED that the parties shall file a joint letter by 12 p.m. on December 12, 2024, setting forth any corrections or objections to the Court's Proposed Preliminary Jury Instructions. The Court intends to read the Preliminary Jury Instructions following jury selection on December 13, 2024. Ordered by Judge Jennifer L. Hall on 12/11/2024. (ceg) (Entered: 12/11/2024) (0) |
| Dec 11, 2024 | 669 | ORDER AFTER PRETRIAL CONFERENCE: The Proposed Amended Joint Pretrial Order (D.I. 646 ) will be ADOPTED as modified by this Order and any discussions at the December 9, 2024 Pretrial Conference. (*See Order for details). Signed by Judge Jennifer L. Hall on 12/11/2024. (ceg) (Entered: 12/11/2024) (5) |
| Dec 9, 2024 | 662 | REDACTED VERSION of 651 Letter, by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc.. (Dudash, Amy) (Entered: 12/09/2024) (6) |
| Dec 6, 2024 | 658 | SO ORDERED, granting 655 Defendants' Motion and Order for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices for purposes of the pretrial conference, jury selection, courtroom setup, and jury trial. Signed by Judge Jennifer L. Hall on 12/6/2024. (ceg) (Main Document 658 replaced on 12/6/2024) (ceg). (Entered: 12/06/2024) (4) |
| Dec 6, 2024 | 659 | ORDER granting 657 Plaintiff/Counter-Defendant Nippon Shinyaku Co., Ltd. and Counter-Defendant NS Pharma, Inc.'s Motion for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices for purposes of the pretrial conference, jury selection, courtroom setup, and jury trial. Signed by Judge Jennifer L. Hall on 12/6/2024. (ceg) (Entered: 12/06/2024) (3) |
| Dec 6, 2024 | 660 | MOTION for Pro Hac Vice Appearance of Attorney Drew Wiley Roberts, Tiffany Weston, and Daniel Hemming - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 12/06/2024) (7) |
| Dec 6, 2024 | 661 | Pro Hac Vice Fee - Credit Card Payment received for Drew Wiley Roberts, Tiffany Weston, and Daniel Hemming. ( re 660 MOTION for Pro Hac Vice Appearance of Attorney Drew Wiley Roberts, Tiffany Weston, and Daniel Hemming )( Payment of $ 150, receipt number ADEDC-4564702).(Dellinger, Megan) (Entered: 12/06/2024) (0) |
| Dec 5, 2024 | 657 | MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc.. (Attachments: # 1 Text of Proposed Order)(Dudash, Amy) (Entered: 12/05/2024) (0) |
| Dec 4, 2024 | 655 | MOTION for Exemption of Persons from the District of Delaware's May 17, 2024 Standing Order on Personal Devices - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 12/04/2024) (4) |
| Dec 4, 2024 | 656 | REDACTED VERSION of 649 Letter, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 12/04/2024) (30) |
| Dec 3, 2024 | 654 | SO ORDERED, re 650 Stipulation and Order to Extend Time to file a public redacted version of the Proposed Amended Joint Pretrial Order (D.I. 646 ) to January 3, 2025. Signed by Judge Jennifer L. Hall on 12/3/2024. (ceg) (Entered: 12/03/2024) (2) |
| Dec 2, 2024 | 650 | STIPULATION TO EXTEND TIME to file a public version of the [Proposed] Amended Joint Pretrial Order (D.I. 646) to January 3, 2025 - filed by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc.. (Dudash, Amy) (Entered: 12/02/2024) (2) |
| Dec 2, 2024 | 651 | [SEALED] Letter to Honorable Jennifer L. Hall from Amy M. Dudash regarding Reply in Support of Motion to Strike - re 640 MOTION to Strike Certain Supplemental Opinions from Sarepta's Economic Expert John Jarosz. (Dudash, Amy) (Entered: 12/02/2024) (0) |
| Dec 2, 2024 | 652 | Letter to the Honorable Jennifer L. Hall from Amy M. Dudash regarding Parties' Request for Telephone Conference to address Motion to Strike - re 640 MOTION to Strike Certain Supplemental Opinions from Sarepta's Economic Expert John Jarosz. (Dudash, Amy) (Entered: 12/02/2024) (1) |
| Dec 2, 2024 | 653 | REDACTED VERSION of 641 Letter, by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc.. (Attachments: # 1 Exhibit A)(Dudash, Amy) (Entered: 12/02/2024) (0) |
| Nov 27, 2024 | 649 | [SEALED] Letter to The Honorable Jennifer L. Hall from Megan E. Dellinger regarding Response to NS's Motion to Strike - re 640 MOTION to Strike Certain Supplemental Opinions from Sarepta's Economic Expert John Jarosz. (Attachments: # 1 Exhibits A-E)(Dellinger, Megan) (Entered: 11/27/2024) (0) |
| Nov 26, 2024 | 646 | [SEALED] Proposed Pretrial Order [Amended] by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc.. (Attachments: # 1 Exhibit A - Table of Abbreviations, # 2 Exhibit 1 - Jt Asserted Claims, # 3 Exhibit 2 - Jt Undisputed Facts, # 4 Exhibit 3 - NS Contested Facts, # 5 Exhibit 4 - Sarepta-UWA Contested Facts, # 6 Exhibit 5 - NS Issues of Law, # 7 Exhibit 6 - Sarepta Issues of Law, # 8 Exhibit 7 - NS Exhibit List, # 9 Exhibit 8 - Sarepta Exhibit List, # 10 Exhibit 9 - Jt Exhibit List, # 11 Exhibit 10 - NS Witness List, # 12 Exhibit 11 - Sarepta-UWA Witness List, # 13 Exhibit 12 - NS Depo Designations, # 14 Exhibit 13 - Sarepta-UWA Depo Designations, # 15 Certificate of Service)(Dudash, Amy) (Entered: 11/26/2024) (0) |
| Nov 26, 2024 | 647 | MOTION for Pro Hac Vice Appearance of Attorney D. Brian Kacedon - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 11/26/2024) (5) |
| Nov 26, 2024 | 648 | Pro Hac Vice Fee - Credit Card Payment received for D. Brian Kacedon. ( re 647 MOTION for Pro Hac Vice Appearance of Attorney D. Brian Kacedon )( Payment of $ 50, receipt number ADEDC-4558301).(Dellinger, Megan) (Entered: 11/26/2024) (0) |
| Nov 25, 2024 | 642 | Proposed Jury Instructions by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc. [Proposed Preliminary Jury Instructions]. (Dudash, Amy) (Entered: 11/25/2024) (25) |
| Nov 25, 2024 | 643 | Proposed Jury Instructions by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc. [Proposed Final Jury Instructions]. (Dudash, Amy) (Entered: 11/25/2024) (30) |
| Nov 25, 2024 | 644 | Proposed Voir Dire by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc.. (Dudash, Amy) (Entered: 11/25/2024) (5) |
| Nov 25, 2024 | 645 | VERDICT SHEET by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc. [Proposed Verdict Form]. (Attachments: # 1 Exhibit A - NS Proposed Verdict Form, # 2 Exhibit B - Sarepta-UWA Proposed Verdict Form)(Dudash, Amy) (Entered: 11/25/2024) (0) |
| Nov 22, 2024 | 638 | STIPULATION TO EXTEND TIME for the parties to submit a Joint Proposed Pretrial Order, Revised Proposed Voir Dire, Preliminary Jury Instructions, Final Jury Instructions, and Verdict Form to November 27, 2024 - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 11/22/2024) (2) |
| Nov 22, 2024 | 639 | SO ORDERED, re 638 Stipulation to Extend Time. The deadline for the parties to submit a Joint Proposed Pretrial Order, Revised Proposed Voir Dire, Preliminary Jury Instructions, Final Jury Instructions, and Verdict Form is extended from November 22, 2024 to November 26, 2024, at 9:00 AM. Signed by Judge Jennifer L. Hall on 11/22/2024. (twk) (Entered: 11/22/2024) (2) |
| Nov 22, 2024 | 640 | MOTION to Strike Certain Supplemental Opinions from Sarepta's Economic Expert John Jarosz - filed by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc.. (Attachments: # 1 Text of Proposed Order)(Dudash, Amy) (Entered: 11/22/2024) (0) |
| Nov 22, 2024 | 641 | [SEALED] Letter to the Honorable Jennifer L. Hall from Amy M. Dudash regarding Request to Strike Certain Supplemental Opinions from Sarepta's Economic Expert John Jarosz - re 640 MOTION to Strike Certain Supplemental Opinions from Sarepta's Economic Expert John Jarosz. (Attachments: # 1 Exhibit A)(Dudash, Amy) (Entered: 11/22/2024) (0) |
| Nov 18, 2024 | 634 | ORAL ORDER Rescheduling Pretrial Conference: Due to a conflict on the Court's calendar, the pretrial conference scheduled for December 6, 2024, is RESCHEDULED to December 9, 2024, at 3:00 PM in courtroom 2B. Ordered by Judge Jennifer L. Hall on 11/18/2024. (ceg) (Entered: 11/18/2024) (0) |
| Nov 18, 2024 | 635 | NOTICE OF SERVICE of Second Supplemental Rebuttal Expert Report of John C. Jarosz filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 11/18/2024) (6) |
| Nov 18, 2024 | 636 | NOTICE to Take Deposition of Donald Foy on November 20, 2024 filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 11/18/2024) (5) |
| Nov 18, 2024 | 637 | NOTICE OF SERVICE of Second Supplemental Rebuttal Expert Report and Disclosure of Mark J. Hosfield filed by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc..(Dudash, Amy) (Entered: 11/18/2024) (4) |
| Nov 6, 2024 | 633 | NOTICE OF SERVICE of (1) Second Supplemental Expert Report and Disclosure of Mark J. Hosfield; and (2) Second Supplemental Opening Expert Report of John C. Jarosz filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 11/06/2024) (5) |
| Oct 30, 2024 | 631 | REDACTED VERSION of 627 Reply Brief,, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 10/30/2024) (18) |
| Oct 30, 2024 | 632 | REDACTED VERSION of 628 Reply Brief by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 10/30/2024) (7) |
| Oct 23, 2024 | 624 | REDACTED VERSION of 621 Response to Motion by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 10/23/2024) (10) |
| Oct 23, 2024 | 625 | REDACTED VERSION of 622 Declaration by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 1-2)(Dellinger, Megan) (Entered: 10/23/2024) (0) |
| Oct 23, 2024 | 626 | REDACTED VERSION of 623 Answering Brief in Opposition,,, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Dudash, Amy) (Entered: 10/23/2024) (0) |
| Oct 23, 2024 | 627 | [SEALED] REPLY BRIEF re 610 MOTION to Preclude Dr. Michelle L. Hasting's Opinions and Testimony Applying Incorrect Written Description Law (No. 4), 607 MOTION to Preclude NS's Expert Opinions and Testimony Applying a New and Improper Construction of "Morpholino" (No. 1), 609 MOTION to Preclude Dr. Michelle L. Hasting's Opinions and Testimony Concerning Enablement of 5'-and 3'-End Modifications (No. 3), 608 MOTION to Preclude Dr. Matthew J.A. Wood's Irrelevant and Unhelpful Opinions and Testimony (No. 2) filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 10/23/2024) (0) |
| Oct 23, 2024 | 628 | [SEALED] REPLY BRIEF re 613 MOTION to Preclude Opinions of Dr. Steven Dowdy, Ph.D. filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 10/23/2024) (0) |
| Oct 16, 2024 | 621 | [SEALED] RESPONSE to Motion re 613 MOTION to Preclude Opinions of Dr. Steven Dowdy, Ph.D. filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 10/16/2024) (0) |
| Oct 16, 2024 | 622 | [SEALED] DECLARATION re 621 Response to Motion -- Declaration of Megan E. Dellinger -- by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 1-2)(Dellinger, Megan) (Entered: 10/16/2024) (0) |
| Oct 16, 2024 | 623 | [SEALED] ANSWERING BRIEF in Opposition re 607 MOTION to Preclude NS's Expert Opinions and Testimony Applying a New and Improper Construction of "Morpholino" (No. 1), 609 MOTION to Preclude Dr. Michelle L. Hasting's Opinions and Testimony Concerning Enablement of 5'-and 3'-End Modifications (No. 3), 608 MOTION to Preclude Dr. Matthew J.A. Wood's Irrelevant and Unhelpful Opinions and Testimony (No. 2), 610 MOTION to Preclude Dr. Michelle L. Hasting's Opinions and Testimony Applying Incorrect Written Description Law (No. 4) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Reply Brief due date per Local Rules is 10/23/2024. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Dudash, Amy) (Entered: 10/16/2024) (0) |
| Oct 9, 2024 | 618 | REDACTED VERSION of 611 Opening Brief in Support,,, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 10/09/2024) (29) |
| Oct 9, 2024 | 619 | REDACTED VERSION of 612 Declaration,,, by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 1-19)(Dellinger, Megan) (Entered: 10/09/2024) (0) |
| Oct 9, 2024 | 620 | REDACTED VERSION of 613 MOTION to Preclude Opinions of Dr. Steven Dowdy, Ph.D. by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A, # 2 Text of Proposed Order)(Dudash, Amy) (Entered: 10/09/2024) (0) |
| Oct 7, 2024 | 617 | REDACTED VERSION of 605 Letter by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 10/07/2024) (6) |
| Oct 3, 2024 | 614 | ORAL ORDER: Having reviewed Plaintiff's Request for Leave to file Motion for Summary Judgment (D.I. 604 ) and the parties' accompanying letter briefs (D.I. 604 , 605 , 606 ), IT IS HEREBY ORDERED that Plaintiff's Request (D.I. 604 ) is DENIED. Plaintiff previously filed a motion for summary judgment on this issue and that motion was denied at least because there appeared to be genuine disputes of material facts. (See D.I. 400 , 549 .) Although Plaintiff asserts that new information was obtained through supplemental expert discovery, there still appear to be genuine disputes of material facts. Ordered by Judge Jennifer L. Hall on 10/3/2024. (ceg) (Entered: 10/03/2024) (0) |
| Oct 3, 2024 | 615 | STATEMENT re 613 MOTION to Preclude Opinions of Dr. Steven Dowdy, Ph.D. [Rule 7.1.1 Statement] by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 10/03/2024) (2) |
| Oct 3, 2024 | 616 | REDACTED VERSION of 604 Letter, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Text of Proposed Order, # 2 Exhibit A, # 3 Exhibit A-1 - Memorandum of Law, # 4 Exhibit A-2 - Statement of Facts, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Text of Proposed Order)(Dudash, Amy) (Entered: 10/03/2024) (0) |
| Oct 2, 2024 | 607 | MOTION to Preclude NS's Expert Opinions and Testimony Applying a New and Improper Construction of "Morpholino" (No. 1) - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 10/02/2024) (8) |
| Oct 2, 2024 | 608 | MOTION to Preclude Dr. Matthew J.A. Wood's Irrelevant and Unhelpful Opinions and Testimony (No. 2) - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 10/02/2024) (8) |
| Oct 2, 2024 | 609 | MOTION to Preclude Dr. Michelle L. Hasting's Opinions and Testimony Concerning Enablement of 5'-and 3'-End Modifications (No. 3) - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 10/02/2024) (8) |
| Oct 2, 2024 | 610 | MOTION to Preclude Dr. Michelle L. Hasting's Opinions and Testimony Applying Incorrect Written Description Law (No. 4) - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 10/02/2024) (8) |
| Oct 2, 2024 | 611 | [SEALED] OPENING BRIEF in Support re 610 MOTION to Preclude Dr. Michelle L. Hasting's Opinions and Testimony Applying Incorrect Written Description Law (No. 4), 607 MOTION to Preclude NS's Expert Opinions and Testimony Applying a New and Improper Construction of "Morpholino" (No. 1), 609 MOTION to Preclude Dr. Michelle L. Hasting's Opinions and Testimony Concerning Enablement of 5'-and 3'-End Modifications (No. 3), 608 MOTION to Preclude Dr. Matthew J.A. Wood's Irrelevant and Unhelpful Opinions and Testimony (No. 2) filed by Sarepta Therapeutics, Inc., The University of Western Australia.Answering Brief/Response due date per Local Rules is 10/16/2024. (Dellinger, Megan) (Entered: 10/02/2024) (0) |
| Oct 2, 2024 | 612 | [SEALED] DECLARATION re 610 MOTION to Preclude Dr. Michelle L. Hasting's Opinions and Testimony Applying Incorrect Written Description Law (No. 4), 607 MOTION to Preclude NS's Expert Opinions and Testimony Applying a New and Improper Construction of "Morpholino" (No. 1), 609 MOTION to Preclude Dr. Michelle L. Hasting's Opinions and Testimony Concerning Enablement of 5'-and 3'-End Modifications (No. 3), 608 MOTION to Preclude Dr. Matthew J.A. Wood's Irrelevant and Unhelpful Opinions and Testimony (No. 2) -- Declaration of Megan E. Dellinger -- by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 1-19)(Dellinger, Megan) (Entered: 10/02/2024) (0) |
| Oct 2, 2024 | 613 | [SEALED] MOTION to Preclude Opinions of Dr. Steven Dowdy, Ph.D. - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A, # 2 Text of Proposed Order)(Dudash, Amy) (Entered: 10/02/2024) (0) |
| Oct 1, 2024 | 606 | Letter to the Honorable Jennifer L. Hall from Amy M. Dudash regarding Reply in Support of Request for Leave to File Motion for Summary Judgment - re 604 Letter,. (Dudash, Amy) (Entered: 10/01/2024) (3) |
| Sep 30, 2024 | 605 | [SEALED] Letter to The Honorable Jennifer L. Hall from Megan E. Dellinger regarding Opposition to NS's Motion for Leave to File Motion for Summary Judgment - re 604 Letter,. (Dellinger, Megan) (Entered: 09/30/2024) (0) |
| Sep 26, 2024 | 604 | [SEALED] Letter to the Honorable Jennifer L. Hall from Amy M. Dudash regarding Request for Leave to file Motion for Summary Judgment. (Attachments: # 1 Text of Proposed Order, # 2 Exhibit A - Motion for Summary Judgment, # 3 Exhibit A-1 - Memorandum of Law, # 4 Exhibit A-2 - Statement of Facts, # 5 Exhibit 1, # 6 Exhibit 2, # 7 Exhibit 3, # 8 Exhibit 4, # 9 Exhibit 5, # 10 Exhibit 6, # 11 Exhibit 7, # 12 Text of Proposed Order)(Dudash, Amy) (Entered: 09/26/2024) (0) |
| Sep 9, 2024 | 602 | MOTION for Pro Hac Vice Appearance of Attorney Julie S. Goldemberg - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) (Entered: 09/09/2024) (0) |
| Sep 9, 2024 | 603 | Pro Hac Vice Fee - Credit Card Payment received for Julie S. Goldemberg. ( Payment of $ 50, receipt number ADEDC-4494061).(Dudash, Amy) (Entered: 09/09/2024) (0) |
| Aug 24, 2024 | 600 | Official Transcript of Teleconference held on 04-18-2024 before Judge Hall. Court Reporter Stacy Ingram,Email: stacy_ingram@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/16/2024. Redacted Transcript Deadline set for 9/24/2024. Release of Transcript Restriction set for 11/22/2024. (Ingram, Stacy) (Entered: 08/24/2024) (0) |
| Aug 24, 2024 | 601 | Official Transcript of Teleconference held on 05-09-2024 before Judge Hall. Court Reporter Stacy Ingram,Email: stacy_ingram@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 9/16/2024. Redacted Transcript Deadline set for 9/24/2024. Release of Transcript Restriction set for 11/22/2024. (Ingram, Stacy) (Entered: 08/24/2024) (0) |
| Aug 15, 2024 | 599 | NOTICE OF SERVICE of Supplemental Rebuttal Expert Report of Steven F. Dowdy, Ph.D. filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 08/15/2024) (5) |
| Aug 6, 2024 | 598 | NOTICE requesting Clerk to remove Eric J. Lee as co-counsel. Reason for request: No longer with firm. (Dellinger, Megan) (Entered: 08/06/2024) (4) |
| Jul 2, 2024 | 596 | SO ORDERED, re 595 Stipulation of Dismissal of Claim I (Breach of Contract) of Nippon Shinyakus Second Amended Complaint. Signed by Judge Jennifer L. Hall on 7/2/2024. (ceg) (Entered: 07/02/2024) (2) |
| Jul 2, 2024 | 597 | SO ORDERED WITH MODIFICATION, re 594 Stipulation and Amended Scheduling Order to Extend certain discovery deadlines and limitations in connection with the continued trial. (*See Order for details and the Court's footnote on page 2). Signed by Judge Jennifer L. Hall on 7/2/2024. (ceg) (Main Document 597 replaced on 7/2/2024) (ceg). (Entered: 07/02/2024) (3) |
| Jul 1, 2024 | 594 | Letter to Honorable Jennifer L. Hall from Amy M. Dudash regarding pre-trial scheduling (Joint). (Attachments: # 1 Exhibit A)(Dudash, Amy) (Entered: 07/01/2024) (0) |
| Jul 1, 2024 | 595 | STIPULATION of Dismissal [Stipulation of Partial Dismissal] by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 07/01/2024) (2) |
| Jun 24, 2024 | 593 | NOTICE of of Withdrawal of Attorney Guylaine Hach, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd. (Dudash, Amy) Modified on 6/24/2024 (ceg). (Entered: 06/24/2024) (2) |
| Jun 21, 2024 | 592 | ORDER Setting Video Mediation Conference: A Video Mediation Conference is set for 8/5/2024 at 03:00 PM before Judge Sherry R. Fallon. Signed by Judge Sherry R. Fallon on 6/21/2024. (lih) (Entered: 06/21/2024) (6) |
| May 28, 2024 | 591 | ORAL ORDER: The redactions at D.I. 587 as supported by the declaration at D.I. 589 are APPROVED. Ordered by Judge Jennifer L. Hall on 5/28/2024. (ceg) (Entered: 05/28/2024) (0) |
| May 24, 2024 | 590 | REDACTED VERSION of 536 Proposed Pretrial Order,,,, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A - Table of Abbreviations, # 2 Exhibit 1 - Jt Asserted Claims, # 3 Exhibit 2 - Jt Undisputed Facts, # 4 Exhibit 3 - NS Contested Facts, # 5 Exhibit 4 - Sarepta-UWA Contested Facts, # 6 Exhibit 5 - NS Issues of Law, # 7 Exhibit 6 - Sarepta Issues of Law, # 8 Exhibit 7 - NS Exhibit List, # 9 Exhibit 8 - Sarepta Exhibit List, # 10 Exhibit 9 - Jt Exhibit List, # 11 Exhibit 10 - NS Witness List, # 12 Exhibit 11 - Sarepta-UWA Witness List, # 13 Exhibit 12 - NS Depo Designations, # 14 Exhibit 13 - Sarepta-UWA Depo Designations, # 15 Exhibit 14A - NS MIL No. 1, # 16 Exhibit 14B - NS MIL No. 2, # 17 Exhibit 14C - NS MIL No. 3, # 18 Exhibit 15A - Sarepta-UWA MIL No. 1, # 19 Exhibit 15B - Sarepta-UWA MIL No. 2, # 20 Exhibit 15C - Sarepta-UWA MIL No. 3, # 21 Proof of Service)(Dudash, Amy) (Entered: 05/24/2024) (0) |
| May 22, 2024 | 586 | Letter to The Honorable Jennifer L. Hall from Megan E. Dellinger regarding Redacted Letter Briefs. (Dellinger, Megan) Modified on 5/22/2024 (ceg). (Entered: 05/22/2024) (2) |
| May 22, 2024 | 587 | REDACTED VERSION of 568 Letter//Revised Redactions to Exhibits A-N, by Sarepta Therapeutics, Inc. (Dellinger, Megan) Modified on 5/22/2024 (ceg). (Entered: 05/22/2024) (30) |
| May 22, 2024 | 588 | REDACTED VERSION of 572 Letter, by Sarepta Therapeutics, Inc.. (Attachments: # 1 Exhibits 1-4)(Dellinger, Megan) (Entered: 05/22/2024) (0) |
| May 22, 2024 | 589 | DECLARATION re 582 Order, 588 Redacted Document, 587 Redacted Document, 586 Letter (Declaration of John X. Haberman in Support of Redacting Sarepta's Confidential Material), by Sarepta Therapeutics, Inc. (Dellinger, Megan) Modified on 5/22/2024 (ceg). (Entered: 05/22/2024) (5) |
| May 17, 2024 | 585 | ORAL ORDER: Having reviewed the parties' letter (D.I. 584 ), IT IS HEREBY ORDERED that a 5-day jury trial is scheduled beginning December 16, 2024, with a pretrial conference scheduled for December 6, 2024, at 10:00 AM in Courtroom 6D. Ordered by Judge Jennifer L. Hall on 5/17/2024. (ceg) (Entered: 05/17/2024) (0) |
| May 16, 2024 | 584 | Joint Letter to the Honorable Jennifer L. Hall from Amy M. Dudash regarding trial rescheduling. (Attachments: # 1 Exhibit A)(Dudash, Amy) Modified on 5/16/2024 (ceg). (Entered: 05/16/2024) (0) |
| May 15, 2024 | 582 | ORAL ORDER: Upon review of the redacted version filed at D.I. 581 , it appears parts of it are redacted in its entirety. IT IS HEREBY ORDERED that counsel is to supplement the record and file a declaration in support of the redactions within 5 business days. Ordered by Judge Jennifer L. Hall on 5/15/2024. (ceg) (Entered: 05/15/2024) (0) |
| May 15, 2024 | 583 | STIPULATION TO EXTEND TIME to file a redacted version of D.I. 572 to May 22, 2024 - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 05/15/2024) (2) |
| May 14, 2024 | 581 | REDACTED VERSION of 568 Letter, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N)(Dudash, Amy) (Entered: 05/14/2024) (0) |
| May 10, 2024 | 580 | Letter to Honorable Jennifer L. Hall from Amy M. Dudash regarding Resolution of NS's Breach of Contract Claim - re 575 Order. (Dudash, Amy) (Entered: 05/10/2024) (1) |
| May 9, 2024 | 574 | SO ORDERED, granting 567 Sarepta's Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices. Signed by Judge Jennifer L. Hall on 5/9/2024. (ceg) (Entered: 05/09/2024) (4) |
| May 9, 2024 | 575 | ORAL ORDER: IT IS HEREBY ORDERED that the parties shall submit a letter by COB on May 10, 2024, stating their positions regarding the bench trial on the breach of contract claim. Ordered by Judge Jennifer L. Hall on 5/9/2024. (ceg) (Entered: 05/09/2024) (0) |
| May 9, 2024 | 576 | ORAL ORDER REFERRING CASE to Mediation: IT IS HEREBY ORDERED that this case is referred to Judge Fallon for mediation. Ordered by Judge Jennifer L. Hall on 5/9/2024. (ceg) (Entered: 05/09/2024) (0) |
| May 9, 2024 | 577 | ORAL ORDER- An ADR status teleconference is set for TODAY at 02:30 PM before Judge Sherry R. Fallon. Counsel for the plaintiff shall initiate the call to 302-573-4557. Ordered by Judge Sherry R. Fallon on 5/9/2024. (lih) (Entered: 05/09/2024) (0) |
| May 9, 2024 | 578 | NOTICE requesting Clerk to remove Jesse Aaron Vella as co-counsel. Reason for request: No longer with firm. (Dellinger, Megan) (Entered: 05/09/2024) (5) |
| May 9, 2024 | 579 | ORDER Setting Mediation Conference: A Mediation Conference is set for 5/14/2024 at 10:00 AM in Courtroom 6C before Judge Sherry R. Fallon. Signed by Judge Sherry R. Fallon on 5/9/2024. (lih) (Entered: 05/09/2024) (6) |
| May 8, 2024 | 570 | Official Transcript of Pretrial Conference held on 5/6/2024 before Judge Jennifer L. Hall. Court Reporter/Transcriber Stacy Ingram, Email: Stacy_Ingram@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER Redaction Request due 5/29/2024. Redacted Transcript Deadline set for 6/10/2024. Release of Transcript Restriction set for 8/6/2024. (ceg) (Entered: 05/08/2024) (88) |
| May 8, 2024 | 571 | Letter to The Honorable Jennifer L. Hall from Megan E. Dellinger regarding Response to Order (D.I. 566) and Nippon's May 7, 2024 Letter (D.I. 569). (Dellinger, Megan) Modified on 5/8/2024 (ceg). (Entered: 05/08/2024) (3) |
| May 8, 2024 | 572 | [SEALED] Letter to The Honorable Jennifer L. Hall from Megan E. Dellinger regarding Response to Nippon's Letter Brief (D.I. 568). (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4)(Dellinger, Megan) Modified on 5/9/2024 (ceg). (Entered: 05/08/2024) (0) |
| May 8, 2024 | 573 | ORAL ORDER: Having had an opportunity to further review the record pertaining to the parties' claim construction dispute about whether claim 1 of the '851 patent requires 100% complementarity throughout the entire length of the antisense oligonucleotide (including but not limited to the record associated with the Markman proceedings and the parties' arguments at the pretrial conference), the Court is persuaded that the construction should be clarified and/or amended to make clear that the claim requires 100% complementarity to consecutive bases of a target region of exon 53 throughout the entire length of the antisense oligonucleotide. See Level Sleep LLC v. Sleep No. Corp., No. 2020-1718, 2021 WL 2934816, at *3 (Fed. Cir. July 13, 2021) (explaining that district courts can revisit claim construction as the case progresses). The Court may in the future issue a memorandum that fully explains its reasoning; however, in view of NS's representation that it is "not in a position to proceed to trial" on the '851 patent under the current circumstances (see D.I. 569 at 3), as well as the Court's conclusion that both sides' patents should be tried together, IT IS HEREBY ORDERED that the trial on the substantive patent issues is CONTINUED. The parties shall be prepared to discuss the following issues at the teleconference scheduled for May 9, 2024: whether the Court should proceed with a bench trial next week on NS's breach of contract claim; whether there is any reason why the Court shouldn't order the decision-makers for the parties to meet in person in the Court's conference room next week--either before or after the bench trial on the contract claim--to discuss settlement; and whether the parties could be ready to try the case to the jury the week of August 12, 2024. Ordered by Judge Jennifer L. Hall on 5/8/2024. (ceg) (Entered: 05/08/2024) (0) |
| May 7, 2024 | 565 | Letter to The Honorable Jennifer L. Hall from Megan E. Dellinger regarding response to the Court's order during May 6, 2024 pretrial conference. (Dellinger, Megan) (Entered: 05/07/2024) (2) |
| May 7, 2024 | 566 | ORAL ORDER: IT IS HEREBY ORDERED that the parties shall submit letters by COB on May 8, 2024, stating their positions on the matters discussed at the conclusion of the hearing on May 6, 2024. IT IS FURTHER ORDERED that a status telephone conference is scheduled for May 9, 2024 at 10:00 AM before Judge Jennifer L. Hall. The parties shall call the Court's conference line at (877) 336-1829, access code: 7090640. Ordered by Judge Jennifer L. Hall on 5/7/2024. (ceg) (Entered: 05/07/2024) (0) |
| May 7, 2024 | 567 | MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 05/07/2024) (4) |
| May 7, 2024 | 568 | [SEALED] Letter to Judge Jennifer L. Hall from Amy Dudash regarding Regarding Late Produced Licensing and No Lost Profits. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N)(Dudash, Amy) (Entered: 05/07/2024) (0) |
| May 7, 2024 | 569 | Letter to Honorable Jennifer L. Hall from Amy M. Dudash regarding Claim Construction and Trial. (Dudash, Amy) Modified on 5/8/2024 (ceg). (Entered: 05/07/2024) (4) |
| May 6, 2024 | 563 | Proposed Preliminary Jury Instructions, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd. (Dudash, Amy) Modified on 5/6/2024 (ceg). (Entered: 05/06/2024) (25) |
| May 6, 2024 | 564 | Proposed Voir Dire by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 05/06/2024) (4) |
| May 3, 2024 | 555 | MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Text of Proposed Order)(Dudash, Amy) (Entered: 05/03/2024) (0) |
| May 3, 2024 | 556 | ORAL ORDER: Having reviewed NS's Daubert Motion to Exclude Testimony and Opinions of Dr. Andrew Hirshfeld (D.I. 423 ), it appearing that the parties agree that it would be inappropriate for Dr. Hirshfeld to offer legal opinions to the jury, and it further appearing that Dr. Hirshfeld will not be testifying during the jury trial portion of this case (D.I. 536 , Ex. 11), IT IS ORDERED that the motion is GRANTED to the extent that Sarepta seeks to offer the challenged opinions to the jury. Ordered by Judge Jennifer L. Hall on 5/3/2024. (ceg) (Entered: 05/03/2024) (0) |
| May 3, 2024 | 558 | Pro Hac Vice Fee - Credit Card Payment received for Rachel Renee Blitzer. ( re 560 MOTION for Pro Hac Vice Appearance of Attorney Rachel Renee Blitzer )(Payment of $ 50, receipt number ADEDC-4399444).(Dellinger, Megan) Modified on 5/3/2024 (ceg). (Entered: 05/03/2024) (0) |
| May 3, 2024 | 559 | STIPULATION TO EXTEND TIME to file a public version of the [Proposed] Joint Pretrial Order (D.I. 536) to May 24, 2024 - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 05/03/2024) (2) |
| May 3, 2024 | 560 | MOTION for Pro Hac Vice Appearance of Attorney Rachel Renee Blitzer - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 05/03/2024) (5) |
| May 3, 2024 | 561 | ORAL ORDER: Having reviewed the remaining portions of NS's Daubert Motion to Exclude the Testimony and Opinions of Steven F. Dowdy, Ph.D. (D.I. 419 ; see also D.I. 545 at 3), IT IS ORDERED that the motion is DENIED to the extent that it seeks to preclude Dr. Dowdy from offering opinions based on his understanding of how a POSA would understand the term "antisense oligonucleotide." The parties did not ask the Court to construe that term; accordingly, the Court is unpersuaded that Dr. Dowdy's opinions misapply the Court's prior claim construction (issued before the case was reassigned to me). Further, the Court having reviewed the record of the earlier Markman proceedings as well as the parties' briefing regarding Sarepta's MIL No. 3 (D.I. 536 , Ex. 15C), the parties are advised that the Court is considering whether to clarify and/or amend the Court's construction of "base sequence" before the case goes to the jury. See Level Sleep LLC v. Sleep No. Corp., No. 2020-1718, 2021 WL 2934816, at *3 (Fed. Cir. July 13, 2021) (explaining that district courts can revisit claim construction as the case progresses). The parties should be prepared to discuss at the pretrial conference how that might affect the opinions to be presented at trial and the issues to be tried. IT IS FURTHER ORDERED that the Court will hear argument at the pretrial conference on NS's request to preclude Dr. Dowdy from testifying about the PTAB's preliminary decisions in the IPRs in support of his obviousness opinion in conjunction with argument on NS's MIL No. 3. Ordered by Judge Jennifer L. Hall on 5/3/2024. (ceg) (Entered: 05/03/2024) (0) |
| May 3, 2024 | 562 | ORDER granting 555 Parties' Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices for purposes of pretrial conference, set-up, and trial. Signed by Judge Jennifer L. Hall on 5/3/2024. (ceg) (Entered: 05/03/2024) (3) |
| May 2, 2024 | 554 | SO ORDERED, granting 552 Defendants' Motion for Limited Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices as to Mr. Morin, Mr. Yakob, Ms. Borah, Mr. Cremer and Mr. Kozikowski for purposes of the May 6, 2024 pretrial conference. Signed by Judge Jennifer L. Hall on 5/2/2024. (ceg) (Entered: 05/02/2024) (4) |
| May 1, 2024 | 541 | MEMORANDUM OPINION. Signed by Judge Jennifer L. Hall on 5/1/2024. (ceg) (Entered: 05/01/2024) (4) |
| May 1, 2024 | 542 | ORDER re 541 Memorandum Opinion: IT IS ORDERED that Sarepta Therapeutics, Inc. and the University of Western Australia's Motion for Summary Judgment of Infringement of U.S. Patent Nos. 9,994,851 and 10,277,590 (Motion #1) (D.I. 396 ) is GRANTED. Signed by Judge Jennifer L. Hall on 5/1/2024. (ceg) (Entered: 05/01/2024) (1) |
| May 1, 2024 | 543 | ORAL ORDER: Sarepta's Motion for Leave to File a Reply in Support of Its Motion to Exclude Dr. Wood as an Expert Witness (D.I. 321 ) is GRANTED. Having reviewed the briefing related to Sarepta's Motion to Exclude Dr. Matthew Wood as an Expert Witness (D.I. 220 , 298 , 299 , 308 , 309 , 313 , 321 , 517 ) and Sarepta's Motion to Strike Dr. Matthew Wood's Expert Reports (D.I. 384 , 385 , 389 , 517 ), IT IS HEREBY ORDERED that the motions are DENIED. Federal courts have the inherent authority to disqualify experts under certain circumstances to protect the integrity of the adversary process and to promote public confidence in the legal system. This is not a classic "switching sides" situation. While it is undisputed that Dr. Wood performed some consulting and expert work for Sarepta in the past, the Court is unpersuaded on this record that Dr. Wood received the type of information in those engagements that would require his disqualification in this litigation, particularly since Dr. Wood's expert reports in this case rely on public information (and discovery is now complete). Ordered by Judge Jennifer L. Hall on 5/1/2024. (ceg) (Entered: 05/01/2024) (0) |
| May 1, 2024 | 544 | ORAL ORDER: NS's Motion for Partial Summary Judgment on the issue of infringement of certain NS patents (D.I. 402 ) is GRANTED in view of Sarepta's stipulation to infringement during the April 18, 2024 teleconference. (Apr. 18, 2024 Tr. at 20.). Ordered by Judge Jennifer L. Hall on 5/1/2024. (ceg) (Entered: 05/01/2024) (0) |
| May 1, 2024 | 545 | ORDER: IT IS HEREBY ORDERED that the motions for summary judgment relating to inequitable conduct (D.I. 398 , 414 ) are DENIED. IT IS FURTHER ORDERED that the motions to exclude expert testimony pertaining to inequitable conduct (D.I. 391 , 419 (to the extent it relates to testimony regarding inequitable conduct), 423 (to the extent it relates to testimony regarding inequitable conduct)) are DENIED with leave to renew during trial at the appropriate time. (*See Order for details). Signed by Judge Jennifer L. Hall on 5/1/2024. (ceg) (Entered: 05/01/2024) (3) |
| May 1, 2024 | 546 | MOTION for Pro Hac Vice Appearance of Attorney Jameson K. Gardner - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 05/01/2024) (5) |
| May 1, 2024 | 547 | Pro Hac Vice Fee - Credit Card Payment received for Jameson K. Gardner. ( re 546 MOTION for Pro Hac Vice Appearance of Attorney Jameson K. Gardner )( Payment of $ 50, receipt number ADEDC-4397089).(Dellinger, Megan) (Entered: 05/01/2024) (0) |
| May 1, 2024 | 548 | ORAL ORDER: Having reviewed the record pertaining to Sarepta's Motion for Summary Judgment of No Lost Profits (Motion #2) (D.I. 397 , 409 , 411 , 413 , 417 , 418 , 420 , 422 , 425 , 426 , 462 , 463 , 466 , 468 , 490 , 491 , 492 ), and it appearing that there is a genuine dispute of material fact as to whether NS Japan has itself suffered damages in the form of lost profits, IT IS ORDERED that the motion is DENIED. Ordered by Judge Jennifer L. Hall on 5/1/2024. (ceg) (Entered: 05/01/2024) (0) |
| May 1, 2024 | 549 | ORAL ORDER: Having reviewed the record pertaining to NS's and NS Pharma's Motion for Summary Judgment No. 1 Regarding Invalidity of the UWA Patents (D.I. 399 , 400 , 401 , 427 , 428 , 469 , 470 , 471 , 472 , 493 , 495 , 496 ), and it appearing that there are genuine disputes of material fact as to whether the patent disclosure reasonably conveys to a POSA that the inventor had possession of the claimed subject matter as of the filing date, and it further appearing that there are genuine disputes of material fact as to whether the specification teaches a POSA how to make and use the full scope of the claimed invention without undue experimentation, IT IS ORDERED that the motion is DENIED. Ordered by Judge Jennifer L. Hall on 5/1/2024. (ceg) (Entered: 05/01/2024) (0) |
| May 1, 2024 | 550 | ORAL ORDER: WHEREAS, NS has filed Motion for Partial Summary Judgment No. 3 Regarding Breach of Contract Claim (D.I. 405 , 406 , 407 , 427 , 428 , 469 , 470 , 471 , 472 , 493 , 495 , 496 ); WHEREAS, the scheduling order entered in this case (before it was reassigned to me) states that "[i]f the Court decides to deny a motion filed by [a] party, barring exceptional reasons..., the Court will not review any lower ranked summary judgment motions filed by the party" (D.I. 143); WHEREAS, the parties agree that the breach of contract claim should proceed via bench trial, and the Court generally does not entertain summary judgment motions on issues that will be tried to the bench; and, WHEREAS, it appears from the record that the parties dispute the amount of damages; NOW, THEREFORE, IT IS HEREBY ORDERED that the Motion (D.I. 405) is DENIED. Ordered by Judge Jennifer L. Hall on 5/1/2024. (ceg) (Entered: 05/01/2024) (0) |
| May 1, 2024 | 551 | ORAL ORDER: Sarepta's Motion to Exclude Noninfringement Opinions and Testimony of Dr. Christine C. Esau (D.I. 392 ) is DISMISSED as MOOT. (See D.I. 536 , 542 .). Ordered by Judge Jennifer L. Hall on 5/1/2024. (ceg) (Entered: 05/01/2024) (0) |
| May 1, 2024 | 552 | MOTION for Limited Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 05/01/2024) (4) |
| May 1, 2024 | 553 | ORAL ORDER: Having reviewed the briefing and exhibits filed in connection with Sarepta and UWA's Motion to Exclude Certain Opinions and Testimony of Drs. Christine C. Esau, Michelle L. Hastings, and Matthew J.A. Wood (D.I. 393 , 395 , 458 , 489 ), IT IS ORDERED that the Motion is GRANTED-IN-PART and DENIED-IN-PART. The opinions of Dr. Esau relating to willful infringement in Sections XI.D and XII.D of her Opening Expert Report and the opinions of Dr. Hastings relating to willful infringement in Section VIII of her Reply Report are excluded under FRE 702 because they will not be helpful to the jury. The Court is unpersuaded that Section V of Dr. Wood's Opening Report and Section II of his Reply Report amount to improper opinions about the inventors' states of mind; accordingly, they will not be excluded on that basis. Ordered by Judge Jennifer L. Hall on 5/1/2024. (ceg) (Entered: 05/01/2024) (0) |
| Apr 30, 2024 | 537 | Proposed Preliminary Jury Instructions, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd. (Dudash, Amy) Modified on 5/1/2024 (ceg). (Entered: 04/30/2024) (26) |
| Apr 30, 2024 | 538 | Proposed Final Jury Instructions, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd. (Dudash, Amy) Modified on 5/1/2024 (ceg). (Entered: 04/30/2024) (30) |
| Apr 30, 2024 | 539 | Proposed Voir Dire by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 04/30/2024) (5) |
| Apr 30, 2024 | 540 | Proposed Verdict Form, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd. (Dudash, Amy) Modified on 5/1/2024 (ceg). (Entered: 04/30/2024) (14) |
| Apr 29, 2024 | 534 | STIPULATION TO EXTEND TIME for the Parties to file their proposed final voir dire, preliminary jury instructions, final jury instructions and verdict form to April 30, 2024 - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 04/29/2024) (2) |
| Apr 29, 2024 | 535 | SO ORDERED, re 534 Stipulation and Order to Extend Time for the parties to file their proposed final voir dire, preliminary jury instructions, final jury instructions, and verdict form to April 30, 2024. Signed by Judge Jennifer L. Hall on 4/29/2024. (ceg) (Entered: 04/29/2024) (2) |
| Apr 29, 2024 | 536 | [SEALED] Proposed Joint Pretrial Order, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A - Table of Abbreviations, # 2 Exhibit 1 - Jt Asserted Claims, # 3 Exhibit 2 - Jt Undisputed Facts, # 4 Exhibit 3 - NS Contested Facts, # 5 Exhibit 4 - Sarepta-UWA Contested Facts, # 6 Exhibit 5 - NS Issues of Law, # 7 Exhibit 6 - Sarepta Issues of Law, # 8 Exhibit 7 - NS Exhibit List, # 9 Exhibit 8 - Sarepta Exhibit List, # 10 Exhibit 9 - Jt Exhibit List, # 11 Exhibit 10 - NS Witness List, # 12 Exhibit 11 - Sarepta-UWA Witness List, # 13 Exhibit 12 - NS Depo Designations, # 14 Exhibit 13 - Sarepta-UWA Depo Designations, # 15 Exhibit 14A - NS MIL No. 1, # 16 Exhibit 14B - NS MIL No. 2, # 17 Exhibit 14C - NS MIL No. 3, # 18 Exhibit 15A - Sarepta-UWA MIL No. 1, # 19 Exhibit 15B - Sarepta-UWA MIL No. 2, # 20 Exhibit 15C - Sarepta-UWA MIL No. 3, # 21 Proof of Service)(Dudash, Amy) Modified on 4/30/2024 (ceg). (Attachment 15 replaced on 5/1/2024) (ceg). (Attachment 16 replaced on 5/1/2024) (ceg). (Attachment 17 replaced on 5/1/2024) (ceg). (Entered: 04/29/2024) (0) |
| Apr 26, 2024 | 533 | SO ORDERED, re 530 Stipulation and Order to Extend Time for the parties to file their proposed final voir dire, preliminary jury instructions, final jury instructions, and verdict form to April 29, 2024. Signed by Judge Jennifer L. Hall on 4/26/2024. (ceg) (Entered: 04/26/2024) (2) |
| Apr 25, 2024 | 530 | STIPULATION TO EXTEND TIME for the Parties to file their proposed final voir dire, preliminary jury instructions, final jury instructions, and verdict form to April 29, 2024 - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 04/25/2024) (2) |
| Apr 25, 2024 | 531 | MOTION for Pro Hac Vice Appearance of Attorney David L. Schrader - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) (Entered: 04/25/2024) (0) |
| Apr 25, 2024 | 532 | Pro Hac Vice Fee - Credit Card Payment received for David L. Schrader. ( re 531 MOTION for Pro Hac Vice Appearance of Attorney David L. Schrader )( Payment of $ 50, receipt number ADEDC-4393221).(Dudash, Amy) (Entered: 04/25/2024) (0) |
| Apr 18, 2024 | 529 | ORAL ORDER: Having reviewed the parties' briefing on Sarepta's Motion to Bifurcate and Stay Antitrust counterclaim (D.I. 345 ), as modified by the parties' April 15, 2024 letter (D.I. 526 ), and having heard the parties' respective positions during the April 18, 2024 status teleconference (see D.I. 528), IT IS ORDERED that the Motion to Bifurcate is GRANTED-IN-PART, as follows: the Court is persuaded that bifurcating NS's antitrust claim from the substantive patent issues for trial may avoid prejudice and enhance juror comprehension, and has the potential to economize. See FRCP 42(b). In view of the parties' agreement during the April 18, 2024 teleconference that both sides' inequitable conduct claims may properly be tried to the bench, and the parties' further agreement that the Court's findings and conclusions regarding NS's inequitable conduct claim will be binding on the parties with respect to the inequitable conduct elements of NS's Walker Process antitrust claim, the Court concludes that the best and most efficient course of action is to hold a bench trial on inequitable conduct simultaneously with the jury trial on the patent issues, with evidence pertaining solely to inequitable conduct being presented to the Court after the jury is released at the end of each day and/or while the jury is deliberating. The parties shall advise the Court at the pretrial conference how many hours of bench trial time is needed. Ordered by Judge Jennifer L. Hall on 4/18/2024. (twk) (Entered: 04/18/2024) (0) |
| Apr 17, 2024 | 528 | ORAL ORDER Setting Teleconference: Having reviewed the parties' April 15, 2024 letter (D.I. 526 ), as well as the parties briefing on Sarepta's motion to bifurcate NS's antitrust claim for trial (D.I. 345 ), IT IS ORDERED that the Court shall hold a status teleconference on April 18, 2024 at 11:00 am. The parties are advised that the Court is inclined to bifurcate NS's antitrust claim for trial. In view of that, the Court has questions about the most appropriate way to proceed on the parties' respective inequitable conduct allegations, including but not limited to the following: (1) Do the parties agree that a jury finding that NS failed to prove invalidity would be dispositive of NS's inequitable conduct and antitrust claims? (see, e.g., D.I. 358 at 8 n.4); (2) Do the parties agree that a jury finding that Sarepta failed to prove invalidity under 35 U.S.C. 112 would be dispositive of Sarepta's inequitable conduct claims?; (3) Does NS's suggestion that the Court submit the parties' inequitable conduct allegations to the jury for an "advisory" verdict (D.I. 526 at 2) mean that NS is amenable to the Judge making findings regarding the conduct underlying its inequitable conduct claim in the first instance and, if so, does NS agree that a finding of no inequitable conduct by the Judge would be dispositive of its Walker Process antitrust claim? The parties shall call the Court's conference line at (877) 336-1829, access code: 7090640. Ordered by Judge Jennifer L. Hall on 4/17/2024. (ceg) (Entered: 04/17/2024) (0) |
| Apr 16, 2024 | 527 | ORAL ORDER: IT IS HEREBY ORDERED that the following motions are DENIED as moot as the parties agreed in their April 15, 2024 letter (D.I. 526 ): Sarepta's and the University of Western Australia's Motion to Stay Antitrust Counterclaim Deadlines Pending Resolution of Sarepta's and the University of Western Australia's Motion to Bifurcate and Stay (D.I. 353 ); Nippon Shinyaku's Motion Regarding Disclosure of Sarepta-Designated Information to Dr. Matthew Wood (D.I. 300 ); Nippon Shinyaku's Motion for Leave to File Reply Letter Brief Regarding Disclosure of Sarepta-Designated Information to Dr. Matthew Wood (D.I. 320 ); Nippon Shinyaku's and NS Pharma's Objections to Special Master Order No. 1 Denying Motion to Compel Production of License Agreements (D.I. 285 ); Nippon Shinyaku's Motion for Leave to Serve Amended Final Infringement Contentions (D.I. 301 ); Nippon Shinyaku's Motion for Summary Judgment No. 4 - No Anticipation (D.I. 408 ); and Sarepta's Motion on Exclusion of Dr. Luedtke's Doctrine of Equivalents Opinions and Testimony (D.I. 394 ). Ordered by Judge Jennifer L. Hall on 4/16/2024. (ceg) (Entered: 04/16/2024) (0) |
| Apr 15, 2024 | 526 | Letter to The Honorable Jennifer L. Hall from Megan E. Dellinger regarding response to April 12, 2024 Oral Order. (Dellinger, Megan) Modified on 4/15/2024 (ceg). (Entered: 04/15/2024) (5) |
| Apr 12, 2024 | 523 | ORAL ORDER: Having reviewed the parties' joint letter regarding their request to send out a juror questionnaire (D.I. 522 ), IT IS ORDERED THAT the request is DENIED. The Court does not see a reason to burden the prospective jurors with an additional questionnaire; the Court's voir dire will cover most if not all of the same subjects. Ordered by Judge Jennifer L. Hall on 4/12/2024. (ceg) (Entered: 04/12/2024) (0) |
| Apr 12, 2024 | 524 | NOTICE OF SERVICE of Section 282 Notice filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 04/12/2024) (5) |
| Apr 12, 2024 | 525 | ORAL ORDER: Having been recently reassigned this case, and it appearing from the docket that (i) the case is set for trial on May 13, 2024, (ii) there are more than 20 pending motions on the docket (some with multiple subparts), as well as pending objections to the orders of the Special Master, (iii) discovery has closed since some of the motions were filed, and (iv) some claims have been resolved since some of the motions were filed (e.g., D.I. 475, 498), IT IS ORDERED as follows: by COB April 15, 2024, the parties must file a letter listing (a) all claims and defenses that remain in the case, including for any patent claims, the patents and claims at issue, (b) the motions that still need to be resolved by the Court, and (c) the portions of any pending motions (including page numbers) that may be disregarded by the Court because the issues they pertain to have been resolved. The Court may thereafter hold a status conference. The parties are advised that it is unlikely that they will be afforded seven trial days. Signed by Judge Jennifer L. Hall on 4/12/24. (jlh) (Entered: 04/12/2024) (0) |
| Apr 10, 2024 | 522 | Joint Letter to The Honorable Jennifer L. Hall from Megan E. Dellinger Requesting Juror Questionnaire. (Attachments: # 1 Exhibit 1)(Dellinger, Megan) (Entered: 04/10/2024) (0) |
| Apr 3, 2024 | 519 | MOTION for Pro Hac Vice Appearance of Attorney Michele D. Johnson and Bornali Rashmi Borah - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 04/03/2024) (5) |
| Apr 3, 2024 | 520 | Pro Hac Vice Fee - Credit Card Payment received for Michele D. Johnson and Bornali Rashmi Borah. ( re 519 MOTION for Pro Hac Vice Appearance of Attorney Michele D. Johnson and Bornali Rashmi Borah )( Payment of $ 100, receipt number ADEDC-4376609).(Dellinger, Megan) (Entered: 04/03/2024) (0) |
| Apr 3, 2024 | 521 | NOTICE of Change of Address for Will Orlady by Sarepta Therapeutics, Inc. (Dellinger, Megan) (Entered: 04/03/2024) (3) |
| Apr 2, 2024 | 518 | STATEMENT re 517 Notice (Other), [NS's Response to Sarepta's Notice of Subsequent Authority] by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 04/02/2024) (4) |
| Mar 28, 2024 | 517 | NOTICE of Subsequent Authority by Sarepta Therapeutics, Inc., The University of Western Australia re 300 Letter, 384 MOTION to Strike Dr. Matthew Wood's Expert Reports, 298 Letter (Attachments: # 1 Exhibit A)(Dellinger, Megan) (Entered: 03/28/2024) (0) |
| Mar 20, 2024 | 516 | SO ORDERED, re 515 Joint Stipulation Amending Stipulated Protective Order. Signed by Judge Jennifer L. Hall on 3/20/2024. (ceg) (Entered: 03/20/2024) (2) |
| Mar 19, 2024 | 515 | Joint STIPULATION Amending Stipulated Protective Order, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) Modified on 3/19/2024 (ceg). (Entered: 03/19/2024) (2) |
| Mar 11, 2024 | 511 | MOTION for Pro Hac Vice Appearance of Attorney Will Orlady - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 03/11/2024) (4) |
| Mar 11, 2024 | 512 | Pro Hac Vice Fee - Credit Card Payment received for Will Orlady. ( re 511 MOTION for Pro Hac Vice Appearance of Attorney Will Orlady )( Payment of $ 50, receipt number ADEDC-4357893).(Dellinger, Megan) (Entered: 03/11/2024) (0) |
| Mar 11, 2024 | 513 | MOTION for Pro Hac Vice Appearance of Attorney Jason C. White - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) (Entered: 03/11/2024) (0) |
| Mar 11, 2024 | 514 | Pro Hac Vice Fee - Credit Card Payment received for Jason C. White. ( re 513 MOTION for Pro Hac Vice Appearance of Attorney Jason C. White )( Payment of $ 50, receipt number ADEDC-4358264).(Dudash, Amy) (Entered: 03/11/2024) (0) |
| Feb 21, 2024 | 510 | SO ORDERED, re 509 Stipulation and Order Regarding Authenticity. Signed by Judge Jennifer L. Hall on 2/21/2024. (ceg) (Entered: 02/21/2024) (2) |
| Feb 14, 2024 | 509 | STIPULATION and [Proposed] Order Regarding Authenticity by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 02/14/2024) (2) |
| Feb 2, 2024 | 499 | REDACTED VERSION of 493 Reply Brief,, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 02/02/2024) (30) |
| Feb 2, 2024 | 500 | REDACTED VERSION of 494 Reply Brief, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 02/02/2024) (10) |
| Feb 2, 2024 | 501 | REDACTED VERSION of 495 Statement by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 02/02/2024) (16) |
| Feb 2, 2024 | 502 | REDACTED VERSION of 496 Declaration, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit 60, # 2 Exhibit 61, # 3 Exhibit 62)(Dudash, Amy) (Entered: 02/02/2024) (0) |
| Feb 2, 2024 | 503 | REQUEST for Oral Argument by Sarepta Therapeutics, Inc., The University of Western Australia re 394 MOTION to Preclude Doctrine of Equivalents Opinions and Testimony of Dr. Nathan W. Luedtke, 391 MOTION to Preclude Inequitable Conduct Opinions and Testimony from Scott E. Kamholz, Esq., 408 MOTION for Partial Summary Judgment No. 4 Regarding No Anticipation, 405 MOTION for Partial Summary Judgment No. 3 Regarding Breach of Contract Claim, 396 MOTION for Summary Judgment of Infringement of U.S. Patent Nos. 9,994,851 and 10,227,590 (Motion #1), 397 MOTION for Summary Judgment of Lost Profits (Motion #2), 402 MOTION for Partial Summary Judgment No. 2 Regarding Infringement of Certain NS Patents, 393 MOTION to Preclude Certain Opinions and Testimony of Drs. Christine C. Esau, Michelle L. Hastings, and Matthew J.A. Wood, 423 MOTION Daubert Motion to Exclude Testimony and Opinions of Andrew Hirshfeld , 398 MOTION for Summary Judgment of No Inequitable Conduct and No Walker Process Faud Relating to U.S. Patent Nos. 9,994,851; 10,227,590; and 10,266,827 (Motion #3), 419 MOTION Daubert Motion to Exclude Testimony and Opinions of Steven F. Dowdy, Ph.D. , 392 MOTION to Preclude Noninfringement Opinions and Testimony of Dr. Christine C. Esau, 414 MOTION for Partial Summary Judgment No. 5 Regarding No Inequitable Conduct, 399 MOTION for Summary Judgment No. 1 Regarding Invalidity of the UWA Patents. (Dellinger, Megan) (Entered: 02/02/2024) (4) |
| Feb 2, 2024 | 504 | REQUEST for Oral Argument by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd. re 394 MOTION to Preclude Doctrine of Equivalents Opinions and Testimony of Dr. Nathan W. Luedtke, 391 MOTION to Preclude Inequitable Conduct Opinions and Testimony from Scott E. Kamholz, Esq., 408 MOTION for Partial Summary Judgment No. 4 Regarding No Anticipation, 405 MOTION for Partial Summary Judgment No. 3 Regarding Breach of Contract Claim, 396 MOTION for Summary Judgment of Infringement of U.S. Patent Nos. 9,994,851 and 10,227,590 (Motion #1), 402 MOTION for Partial Summary Judgment No. 2 Regarding Infringement of Certain NS Patents, 397 MOTION for Summary Judgment of Lost Profits (Motion #2), 393 MOTION to Preclude Certain Opinions and Testimony of Drs. Christine C. Esau, Michelle L. Hastings, and Matthew J.A. Wood, 423 MOTION Daubert Motion to Exclude Testimony and Opinions of Andrew Hirshfeld , 398 MOTION for Summary Judgment of No Inequitable Conduct and No Walker Process Faud Relating to U.S. Patent Nos. 9,994,851; 10,227,590; and 10,266,827 (Motion #3), 419 MOTION Daubert Motion to Exclude Testimony and Opinions of Steven F. Dowdy, Ph.D. , 392 MOTION to Preclude Noninfringement Opinions and Testimony of Dr. Christine C. Esau, 414 MOTION for Partial Summary Judgment No. 5 Regarding No Inequitable Conduct, 399 MOTION for Summary Judgment No. 1 Regarding Invalidity of the UWA Patents. (Dudash, Amy) (Entered: 02/02/2024) (2) |
| Feb 2, 2024 | 505 | REDACTED VERSION of 489 Reply Brief, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) Modified on 2/2/2024 (ceg). (Entered: 02/02/2024) (14) |
| Feb 2, 2024 | 506 | REDACTED VERSION of 490 Reply Brief, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) Modified on 2/2/2024 (ceg). (Entered: 02/02/2024) (25) |
| Feb 2, 2024 | 507 | REDACTED VERSION of 491 Statement, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) Modified on 2/2/2024 (ceg). (Entered: 02/02/2024) (14) |
| Feb 2, 2024 | 508 | REDACTED VERSION of 492 Declaration, by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 1-15)(Dellinger, Megan) Modified on 2/2/2024 (ceg). (Entered: 02/02/2024) (0) |
| Jan 29, 2024 | 498 | SO ORDERED, re 497 Stipulation of Partial Dismissal re 86 Amended Complaint. Signed by Judge Jennifer L. Hall on 1/29/2024. (ceg) (Entered: 01/29/2024) (2) |
| Jan 26, 2024 | 489 | [SEALED] REPLY BRIEF re 394 MOTION to Preclude Doctrine of Equivalents Opinions and Testimony of Dr. Nathan W. Luedtke, 391 MOTION to Preclude Inequitable Conduct Opinions and Testimony from Scott E. Kamholz, Esq., 393 MOTION to Preclude Certain Opinions and Testimony of Drs. Christine C. Esau, Michelle L. Hastings, and Matthew J.A. Wood, 392 MOTION to Preclude Noninfringement Opinions and Testimony of Dr. Christine C. Esau filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 01/26/2024) (0) |
| Jan 26, 2024 | 490 | [SEALED] REPLY BRIEF re 397 MOTION for Summary Judgment of Lost Profits (Motion #2), 398 MOTION for Summary Judgment of No Inequitable Conduct and No Walker Process Faud Relating to U.S. Patent Nos. 9,994,851; 10,227,590; and 10,266,827 (Motion #3), 396 MOTION for Summary Judgment of Infringement of U.S. Patent Nos. 9,994,851 and 10,227,590 (Motion #1) filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 01/26/2024) (0) |
| Jan 26, 2024 | 491 | [SEALED] STATEMENT re 490 Reply Brief,, --Response to NS's Concise Statement of Facts-- by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 01/26/2024) (0) |
| Jan 26, 2024 | 492 | [SEALED] DECLARATION re 490 Reply Brief,, 489 Reply Brief,, --Declaration of Megan E. Dellinger -- by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibit 1 - Luedtke Tr., # 2 Exhibit 2 - Fletcher Tr., # 3 Exhibit 3 - Mandragouras Tr., # 4 Exhibit 4 - Gendron Tr., # 5 Exhibit 5 - Adams Tr., # 6 Exhibit. 6 - Wilton Tr, # 7 Exhibit 7 - Toda Tr., # 8 Exhibit 8 - Wilton Depo. Exhibit 1, # 9 Exhibit 9 - Toda 36, # 10 Exhibit 10 - Toda 36A, # 11 Exhibit 11 - SRPT-VYDS-0228972-75, # 12 Exhibit 12 - EIS PTC Excerpt, # 13 Exhibit 13 - SRPT-VYDS-0091229 - 15-274,772 FH, # 14 Exhibit 14 - SRPT-VYDS-0123193 - 14-740,097 FH, # 15 Exhibit 15 - SRPT-VYDS-0130130 - 13-741,150 FH)(Dellinger, Megan) (Entered: 01/26/2024) (0) |
| Jan 26, 2024 | 493 | [SEALED] REPLY BRIEF re 402 MOTION for Partial Summary Judgment No. 2 Regarding Infringement of Certain NS Patents, 408 MOTION for Partial Summary Judgment No. 4 Regarding No Anticipation, 414 MOTION for Partial Summary Judgment No. 5 Regarding No Inequitable Conduct, 405 MOTION for Partial Summary Judgment No. 3 Regarding Breach of Contract Claim, 399 MOTION for Summary Judgment No. 1 Regarding Invalidity of the UWA Patents filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/26/2024) (0) |
| Jan 26, 2024 | 494 | [SEALED] REPLY BRIEF re 423 MOTION Daubert Motion to Exclude Testimony and Opinions of Andrew Hirshfeld , 419 MOTION Daubert Motion to Exclude Testimony and Opinions of Steven F. Dowdy, Ph.D. filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/26/2024) (0) |
| Jan 26, 2024 | 495 | [SEALED] STATEMENT re 470 Statement, NS's Responses to Sarepta Therapeutics, Inc. and The University of Western Australia's Responsive Concise Statement of Facts by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/26/2024) (0) |
| Jan 26, 2024 | 496 | [SEALED] DECLARATION re 493 Reply Brief,, 494 Reply Brief, 495 Statement Declaration of Amy M. Dudash by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit 60 - Steven F. Dowdy, Ph.D. Depo Excerpts, # 2 Exhibit 61 - Markman Hearing Transcript Excerpts, # 3 Exhibit 62 - Naoki Watanabe Vol 2 Dep Excerpts)(Dudash, Amy) (Entered: 01/26/2024) (0) |
| Jan 26, 2024 | 497 | Joint STIPULATION of Partial Dismissal re 86 Amended Complaint by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/26/2024) (2) |
| Jan 19, 2024 | 476 | REDACTED VERSION of 456 Answering Brief in Opposition, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/19/2024) (8) |
| Jan 19, 2024 | 477 | REDACTED VERSION of 458 Answering Brief in Opposition, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/19/2024) (9) |
| Jan 19, 2024 | 478 | REDACTED VERSION of 459 Answering Brief in Opposition, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/19/2024) (7) |
| Jan 19, 2024 | 479 | REDACTED VERSION of 462 Answering Brief in Opposition by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/19/2024) (20) |
| Jan 19, 2024 | 480 | REDACTED VERSION of 463 Statement, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/19/2024) (7) |
| Jan 19, 2024 | 481 | REDACTED VERSION of 464 Answering Brief in Opposition, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/19/2024) (15) |
| Jan 19, 2024 | 482 | REDACTED VERSION of 465 Statement, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/19/2024) (7) |
| Jan 19, 2024 | 483 | REDACTED VERSION of 466 Statement by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/19/2024) (21) |
| Jan 19, 2024 | 484 | REDACTED VERSION of 468 Declaration,,, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit 38, # 2 Exhibit 39, # 3 Exhibit 40, # 4 Exhibit 41, # 5 Exhibit 42, # 6 Exhibit 43, # 7 Exhibit 44, # 8 Exhibit 45, # 9 Exhibit 46, # 10 Exhibit 47, # 11 Exhibit 48, # 12 Exhibit 49, # 13 Exhibit 50, # 14 Exhibit 51, # 15 Exhibit 52, # 16 Exhibit 53, # 17 Exhibit 54, # 18 Exhibit 55, # 19 Exhibit 56, # 20 Exhibit 57, # 21 Exhibit 58, # 22 Exhibit 59)(Dudash, Amy) (Entered: 01/19/2024) (0) |
| Jan 19, 2024 | 485 | REDACTED VERSION of 467 Answering Brief in Opposition, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 01/19/2024) (20) |
| Jan 19, 2024 | 486 | REDACTED VERSION of 469 Answering Brief in Opposition,, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 01/19/2024) (30) |
| Jan 19, 2024 | 487 | REDACTED VERSION of 470 Statement, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 01/19/2024) (30) |
| Jan 19, 2024 | 488 | REDACTED VERSION of 471 Declaration, by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exs. 1-4, # 2 Exs. 5-10, # 3 Ex. 11, # 4 Ex. 12, # 5 Exs. 13-16, # 6 Ex. 17, # 7 Exs. 18-23)(Dellinger, Megan) (Entered: 01/19/2024) (0) |
| Jan 17, 2024 | 475 | SO ORDERED, re 455 Joint Stipulation Regarding Dismissal of Certain Claims and Defenses. Signed by Judge Jennifer L. Hall on 1/17/2024. (ceg) (Entered: 01/17/2024) (3) |
| Jan 16, 2024 | 474 | CERTIFICATE OF SERVICE of NS's Response to Daubert Motion No. 1 to Exclude Testimony and Opinions of Scott E. Kamholz by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd. re 456 Answering Brief in Opposition, (Dudash, Amy) (Entered: 01/16/2024) (2) |
| Jan 12, 2024 | 456 | ANSWERING BRIEF in Opposition re 391 MOTION to Preclude Inequitable Conduct Opinions and Testimony from Scott E. Kamholz, Esq. filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Reply Brief due date per Local Rules is 1/19/2024. (Dudash, Amy) (Entered: 01/12/2024) (0) |
| Jan 12, 2024 | 457 | ANSWERING BRIEF in Opposition re 392 MOTION to Preclude Noninfringement Opinions and Testimony of Dr. Christine C. Esau filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Reply Brief due date per Local Rules is 1/19/2024. (Dudash, Amy) (Entered: 01/12/2024) (4) |
| Jan 12, 2024 | 458 | [SEALED] ANSWERING BRIEF in Opposition re 393 MOTION to Preclude Certain Opinions and Testimony of Drs. Christine C. Esau, Michelle L. Hastings, and Matthew J.A. Wood filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Reply Brief due date per Local Rules is 1/19/2024. (Dudash, Amy) (Entered: 01/12/2024) (0) |
| Jan 12, 2024 | 459 | [SEALED] ANSWERING BRIEF in Opposition re 394 MOTION to Preclude Doctrine of Equivalents Opinions and Testimony of Dr. Nathan W. Luedtke filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Reply Brief due date per Local Rules is 1/19/2024. (Dudash, Amy) (Entered: 01/12/2024) (0) |
| Jan 12, 2024 | 460 | ANSWERING BRIEF in Opposition re 396 MOTION for Summary Judgment of Infringement of U.S. Patent Nos. 9,994,851 and 10,227,590 (Motion #1) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Reply Brief due date per Local Rules is 1/19/2024. (Dudash, Amy) (Entered: 01/12/2024) (14) |
| Jan 12, 2024 | 461 | STATEMENT re 460 Answering Brief in Opposition, [Statement of Facts in Support of Its Response to Sarepta and UWA's Motion for Summary Judgment of Infringement of U.S. Patent Nos. 9,994,851 and 10,227,590 (Motion #1) by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/12/2024) (2) |
| Jan 12, 2024 | 462 | [SEALED] ANSWERING BRIEF in Opposition re 397 MOTION for Summary Judgment of Lost Profits (Motion #2) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Reply Brief due date per Local Rules is 1/19/2024. (Dudash, Amy) (Entered: 01/12/2024) (0) |
| Jan 12, 2024 | 463 | [SEALED] STATEMENT re 462 Answering Brief in Opposition [Statement of Facts in Support of Its Opposition to Defendants' Motion for Summary Judgment of Lost Profits (Motion #2)] by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/12/2024) (0) |
| Jan 12, 2024 | 464 | [SEALED] ANSWERING BRIEF in Opposition re 398 MOTION for Summary Judgment of No Inequitable Conduct and No Walker Process Faud Relating to U.S. Patent Nos. 9,994,851; 10,227,590; and 10,266,827 (Motion #3) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Reply Brief due date per Local Rules is 1/19/2024. (Dudash, Amy) (Entered: 01/12/2024) (0) |
| Jan 12, 2024 | 465 | [SEALED] STATEMENT re 464 Answering Brief in Opposition, [Statement of Facts in Support of Its Response to Sarepta and UWA's Motion for Summary Judgment of No Inequitable Conduct and No Walker Process Faud Relating to U.S. Patent Nos. 9,994,851; 10,227,590; and 10,266,827 (Motion #3)] by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/12/2024) (0) |
| Jan 12, 2024 | 466 | [SEALED] STATEMENT re 411 Statement,, [NS Responses to Concise Statement of Facts in Support of Sarepta and UWA's Motions for Summary Judgment] by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/12/2024) (0) |
| Jan 12, 2024 | 467 | [SEALED] ANSWERING BRIEF in Opposition re 423 MOTION Daubert Motion to Exclude Testimony and Opinions of Andrew Hirshfeld , 419 MOTION Daubert Motion to Exclude Testimony and Opinions of Steven F. Dowdy, Ph.D. filed by Sarepta Therapeutics, Inc., The University of Western Australia.Reply Brief due date per Local Rules is 1/19/2024. (Dellinger, Megan) (Entered: 01/12/2024) (0) |
| Jan 12, 2024 | 468 | [SEALED] DECLARATION re 464 Answering Brief in Opposition, 458 Answering Brief in Opposition, 456 Answering Brief in Opposition, 460 Answering Brief in Opposition, 459 Answering Brief in Opposition, 457 Answering Brief in Opposition, 462 Answering Brief in Opposition of Amy M. Dudash by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit 38, # 2 Exhibit 39, # 3 Exhibit 40, # 4 Exhibit 41, # 5 Exhibit 42, # 6 Exhibit 43, # 7 Exhibit 44, # 8 Exhibit 45, # 9 Exhibit 46, # 10 Exhibit 47, # 11 Exhibit 48, # 12 Exhibit 49, # 13 Exhibit 50, # 14 Exhibit 51, # 15 Exhibit 52, # 16 Exhibit 53, # 17 Exhibit 54, # 18 Exhibit 55, # 19 Exhibit 56, # 20 Exhibit 57, # 21 Exhibit 58, # 22 Exhibit 59)(Dudash, Amy) (Entered: 01/12/2024) (0) |
| Jan 12, 2024 | 469 | [SEALED] ANSWERING BRIEF in Opposition re 402 MOTION for Partial Summary Judgment No. 2 Regarding Infringement of Certain NS Patents, 408 MOTION for Partial Summary Judgment No. 4 Regarding No Anticipation, 414 MOTION for Partial Summary Judgment No. 5 Regarding No Inequitable Conduct, 405 MOTION for Partial Summary Judgment No. 3 Regarding Breach of Contract Claim, 399 MOTION for Summary Judgment No. 1 Regarding Invalidity of the UWA Patents filed by Sarepta Therapeutics, Inc., The University of Western Australia.Reply Brief due date per Local Rules is 1/19/2024. (Dellinger, Megan) (Entered: 01/12/2024) (0) |
| Jan 12, 2024 | 470 | [SEALED] STATEMENT re 412 Statement, 404 Statement, 416 Statement, 407 Statement, 401 Statement, -- Responsive Concise Statement of Facts in Support of Sarepta Therapeutics, Inc. and The University of Western Australia's Opposition to NS's Motions for Summary Judgment -- by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 01/12/2024) (0) |
| Jan 12, 2024 | 471 | [SEALED] DECLARATION re 467 Answering Brief in Opposition, 469 Answering Brief in Opposition,, -- Declaration of Megan E. Dellinger -- by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 1-4, # 2 Exhibits 5-10, # 3 Exhibit 11, # 4 Exhibit 12, # 5 Exhibits 13-16, # 6 Exhibit 17, # 7 Exhibits 18-23)(Dellinger, Megan) (Entered: 01/12/2024) (0) |
| Jan 12, 2024 | 472 | DECLARATION of Steven F. Dowdy, Ph.D. by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 01/12/2024) (3) |
| Jan 12, 2024 | 473 | DECLARATION of John C. Jarosz by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 01/12/2024) (3) |
| Jan 8, 2024 | 455 | Joint STIPULATION Regarding Dismissal of Certain Claims and Defenses by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 01/08/2024) (3) |
| Dec 20, 2023 | 454 | NOTICE OF SERVICE of Sarepta Therapeutics, Inc.'s First Set of Authentication Requests for Admission (Nos. A1-A389) filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 12/20/2023) (5) |
| Dec 18, 2023 | 429 | REDACTED VERSION of 395 Opening Brief in Support,, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 12/18/2023) (28) |
| Dec 18, 2023 | 430 | REDACTED VERSION of 409 Opening Brief in Support,, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 12/18/2023) (30) |
| Dec 18, 2023 | 431 | REDACTED VERSION of 411 Statement,, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 12/18/2023) (21) |
| Dec 18, 2023 | 432 | REDACTED VERSION of 413 Declaration,, by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits A-B)(Dellinger, Megan) (Entered: 12/18/2023) (0) |
| Dec 18, 2023 | 433 | REDACTED VERSION of 417 Declaration,,,, by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 1-2, # 2 Exhibits 3-4, # 3 Exhibit 5, # 4 Exhibit 6, # 5 Exhibit 7, # 6 Exhibit 8)(Dellinger, Megan) (Entered: 12/18/2023) (0) |
| Dec 18, 2023 | 434 | REDACTED VERSION of 418 Declaration,,, by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibit 9, # 2 Exhibit 10-13, # 3 Exhibit 14 (part 1))(Dellinger, Megan) (Entered: 12/18/2023) (0) |
| Dec 18, 2023 | 435 | REDACTED VERSION of 420 Declaration,,, by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibit 14 (part 2), # 2 Exhibit 15)(Dellinger, Megan) (Entered: 12/18/2023) (0) |
| Dec 18, 2023 | 436 | REDACTED VERSION of 422 Declaration,,, by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 16-22)(Dellinger, Megan) (Entered: 12/18/2023) (0) |
| Dec 18, 2023 | 437 | REDACTED VERSION of 425 Declaration,,, by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 23-50)(Dellinger, Megan) (Entered: 12/18/2023) (0) |
| Dec 18, 2023 | 438 | REDACTED VERSION of 426 Declaration,,, by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 51-64)(Dellinger, Megan) (Entered: 12/18/2023) (0) |
| Dec 18, 2023 | 439 | REDACTED VERSION of 389 Letter by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 1-2)(Dellinger, Megan) (Entered: 12/18/2023) (0) |
| Dec 18, 2023 | 440 | REDACTED VERSION of 400 Opening Brief in Support, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/18/2023) (28) |
| Dec 18, 2023 | 441 | REDACTED VERSION of 401 Statement, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/18/2023) (8) |
| Dec 18, 2023 | 442 | REDACTED VERSION of 403 Opening Brief in Support, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/18/2023) (8) |
| Dec 18, 2023 | 443 | REDACTED VERSION of 404 Statement, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/18/2023) (7) |
| Dec 18, 2023 | 444 | REDACTED VERSION of 406 Opening Brief in Support, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/18/2023) (10) |
| Dec 18, 2023 | 445 | REDACTED VERSION of 407 Statement, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/18/2023) (5) |
| Dec 18, 2023 | 446 | REDACTED VERSION of 410 Opening Brief in Support, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/18/2023) (8) |
| Dec 18, 2023 | 447 | REDACTED VERSION of 412 Statement, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/18/2023) (2) |
| Dec 18, 2023 | 448 | REDACTED VERSION of 415 Opening Brief in Support, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/18/2023) (9) |
| Dec 18, 2023 | 449 | REDACTED VERSION of 416 Statement, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/18/2023) (4) |
| Dec 18, 2023 | 450 | REDACTED VERSION of 421 Opening Brief in Support, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/18/2023) (13) |
| Dec 18, 2023 | 451 | REDACTED VERSION of 424 Opening Brief in Support, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/18/2023) (7) |
| Dec 18, 2023 | 452 | REDACTED VERSION of 427 Declaration,,,,,,,,,,, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12, # 13 Exhibit 13, # 14 Exhibit 14, # 15 Exhibit 15, # 16 Exhibit 16, # 17 Exhibit 17, # 18 Exhibit 18, # 19 Exhibit 19, # 20 Exhibit 20, # 21 Exhibit 21, # 22 Exhibit 22, # 23 Exhibit 23, # 24 Exhibit 24, # 25 Exhibit 25, # 26 Exhibit 26, # 27 Exhibit 27, # 28 Exhibit 28)(Dudash, Amy) (Entered: 12/18/2023) (0) |
| Dec 18, 2023 | 453 | REDACTED VERSION of 428 Exhibit to a Document,,,,, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit 29 Part 1, # 2 Exhibit 29 Part 2, # 3 Exhibit 29 Part 3, # 4 Exhibit 29 Part 4, # 5 Exhibit 29 Part 5, # 6 Exhibit 29 Part 6, # 7 Exhibit 30-35, # 8 Exhibit 36-37)(Dudash, Amy) (Entered: 12/18/2023) (0) |
| Dec 11, 2023 | 389 | [SEALED] Letter to The Honorable Gregory B. Williams from Megan E. Dellinger regarding motion to strike - re 384 MOTION to Strike Dr. Matthew Wood's Expert Reports. (Attachments: # 1 Exhibits 1-2)(Dellinger, Megan) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 390 | Letter to The Honorable Gregory B. Williams from Megan E. Dellinger regarding request for teleconference - re 384 MOTION to Strike Dr. Matthew Wood's Expert Reports. (Dellinger, Megan) (Entered: 12/11/2023) (1) |
| Dec 11, 2023 | 391 | MOTION to Preclude Inequitable Conduct Opinions and Testimony from Scott E. Kamholz, Esq. - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 12/11/2023) (7) |
| Dec 11, 2023 | 392 | MOTION to Preclude Noninfringement Opinions and Testimony of Dr. Christine C. Esau - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 12/11/2023) (7) |
| Dec 11, 2023 | 393 | MOTION to Preclude Certain Opinions and Testimony of Drs. Christine C. Esau, Michelle L. Hastings, and Matthew J.A. Wood - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 12/11/2023) (7) |
| Dec 11, 2023 | 394 | MOTION to Preclude Doctrine of Equivalents Opinions and Testimony of Dr. Nathan W. Luedtke - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 12/11/2023) (7) |
| Dec 11, 2023 | 395 | [SEALED] OPENING BRIEF in Support re 394 MOTION to Preclude Doctrine of Equivalents Opinions and Testimony of Dr. Nathan W. Luedtke, 391 MOTION to Preclude Inequitable Conduct Opinions and Testimony from Scott E. Kamholz, Esq., 393 MOTION to Preclude Certain Opinions and Testimony of Drs. Christine C. Esau, Michelle L. Hastings, and Matthew J.A. Wood, 392 MOTION to Preclude Noninfringement Opinions and Testimony of Dr. Christine C. Esau filed by Sarepta Therapeutics, Inc., The University of Western Australia.Answering Brief/Response due date per Local Rules is 12/26/2023. (Dellinger, Megan) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 396 | MOTION for Summary Judgment of Infringement of U.S. Patent Nos. 9,994,851 and 10,227,590 (Motion #1) - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 12/11/2023) (6) |
| Dec 11, 2023 | 397 | MOTION for Summary Judgment of Lost Profits (Motion #2) - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 12/11/2023) (6) |
| Dec 11, 2023 | 398 | MOTION for Summary Judgment of No Inequitable Conduct and No Walker Process Faud Relating to U.S. Patent Nos. 9,994,851; 10,227,590; and 10,266,827 (Motion #3) - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 12/11/2023) (6) |
| Dec 11, 2023 | 399 | MOTION for Summary Judgment No. 1 Regarding Invalidity of the UWA Patents - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Text of Proposed Order)(Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 400 | [SEALED] OPENING BRIEF in Support re 399 MOTION for Summary Judgment No. 1 Regarding Invalidity of the UWA Patents filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Answering Brief/Response due date per Local Rules is 12/26/2023. (Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 401 | [SEALED] STATEMENT re 400 Opening Brief in Support, 399 MOTION for Summary Judgment No. 1 Regarding Invalidity of the UWA Patents (Concise Statement of Facts in Support of) by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 402 | MOTION for Partial Summary Judgment No. 2 Regarding Infringement of Certain NS Patents - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Text of Proposed Order)(Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 403 | [SEALED] OPENING BRIEF in Support re 402 MOTION for Partial Summary Judgment No. 2 Regarding Infringement of Certain NS Patents filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Answering Brief/Response due date per Local Rules is 12/26/2023. (Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 404 | [SEALED] STATEMENT re 402 MOTION for Partial Summary Judgment No. 2 Regarding Infringement of Certain NS Patents, 403 Opening Brief in Support, (Concise Statement of Facts in Support of) by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 405 | MOTION for Partial Summary Judgment No. 3 Regarding Breach of Contract Claim - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Text of Proposed Order)(Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 406 | [SEALED] OPENING BRIEF in Support re 405 MOTION for Partial Summary Judgment No. 3 Regarding Breach of Contract Claim filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Answering Brief/Response due date per Local Rules is 12/26/2023. (Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 407 | [SEALED] STATEMENT re 406 Opening Brief in Support, 405 MOTION for Partial Summary Judgment No. 3 Regarding Breach of Contract Claim (Concise Statement of Facts in Support of) by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 408 | MOTION for Partial Summary Judgment No. 4 Regarding No Anticipation - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Text of Proposed Order)(Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 409 | [SEALED] OPENING BRIEF in Support re 397 MOTION for Summary Judgment of Lost Profits (Motion #2), 398 MOTION for Summary Judgment of No Inequitable Conduct and No Walker Process Faud Relating to U.S. Patent Nos. 9,994,851; 10,227,590; and 10,266,827 (Motion #3), 396 MOTION for Summary Judgment of Infringement of U.S. Patent Nos. 9,994,851 and 10,227,590 (Motion #1) filed by Sarepta Therapeutics, Inc., The University of Western Australia.Answering Brief/Response due date per Local Rules is 12/26/2023. (Dellinger, Megan) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 410 | [SEALED] OPENING BRIEF in Support re 408 MOTION for Partial Summary Judgment No. 4 Regarding No Anticipation filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Answering Brief/Response due date per Local Rules is 12/26/2023. (Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 411 | [SEALED] STATEMENT re 397 MOTION for Summary Judgment of Lost Profits (Motion #2), 398 MOTION for Summary Judgment of No Inequitable Conduct and No Walker Process Faud Relating to U.S. Patent Nos. 9,994,851; 10,227,590; and 10,266,827 (Motion #3), 396 MOTION for Summary Judgment of Infringement of U.S. Patent Nos. 9,994,851 and 10,227,590 (Motion #1) by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 412 | [SEALED] STATEMENT re 410 Opening Brief in Support, 408 MOTION for Partial Summary Judgment No. 4 Regarding No Anticipation (Concise Statement of Facts in Support of) by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 413 | [SEALED] DECLARATION re 393 MOTION to Preclude Certain Opinions and Testimony of Drs. Christine C. Esau, Michelle L. Hastings, and Matthew J.A. Wood, 398 MOTION for Summary Judgment of No Inequitable Conduct and No Walker Process Faud Relating to U.S. Patent Nos. 9,994,851; 10,227,590; and 10,266,827 (Motion #3) --Declaration of Steven F. Dowdy, Ph.D.-- by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits A-B)(Dellinger, Megan) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 414 | MOTION for Partial Summary Judgment No. 5 Regarding No Inequitable Conduct - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Text of Proposed Order)(Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 415 | [SEALED] OPENING BRIEF in Support re 414 MOTION for Partial Summary Judgment No. 5 Regarding No Inequitable Conduct filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Answering Brief/Response due date per Local Rules is 12/26/2023. (Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 416 | [SEALED] STATEMENT re 415 Opening Brief in Support, 414 MOTION for Partial Summary Judgment No. 5 Regarding No Inequitable Conduct (Concise Statement of Facts in Support of) by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 417 | [SEALED] DECLARATION re 394 MOTION to Preclude Doctrine of Equivalents Opinions and Testimony of Dr. Nathan W. Luedtke, 396 MOTION for Summary Judgment of Infringement of U.S. Patent Nos. 9,994,851 and 10,227,590 (Motion #1), 397 MOTION for Summary Judgment of Lost Profits (Motion #2), 393 MOTION to Preclude Certain Opinions and Testimony of Drs. Christine C. Esau, Michelle L. Hastings, and Matthew J.A. Wood, 398 MOTION for Summary Judgment of No Inequitable Conduct and No Walker Process Faud Relating to U.S. Patent Nos. 9,994,851; 10,227,590; and 10,266,827 (Motion #3), 392 MOTION to Preclude Noninfringement Opinions and Testimony of Dr. Christine C. Esau --Declaration of Megan E. Dellinger (Volume 1)-- by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 1-2, # 2 Exhibits 3-4, # 3 Exhibit 5, # 4 Exhibit 6, # 5 Exhibit 7, # 6 Exhibit 8)(Dellinger, Megan) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 418 | [SEALED] DECLARATION re 394 MOTION to Preclude Doctrine of Equivalents Opinions and Testimony of Dr. Nathan W. Luedtke, 396 MOTION for Summary Judgment of Infringement of U.S. Patent Nos. 9,994,851 and 10,227,590 (Motion #1), 397 MOTION for Summary Judgment of Lost Profits (Motion #2), 393 MOTION to Preclude Certain Opinions and Testimony of Drs. Christine C. Esau, Michelle L. Hastings, and Matthew J.A. Wood, 398 MOTION for Summary Judgment of No Inequitable Conduct and No Walker Process Faud Relating to U.S. Patent Nos. 9,994,851; 10,227,590; and 10,266,827 (Motion #3), 392 MOTION to Preclude Noninfringement Opinions and Testimony of Dr. Christine C. Esau --Declaration of Megan E. Dellinger (Volume 2)-- by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibit 9, # 2 Exhibits 10-13, # 3 Exhibit 14 (part 1))(Dellinger, Megan) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 419 | MOTION Daubert Motion to Exclude Testimony and Opinions of Steven F. Dowdy, Ph.D. - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Text of Proposed Order)(Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 420 | [SEALED] DECLARATION re 394 MOTION to Preclude Doctrine of Equivalents Opinions and Testimony of Dr. Nathan W. Luedtke, 396 MOTION for Summary Judgment of Infringement of U.S. Patent Nos. 9,994,851 and 10,227,590 (Motion #1), 397 MOTION for Summary Judgment of Lost Profits (Motion #2), 393 MOTION to Preclude Certain Opinions and Testimony of Drs. Christine C. Esau, Michelle L. Hastings, and Matthew J.A. Wood, 398 MOTION for Summary Judgment of No Inequitable Conduct and No Walker Process Faud Relating to U.S. Patent Nos. 9,994,851; 10,227,590; and 10,266,827 (Motion #3), 392 MOTION to Preclude Noninfringement Opinions and Testimony of Dr. Christine C. Esau --Declaration of Megan E. Dellinger (Volume 3)-- by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibit 14 (part 2), # 2 Exhibit 15)(Dellinger, Megan) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 421 | [SEALED] OPENING BRIEF in Support re 419 MOTION Daubert Motion to Exclude Testimony and Opinions of Steven F. Dowdy, Ph.D. filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Answering Brief/Response due date per Local Rules is 12/26/2023. (Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 422 | [SEALED] DECLARATION re 397 MOTION for Summary Judgment of Lost Profits (Motion #2), 394 MOTION to Preclude Doctrine of Equivalents Opinions and Testimony of Dr. Nathan W. Luedtke, 393 MOTION to Preclude Certain Opinions and Testimony of Drs. Christine C. Esau, Michelle L. Hastings, and Matthew J.A. Wood, 398 MOTION for Summary Judgment of No Inequitable Conduct and No Walker Process Faud Relating to U.S. Patent Nos. 9,994,851; 10,227,590; and 10,266,827 (Motion #3), 392 MOTION to Preclude Noninfringement Opinions and Testimony of Dr. Christine C. Esau, 396 MOTION for Summary Judgment of Infringement of U.S. Patent Nos. 9,994,851 and 10,227,590 (Motion #1) --Declaration of Megan E. Dellinger (Volume 4)-- by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 16-22)(Dellinger, Megan) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 423 | MOTION Daubert Motion to Exclude Testimony and Opinions of Andrew Hirshfeld - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Text of Proposed Order)(Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 424 | [SEALED] OPENING BRIEF in Support re 423 MOTION Daubert Motion to Exclude Testimony and Opinions of Andrew Hirshfeld filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Answering Brief/Response due date per Local Rules is 12/26/2023. (Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 425 | [SEALED] DECLARATION re 394 MOTION to Preclude Doctrine of Equivalents Opinions and Testimony of Dr. Nathan W. Luedtke, 396 MOTION for Summary Judgment of Infringement of U.S. Patent Nos. 9,994,851 and 10,227,590 (Motion #1), 397 MOTION for Summary Judgment of Lost Profits (Motion #2), 393 MOTION to Preclude Certain Opinions and Testimony of Drs. Christine C. Esau, Michelle L. Hastings, and Matthew J.A. Wood, 398 MOTION for Summary Judgment of No Inequitable Conduct and No Walker Process Faud Relating to U.S. Patent Nos. 9,994,851; 10,227,590; and 10,266,827 (Motion #3), 392 MOTION to Preclude Noninfringement Opinions and Testimony of Dr. Christine C. Esau --Declaration of Megan E. Dellinger (Volume 5)-- by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 23-45, # 2 Exhibits 46-50)(Dellinger, Megan) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 426 | [SEALED] DECLARATION re 397 MOTION for Summary Judgment of Lost Profits (Motion #2), 394 MOTION to Preclude Doctrine of Equivalents Opinions and Testimony of Dr. Nathan W. Luedtke, 393 MOTION to Preclude Certain Opinions and Testimony of Drs. Christine C. Esau, Michelle L. Hastings, and Matthew J.A. Wood, 398 MOTION for Summary Judgment of No Inequitable Conduct and No Walker Process Faud Relating to U.S. Patent Nos. 9,994,851; 10,227,590; and 10,266,827 (Motion #3), 392 MOTION to Preclude Noninfringement Opinions and Testimony of Dr. Christine C. Esau, 396 MOTION for Summary Judgment of Infringement of U.S. Patent Nos. 9,994,851 and 10,227,590 (Motion #1) --Declaration of Megan E. Dellinger (Volume 6)-- by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 51-64)(Dellinger, Megan) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 427 | [SEALED] DECLARATION re 415 Opening Brief in Support, 405 MOTION for Partial Summary Judgment No. 3 Regarding Breach of Contract Claim, 412 Statement, 400 Opening Brief in Support, 414 MOTION for Partial Summary Judgment No. 5 Regarding No Inequitable Conduct, 399 MOTION for Summary Judgment No. 1 Regarding Invalidity of the UWA Patents, 406 Opening Brief in Support, 421 Opening Brief in Support, 403 Opening Brief in Support, 408 MOTION for Partial Summary Judgment No. 4 Regarding No Anticipation, 402 MOTION for Partial Summary Judgment No. 2 Regarding Infringement of Certain NS Patents, 404 Statement, 424 Opening Brief in Support, 410 Opening Brief in Support, 416 Statement, 407 Statement, 401 Statement, 423 MOTION Daubert Motion to Exclude Testimony and Opinions of Andrew Hirshfeld , 419 MOTION Daubert Motion to Exclude Testimony and Opinions of Steven F. Dowdy, Ph.D. by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit 1 - Opening Expert Report of Steven F. Dowdy, Ph.D., # 2 Exhibit 2 - Rebuttal Expert Report of Steven F. Dowdy, Ph.D., # 3 Exhibit 3 - Reply Expert Report of Steven F. Dowdy, Ph.D., # 4 Exhibit 4 - Opening Expert Report of Christine C. Esau, Ph.D., # 5 Exhibit 5 - Expert Report of Dr. Michelle L. Hastings Regarding Invalidity of the UWA Patents, # 6 Exhibit 6 - Responsive Expert Report of Dr. Michelle L. Hastings Regarding the Validity of the NS Patents, # 7 Exhibit 7 - Reply Expert Report of Dr. Michelle L. Hastings Regarding the Invalidity of the UWA Patents, # 8 Exhibit 8 - Expert Report of Andrew H. Hirshfeld, # 9 Exhibit 9 - Expert Rebuttal Report of Andrew H. Hirshfeld, # 10 Exhibit 10 - Rebuttal Expert Report of John C. Jarosz, # 11 Exhibit 11 - Responsive Expert Report of Scott E. Kamholz, Esq., # 12 Exhibit 12 - Opening Expert Report of Stanley Nelson, M.D., # 13 Exhibit 13 - Steven F. Dowdy, Ph.D. Depo Excerpts, # 14 Exhibit 14 - Andrew H. Hirshfeld Depo Excerpts, # 15 Exhibit 15 - Jurjus Jurayj Depo Excerpts, # 16 Exhibit 16 - Amy Mandragouras Depo Excerpts, # 17 Exhibit 17 - Markman Hearing Transcript Excerpts, # 18 Exhibit 18 - Frederick Schnell, Ph.D. Depo Excerpts, # 19 Exhibit 19 - Naoki Watanabe Vol 1 Dep Excerpts, # 20 Exhibit 20 - Naoki Watanabe Vol 2 Dep Excerpts, # 21 Exhibit 21 - Appendix to 1st Suppl Interrog 21 Resp, # 22 Exhibit 22 - Joint Claim Construction Brief for the NS Patents, # 23 Exhibit 23 - UWA Motion 1, Patent Interference No. 106,007, # 24 Exhibit 24 - UWA Reply 1, Patent Interference No. 106,007, # 25 Exhibit 25 - Joint Claim Construction Brief for the Wilton-UWA Patents, # 26 Exhibit 26 - Sareptas Non-Infringement Contentions with- Exs A-1 to A-7, # 27 Exhibit 27 - Sarepta's Resp to Interrog 21, # 28 Exhibit 28 - Patent 99,708,361 FH)(Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 11, 2023 | 428 | [SEALED] EXHIBIT re 406 Opening Brief in Support, 421 Opening Brief in Support, 403 Opening Brief in Support, 415 Opening Brief in Support, 408 MOTION for Partial Summary Judgment No. 4 Regarding No Anticipation, 405 MOTION for Partial Summary Judgment No. 3 Regarding Breach of Contract Claim, 412 Statement, 402 MOTION for Partial Summary Judgment No. 2 Regarding Infringement of Certain NS Patents, 400 Opening Brief in Support, 404 Statement, 424 Opening Brief in Support, 410 Opening Brief in Support, 427 Declaration,,,,,,,,,,, 416 Statement, 407 Statement, 401 Statement, 423 MOTION Daubert Motion to Exclude Testimony and Opinions of Andrew Hirshfeld , 419 MOTION Daubert Motion to Exclude Testimony and Opinions of Steven F. Dowdy, Ph.D. , 414 MOTION for Partial Summary Judgment No. 5 Regarding No Inequitable Conduct, 399 MOTION for Summary Judgment No. 1 Regarding Invalidity of the UWA Patents by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit 29 part 1 - Patent 9,994,851 FH, # 2 Exhibit 29 part 2 - Patent 9,994,851 FH, # 3 Exhibit 29 part 3 - Patent 9,994,851 FH, # 4 Exhibit 29 part 4 - Patent 9,994,851 FH, # 5 Exhibit 29 part 5 - Patent 9,994,851 FH, # 6 Exhibit 29 part 6 - Patent 9,994,851 FH, # 7 Exhibit 30 - 35 Produced Documents, # 8 Exhibit 36 - 37 Produced Documents)(Dudash, Amy) (Entered: 12/11/2023) (0) |
| Dec 7, 2023 | 386 | REDACTED VERSION of 385 Letter by Sarepta Therapeutics, Inc.. (Attachments: # 1 Exhibits 1-4)(Dellinger, Megan) (Entered: 12/07/2023) (0) |
| Dec 7, 2023 | 387 | [SEALED] Letter to The Honorable Gregory B. Williams from Amy M. Dudash regarding Response to Motion to Strike Dr. Matthew J.A. Wood - re 384 MOTION to Strike Dr. Matthew Wood's Expert Reports, 385 Letter. (Dudash, Amy) (Entered: 12/07/2023) (0) |
| Dec 7, 2023 | 388 | [SEALED] EXHIBIT re 387 Letter Response to Motion to Strike Dr. Matthew J.A. Wood by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/07/2023) (0) |
| Nov 30, 2023 | 384 | MOTION to Strike Dr. Matthew Wood's Expert Reports - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 11/30/2023) (5) |
| Nov 30, 2023 | 385 | [SEALED] Letter to The Honorable Gregory B. Williams from Megan E. Dellinger regarding motion to strike - re 384 MOTION to Strike Dr. Matthew Wood's Expert Reports. (Attachments: # 1 Exhibits 1-4)(Dellinger, Megan) (Entered: 11/30/2023) (0) |
| Nov 27, 2023 | 383 | MOTION for Pro Hac Vice Appearance of Attorney Michael A. Morin, David P. Frazier, Rebecca L. Rabenstein, and Ernest Yakob - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Main Document 383 replaced on 11/28/2023) (ntl). Modified on 11/28/2023 (ntl). (Entered: 11/27/2023) (7) |
| Nov 15, 2023 | 382 | NOTICE to Take Deposition of Michelle L. Hastings on November 17, 2023 filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 11/15/2023) (4) |
| Nov 13, 2023 | 381 | NOTICE to Take Deposition of Nathan W. Luedtke, Ph.D. on November 15, 2023 filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 11/13/2023) (4) |
| Nov 8, 2023 | 379 | NOTICE to Take Deposition of Jonathan Strober on November 16, 2023 filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 11/08/2023) (3) |
| Nov 8, 2023 | 380 | MOTION for Pro Hac Vice Appearance of Attorney Jesse Aaron Vella - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 11/08/2023) (4) |
| Nov 2, 2023 | 373 | NOTICE to Take Deposition of Steven F. Dowdy, Ph.D. on November 8, 2023 filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 11/02/2023) (3) |
| Nov 2, 2023 | 374 | NOTICE to Take Deposition of Bradley L. Pentelute, Ph.D. on November 9, 2023 filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 11/02/2023) (3) |
| Nov 2, 2023 | 375 | NOTICE to Take Deposition of John C. Jarosz on November 10, 2023 filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 11/02/2023) (3) |
| Nov 2, 2023 | 376 | NOTICE to Take Deposition of Yao Lu, Ph.D. on November 14, 2023 filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 11/02/2023) (3) |
| Nov 2, 2023 | 377 | NOTICE to Take Deposition of Andrew Hirshfeld on November 17, 2023 filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 11/02/2023) (3) |
| Nov 2, 2023 | 378 | NOTICE to Take Deposition of Stanley Nelson, M.D. on November 17, 2023 filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 11/02/2023) (3) |
| Nov 1, 2023 | 372 | NOTICE to Take Deposition of Robert S. Maness, Ph.D. on November 3, 2023 filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 11/01/2023) (4) |
| Oct 31, 2023 | 371 | NOTICE to Take Deposition of Matthew Wood, Ph.D. on November 10, 2023 filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 10/31/2023) (4) |
| Oct 30, 2023 | 366 | NOTICE OF SERVICE of (1) Reply Expert Report of Stanley Nelson, M.D.; (2) Reply Expert Report of Steven F. Dowdy, Ph.D.; (3) Expert Rebuttal Report of Andrew H. Hirshfeld; and (4) Reply Expert Report of John C. Jarosz filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 10/30/2023) (4) |
| Oct 30, 2023 | 367 | NOTICE OF SERVICE of Reply Expert Report of Christine Esau, Reply Expert Report of Michelle Hastings, Reply Expert Report of Nathan Luedtke, Reply Expert Report of Robert Maness, Reply Expert Report of Matthew J.A. Wood, Reply Expert Report of Scott Kamholz, Reply Technical Expert Report of Jonathan Strober, and Reply Expert Report and Disclosure of Mark Hosfield filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 10/30/2023) (3) |
| Oct 30, 2023 | 368 | NOTICE to Take Deposition of Christine C. Esau on November 3, 2023 filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 10/30/2023) (4) |
| Oct 30, 2023 | 369 | NOTICE to Take Deposition of Mark J. Hosfield on November 1, 2023 filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 10/30/2023) (4) |
| Oct 30, 2023 | 370 | NOTICE to Take Deposition of Scott E. Kamholz on November 3, 2023 filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 10/30/2023) (4) |
| Oct 12, 2023 | 364 | NOTICE OF SERVICE of (1) Rebuttal Expert Report of Bradley L. Pentelute, Ph.D.; (2) Rebuttal Expert Report of Stanley Nelson, M.D.; (3) Rebuttal Expert Report of Steven F. Dowdy, Ph.D.; (4) Expert Report of Andrew H. Hirshfeld; (5) Rebuttal Expert Report of John C. Jarosz; and (6) Rebuttal Expert Report of Yao Lu, Ph.D. filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 10/12/2023) (4) |
| Oct 12, 2023 | 365 | NOTICE OF SERVICE of (1) Rebuttal Expert Report of Christine Esau, Ph.D. (2) Responsive Expert Report of Dr. Michelle Hastings (3) Rebuttal Expert Report and Disclosure of Mark Hosfield, (4) Responsive Expert Report of Scott Kamholz, Esq., (5) Rebuttal Technical Expert Report of Jonathan Strober, M.D., and (6) Expert Rebuttal Report of Dr. Matthew J.A. Wood filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 10/12/2023) (3) |
| Oct 4, 2023 | 362 | NOTICE of withdrawal of appearance of Eric Kraeutler as counsel by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd. (Dudash, Amy) (Entered: 10/04/2023) (2) |
| Oct 4, 2023 | 363 | REPLY BRIEF re 353 MOTION to Stay Antitrust Counterclaim Deadlines Pending Resolution of Sarepta Therapeutics, Inc.'s and UWA's Motion to Bifurcate and Stay (Expedited Request) filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 10/04/2023) (6) |
| Oct 2, 2023 | 361 | REDACTED VERSION of 358 Reply Brief, by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 1-4)(Dellinger, Megan) (Entered: 10/02/2023) (0) |
| Sep 28, 2023 | 360 | ANSWERING BRIEF in Opposition re 353 MOTION to Stay Antitrust Counterclaim Deadlines Pending Resolution of Sarepta Therapeutics, Inc.'s and UWA's Motion to Bifurcate and Stay (Expedited Request) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Reply Brief due date per Local Rules is 10/5/2023. (Dudash, Amy) (Entered: 09/28/2023) (9) |
| Sep 27, 2023 | 359 | REDACTED PUBLIC VERSION of 348 Memorandum Opinion and Special Master Order #5. (ntl) (Entered: 09/27/2023) (20) |
| Sep 25, 2023 | 357 | STIPULATION TO EXTEND TIME certain deadlines to - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 09/25/2023) (3) |
| Sep 25, 2023 | 358 | [SEALED] REPLY BRIEF re 345 MOTION to Bifurcate and MOTION to Stay Antitrust Counterclaim --Sarepta Therapeutics, Inc. and The University of Western Australia's Reply Brief in Support of Their Motion to Bifurcate and Stay Antitrust Counterclaim-- filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 1-4)(Dellinger, Megan) (Entered: 09/25/2023) (0) |
| Sep 19, 2023 | 356 | ANSWERING BRIEF in Opposition re 345 MOTION to Bifurcate and MOTION to Stay Antitrust Counterclaim filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..Reply Brief due date per Local Rules is 9/26/2023. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Dudash, Amy) (Entered: 09/19/2023) (0) |
| Sep 18, 2023 | 355 | REDACTED VERSION of 344 Answer to Counterclaim by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 09/18/2023) (30) |
| Sep 15, 2023 | 354 | MOTION for Pro Hac Vice Appearance of Attorney Anna M. Rathbun and Graham B. Haviland - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 09/15/2023) (5) |
| Sep 14, 2023 | 353 | MOTION to Stay Antitrust Counterclaim Deadlines Pending Resolution of Sarepta Therapeutics, Inc.'s and UWA's Motion to Bifurcate and Stay (Expedited Request) - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 09/14/2023) (8) |
| Sep 12, 2023 | 352 | REDACTED VERSION of 347 Answer to Counterclaim by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 09/12/2023) (30) |
| Sep 11, 2023 | 349 | NOTICE OF SERVICE of 1) Opening Expert Report of Steven F. Dowdy, Ph.D.; 2) Opening Expert Report of Bradley L. Pentelute, Ph.D.; 3) Opening Expert Report of Stanley Nelson, M.D.; and 4) Opening Expert Report of John C. Jarosz filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 09/11/2023) (4) |
| Sep 11, 2023 | 350 | NOTICE OF SERVICE of 1) Expert Report of Mark J. Hosfield; 2) Expert Report of Dr. Matthew J.A. Wood; 3) Expert Report of Dr. Michelle L. Hastings; 4) Expert Report of Robert S. Maness, Ph.D.; 5) Expert Report of Scott E. Kamholz, Esq.; 6) Opening Expert Report of Christine C. Esau, Ph.D.; 7) Opening Expert Report of Nathan W. Luedtke, Ph.D. and 8) Technical Expert Report of Jonathan Strober, M.D. filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 09/11/2023) (3) |
| Sep 11, 2023 | 351 | REDACTED VERSION of 346 Opening Brief in Support, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 09/11/2023) (26) |
| Sep 7, 2023 | 348 | [SEALED] MEMORANDUM OPINION AND SPECIAL MASTER ORDER #5. Signed by Special Master Monte T. Squire, Esq. on 9/7/23.This document has already been emailed to counsel. (ntl) (Entered: 09/07/2023) (0) |
| Sep 5, 2023 | 345 | MOTION to Bifurcate and, MOTION to Stay Antitrust Counterclaim - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 09/05/2023) (4) |
| Sep 5, 2023 | 346 | [SEALED] OPENING BRIEF in Support re 345 MOTION to Bifurcate and MOTION to Stay Antitrust Counterclaim filed by Sarepta Therapeutics, Inc., The University of Western Australia.Answering Brief/Response due date per Local Rules is 9/19/2023. (Attachments: # 1 Exhibits A-B)(Dellinger, Megan) (Entered: 09/05/2023) (0) |
| Sep 5, 2023 | 347 | [SEALED] ANSWER to 344 Amended Answer to Complaint, Counterclaim -- Answer to Counter-Defendants' Counterclaims -- by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) Modified on 9/6/2023 (ntl). (Entered: 09/05/2023) (0) |
| Sep 1, 2023 | 344 | [SEALED] ANSWER to 328 Amended Answer to Complaint,, Counterclaim, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A)(Dudash, Amy) (Entered: 09/01/2023) (0) |
| Aug 31, 2023 | 341 | STIPULATION and [Proposed] Order Regarding Pleadings Deadlines and Extending Deadlines for Expert Reports by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 08/31/2023) (3) |
| Aug 31, 2023 | 342 | MOTION to Compel - filed by NS Pharma, Inc., Nippon Shinyaku Co., Ltd. (ntl) (Entered: 08/31/2023) (2) |
| Aug 31, 2023 | 343 | MOTION to Compel - filed by Sarepta Therapeutics, Inc. (ntl) (Entered: 08/31/2023) (2) |
| Aug 30, 2023 | 340 | STIPULATION TO EXTEND TIME for Filing Answers to Counterclaims to September 1, 2023 - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 08/30/2023) (2) |
| Aug 25, 2023 | 339 | MOTION for Pro Hac Vice Appearance of Attorney Amanda P. Reeves - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 08/25/2023) (4) |
| Aug 23, 2023 | 334 | REDACTED VERSION of 328 Amended Answer to Complaint,, Counterclaim, by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits A-C)(Dellinger, Megan) (Entered: 08/23/2023) (0) |
| Aug 23, 2023 | 335 | REDACTED VERSION of 329 Exhibit to a Document, by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits AA-AC, # 2 Exhibit AD, # 3 Exhibits AE-AF, # 4 Exhibits AG-AK)(Dellinger, Megan) (Entered: 08/23/2023) (0) |
| Aug 23, 2023 | 336 | REDACTED VERSION of 330 Exhibit to a Document, by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits AL-AR, # 2 Exhibits AS-AW)(Dellinger, Megan) (Entered: 08/23/2023) (0) |
| Aug 23, 2023 | 337 | REDACTED VERSION of 331 Exhibit to a Document, by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits AX-BG, # 2 Exhibits BH-BN, # 3 Exhibits BO-BT)(Dellinger, Megan) (Entered: 08/23/2023) (0) |
| Aug 23, 2023 | 338 | REDACTED VERSION of 324 Amended Answer to Complaint, Counterclaim by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A)(Dudash, Amy) (Entered: 08/23/2023) (0) |
| Aug 21, 2023 | 332 | REDACTED VERSION of 320 MOTION for Leave to File Reply Letter Brief Regarding Disclosure of Sarepta-Designated Information to Dr. Matthew J.A. Wood by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Proposed Reply Letter Brief, # 2 Exhibit C, # 3 Exhibit D, # 4 Text of Proposed Order)(Dudash, Amy) (Entered: 08/21/2023) (0) |
| Aug 21, 2023 | 333 | REDACTED VERSION of 321 MOTION for Leave to File a Reply in Support of Its Motion to Exclude Dr. Matthew Wood as an Expert Witness by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 08/21/2023) (16) |
| Aug 16, 2023 | 324 | [SEALED] AMENDED ANSWER to 89 Answer to Amended Complaint, Counterclaim, COUNTERCLAIM against Sarepta Therapeutics, Inc. by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc.. (Attachments: # 1 Exhibit A)(Dudash, Amy) (Entered: 08/16/2023) (0) |
| Aug 16, 2023 | 325 | REDACTED VERSION of 308 Letter Brief regarding Motion to Exclude Dr. Matthew J.A. Wood by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 08/16/2023) (5) |
| Aug 16, 2023 | 326 | REDACTED VERSION of 309 Declaration of Matthew J.A. Wood, Ph.D. by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 08/16/2023) (5) |
| Aug 16, 2023 | 327 | REDACTED VERSION of 307 Letter by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exs. 1-3)(Dellinger, Megan) (Entered: 08/16/2023) (0) |
| Aug 16, 2023 | 328 | [SEALED] AMENDED ANSWER to 86 Amended Complaint, COUNTERCLAIM --Defendant Sarepta Therapeutics, Inc.'s Second Amended Answer, Defenses, and Counterclaims to Plaintiff Nippon Shinyaku Co., Ltd.'s Second Amended Complaint-- against Nippon Shinyaku Co.,Ltd. by Sarepta Therapeutics, Inc.. (Attachments: # 1 Exhibit A-C)(Dellinger, Megan) (Entered: 08/16/2023) (0) |
| Aug 16, 2023 | 329 | [SEALED] EXHIBIT re 328 Amended Answer to Complaint,, Counterclaim, --Exhibits in Support of Defendant Sarepta Therapeutics, Inc.'s Second Amended Answer, Defenses, and Counterclaims to Plaintiff Nippon Shinyaku Co., Ltd.'s Second Amended Complaint (Vol. 1)-- by Sarepta Therapeutics, Inc.. (Attachments: # 1 Exs. AA-AC, # 2 Ex. AD, # 3 Exs. AE-EF, # 4 Exs. AG-AK)(Dellinger, Megan) (Entered: 08/16/2023) (0) |
| Aug 16, 2023 | 330 | [SEALED] EXHIBIT re 328 Amended Answer to Complaint,, Counterclaim, --Exhibits in Support of Defendant Sarepta Therapeutics, Inc.'s Second Amended Answer, Defenses, and Counterclaims to Plaintiff Nippon Shinyaku Co., Ltd.'s Second Amended Complaint (Vol. 2)-- by Sarepta Therapeutics, Inc.. (Attachments: # 1 Exs. AL-AR, # 2 Exs. AS-AW)(Dellinger, Megan) (Entered: 08/16/2023) (0) |
| Aug 16, 2023 | 331 | [SEALED] EXHIBIT re 328 Amended Answer to Complaint,, Counterclaim, --Exhibits in Support of Defendant Sarepta Therapeutics, Inc.'s Second Amended Answer, Defenses, and Counterclaims to Plaintiff Nippon Shinyaku Co., Ltd.'s Second Amended Complaint (Vol. 3)-- by Sarepta Therapeutics, Inc.. (Attachments: # 1 Exs. AX-BG, # 2 Exs. BH-BN, # 3 Exs. BO-BT)(Dellinger, Megan) (Entered: 08/16/2023) (0) |
| Aug 15, 2023 | 322 | NOTICE OF SERVICE of Sarepta's Supplemental Responses and Objections to NS's Interrogatories (Nos. 1-6, 8-23, 25-30, 32-34) filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 08/15/2023) (4) |
| Aug 15, 2023 | 323 | NOTICE OF SERVICE of Nippon Shinyakus and NS Pharmas Second Supplemental Response to First Set of Interrogatories (Nos. 1-11), Second Supplemental Response to Second Set of Interrogatories (No. 12), First Supplemental Response to Third Set of Interrogatories (Nos. 13-17), Second Supplemental Response to Fourth Set of Interrogatories (Nos. 18-22), First Supplemental Response to Fifth Set of Interrogatories (Nos. 23-29), and First Supplemental Responses to Sixth Set of Interrogatories (Nos. 30-35) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 08/15/2023) (3) |
| Aug 14, 2023 | 317 | ORAL ORDER: IT IS HEREBY ORDERED that, for the reasons stated during the hearing held on Thursday, August 3, 2023, which are hereby incorporated by reference, Counter-Defendants Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s Motion for Leave to File an Amended Answer and New Counterclaims (D.I. 177) and Counter-Plaintiff/Defendant Sarepta Therapeutics, Inc.'s Motion for Leave to File a Second Amended Answer and Counterclaims (D.I. 272) are GRANTED. ORDERED by Judge Gregory B. Williams on 8/14/23. (ntl) (Entered: 08/14/2023) (0) |
| Aug 14, 2023 | 318 | REDACTED VERSION of 304 Response to Objections by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 08/14/2023) (13) |
| Aug 14, 2023 | 319 | REDACTED VERSION of 305 Appendix by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 08/14/2023) (30) |
| Aug 14, 2023 | 320 | [SEALED] MOTION for Leave to File Reply Letter Brief Regarding Disclosure of Sarepta-Designated Information to Dr. Matthew J.A. Wood - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Proposed Reply Letter Brief, # 2 Exhibit C, # 3 Exhibit D, # 4 Text of Proposed Order)(Dudash, Amy) (Entered: 08/14/2023) (0) |
| Aug 14, 2023 | 321 | [SEALED] MOTION for Leave to File a Reply in Support of Its Motion to Exclude Dr. Matthew Wood as an Expert Witness - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibit A, # 2 Exhibit 1)(Dellinger, Megan) (Entered: 08/14/2023) (0) |
| Aug 11, 2023 | 316 | REDACTED VERSION of 301 MOTION for Leave to File Serve Amended Final Infringement Contentions (Unopposed) by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Proposed Amended Final Infringement Contentions, # 2 Exhibit 1, # 3 Text of Proposed Order)(Dudash, Amy) (Entered: 08/11/2023) (0) |
| Aug 10, 2023 | 310 | REDACTED VERSION of 298 Letter by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 08/10/2023) (5) |
| Aug 10, 2023 | 311 | REDACTED VERSION of 299 Declaration by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exs. 1-13)(Dellinger, Megan) (Entered: 08/10/2023) (0) |
| Aug 10, 2023 | 312 | NOTICE OF SERVICE of Nippon Shinyaku Co. Ltd.'s and NS Pharma, Inc.'s Validity Contentions filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 08/10/2023) (3) |
| Aug 10, 2023 | 313 | EXHIBIT re 308 Letter to the Honorable Gregory B. Williams Regarding Response to Motion to Exclude Dr. Matthew J.A. Wood by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5)(Dudash, Amy) (Entered: 08/10/2023) (0) |
| Aug 10, 2023 | 314 | NOTICE OF SERVICE of Sarepta Therapeutics, Inc.'s Final Validity Contentions filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 08/10/2023) (4) |
| Aug 10, 2023 | 315 | REDACTED VERSION of 300 Letter regarding Disclosure of Sarepta-Designated Information to Dr. Matthew J.A. Wood by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Dudash, Amy) (Entered: 08/10/2023) (0) |
| Aug 9, 2023 | 306 | SPECIAL MASTER ORDER #4. Signed by Special Master Monte T. Squire, Esq. on 8/9/23. (Attachment: # 1 Joint Discovery Dispute Letter) (ntl) (Entered: 08/09/2023) (0) |
| Aug 9, 2023 | 307 | [SEALED] Letter to The Honorable Gregory B. Williams from Megan E. Dellinger regarding Motion to Exclude Dr. Matthew Wood - re 300 Letter. (Attachments: # 1 Exhibits 1-3)(Dellinger, Megan) (Entered: 08/09/2023) (0) |
| Aug 9, 2023 | 308 | [SEALED] Letter to the Honorable Gregory B. Williams from Amy M. Dudash regarding Response to Motion to Exclude Dr. Matthew J.A. Wood - re 298 Letter. (Dudash, Amy) (Entered: 08/09/2023) (0) |
| Aug 9, 2023 | 309 | [SEALED] DECLARATION re 308 Letter [Declaration of Matthew J.A. Wood, Ph.D.] by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 08/09/2023) (0) |
| Aug 7, 2023 | 302 | REDACTED VERSION of 290 Reply Brief in support of motion for the issuance of a request for international judicial assistance by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 08/07/2023) (9) |
| Aug 7, 2023 | 303 | REDACTED VERSION of 291 Letter, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 08/07/2023) (8) |
| Aug 7, 2023 | 304 | [SEALED] RESPONSE TO OBJECTIONS by Sarepta Therapeutics, Inc., The University of Western Australia re 285 Objections . (Dellinger, Megan) (Entered: 08/07/2023) (0) |
| Aug 7, 2023 | 305 | [SEALED] APPENDIX re 304 Response to Objections by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 08/07/2023) (0) |
| Aug 4, 2023 | 301 | [SEALED] MOTION for Leave to File Serve Amended Final Infringement Contentions (Unopposed) - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Proposed Amended Final Infringement Contentions, # 2 Exhibit 1 - Blackline, # 3 Text of Proposed Order)(Dudash, Amy) (Entered: 08/04/2023) (0) |
| Aug 3, 2023 | 294 | REDACTED VERSION of 283 Answering Brief in Opposition, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 08/03/2023) (22) |
| Aug 3, 2023 | 295 | REDACTED VERSION of 285 Objections to Special Master Order No. 1 denying Motion to Compel Production of License Agreements by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 08/03/2023) (12) |
| Aug 3, 2023 | 296 | REDACTED VERSION of 286 Appendix to Objections to Special Master Order No. 1 by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 08/03/2023) (30) |
| Aug 3, 2023 | 297 | NOTICE OF SERVICE of Sarepta Therapeutics, Inc.'s Supplemental Objections and Responses to Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s Second Set of Requests for Admission (Nos. 36-38) filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 08/03/2023) (4) |
| Aug 3, 2023 | 298 | [SEALED] Letter to The Honorable Gregory B. Williams from Megan E. Dellinger regarding Motion to Exclude Dr. Matthew Wood as an Expert Witness. (Dellinger, Megan) (Entered: 08/03/2023) (0) |
| Aug 3, 2023 | 299 | [SEALED] DECLARATION re 298 Letter -- Declaration of Marc D. Evans -- by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits 1-13)(Dellinger, Megan) (Entered: 08/03/2023) (0) |
| Aug 3, 2023 | 300 | [SEALED] Letter to the Honorable Gregory B. Williams from Amy M. Dudash regarding Disclosure of Sarepta-Designated Information to Dr. Matthew J.A. Wood. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Dudash, Amy) (Entered: 08/03/2023) (0) |
| Aug 2, 2023 | 293 | REDACTED VERSION of 281 Letter, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Dudash, Amy) (Entered: 08/02/2023) (0) |
| Aug 1, 2023 | 292 | ORDER re 274 MOTION for Issuance of Letters Rogatory filed by NS Pharma, Inc., Nippon Shinyaku Co., Ltd. Signed by Judge Gregory B. Williams on 8/1/23. (ntl) (Entered: 08/01/2023) (1) |
| Jul 31, 2023 | 290 | [SEALED] REPLY BRIEF re 274 MOTION for Issuance of Letters Rogatory filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Dudash, Amy) (Entered: 07/31/2023) (0) |
| Jul 31, 2023 | 291 | [SEALED] Letter to The Honorable Gregory B. Williams from Megan E. Dellinger regarding motion for leave to amend - re 272 MOTION for Leave to File a Second Amended Answer, Defenses, and Counterclaims to Hippon Shinyaku Co., Ltd.'s Second Amended Complaint. (Attachments: # 1 Exhibit 3)(Dellinger, Megan) (Entered: 07/31/2023) (0) |
| Jul 28, 2023 | 288 | Letter to The Honorable Gregory B. Williams from Jack B. Blumenfeld regarding Request for a Briefing and Hearing Schedule - re 219 Order Appointing Special Master, 220 Letter. (Blumenfeld, Jack) (Entered: 07/28/2023) (1) |
| Jul 28, 2023 | 289 | ORAL ORDER: Having reviewed the parties' letter requesting a discovery teleconference (D.I. 288) related to the disputes raised, but not adjudicated by Special Master Squire, in D.I. 219, IT IS HEREBY ORDERED THAT by no later than 5:00 p.m. on Thursday, August 3, 2023, the party seeking relief shall file with the Court a letter, not to exceed three (3) pages and in no less than 12-point font, outlining the issues in dispute and its position on those issues. By no later than 5:00 p.m. on Wednesday, August 9, 2023, any party opposing the application for relief shall file a letter, not to exceed three (3) pages and in no less than 12-point font, outlining their positions and reasons for their positions. The parties shall provide the Court with two (2) courtesy paper copies of the respective letters with hard tabs inserted before any exhibits. If the Court determines that the dispute cannot be resolved based on the parties' letter submissions, the Court will schedule a discovery teleconference at a later date. ORDERED by Judge Gregory B. Williams on 7/28/23. (ntl) Modified on 7/31/2023 (ntl). (Entered: 07/28/2023) (0) |
| Jul 27, 2023 | 282 | ORAL ORDER: Having reviewed Counter-Defendants Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s Motion for Leave to File an Amended Answer and New Counterclaims (D.I. 177) and Counter-Plaintiff/Defendant Sarepta Therapeutics, Inc.'s Motion for Leave to File a Second Amended Answer and Counterclaims (D.I. 272), IT IS HEREBY ORDERED that a hearing will be held on Thursday, August 3, 2023 at 11:00 AM in Courtroom 6B. The Court will allocate forty (40) minutes for the hearing, with each side being allocated up to ten (10) minutes to present its argument for each motion. ORDERED by Judge Gregory B. Williams on 7/27/23. (ntl) (Entered: 07/27/2023) (0) |
| Jul 27, 2023 | 283 | [SEALED] ANSWERING BRIEF in Opposition re 274 MOTION for Issuance of Letters Rogatory filed by Sarepta Therapeutics, Inc., The University of Western Australia.Reply Brief due date per Local Rules is 8/3/2023. (Blumenfeld, Jack) (Entered: 07/27/2023) (0) |
| Jul 27, 2023 | 284 | NOTICE OF SERVICE of (1) Sarepta Therapeutics, Inc.'s Objections and Responses to Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s Second Set of Requests for Admission (Nos. 11-56); and (2) Sarepta's Objections and Responses to NS's Third Set of Interrogatories (Nos. 22-34) filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Blumenfeld, Jack) (Entered: 07/27/2023) (4) |
| Jul 27, 2023 | 285 | [SEALED] OBJECTIONS by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd. to 226 Order - Objections to Special Master Order No. 1 Denying Motion to Compel Production of License Agreements. (Dudash, Amy) (Entered: 07/27/2023) (0) |
| Jul 27, 2023 | 286 | [SEALED] APPENDIX re 285 Objections to Special Master Order No. 1 denying Motion to Compel Production of License Agreements by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 07/27/2023) (0) |
| Jul 27, 2023 | 287 | NOTICE OF SERVICE of Nippon Shinyaku and NS Pharmas First Supplemental Response to Interrogatory No. 21, Responses and Objections to Sixth Set of Interrogatories (No. 30-35), Responses and Objections to Second Set of Requests for Admission (No. 38-48) and Responses and Objections to Fifth Request for Production (No. 95-100) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 07/27/2023) (3) |
| Jul 26, 2023 | 278 | REDACTED VERSION of 272 MOTION for Leave to File a Second Amended Answer, Defenses, and Counterclaims to Hippon Shinyaku Co., Ltd.'s Second Amended Complaint by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibit 1 - Second Amended Answer and Counterclaims, # 2 Exhibits A-C to Second Amended Answer, # 3 Exs. AA-AC, # 4 Ex. AD, # 5 Exs. AE-AF, # 6 Exs. AG-AK, # 7 Exs. AL-AR, # 8 Exs. AS-BT, # 9 Exhibit 2 - Redline)(Dellinger, Megan) (Entered: 07/26/2023) (0) |
| Jul 26, 2023 | 279 | REDACTED VERSION of 273 Letter, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 07/26/2023) (6) |
| Jul 26, 2023 | 280 | REDACTED VERSION of 274 MOTION for Issuance of Letters Rogatory by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A)(Dudash, Amy) (Entered: 07/26/2023) (0) |
| Jul 26, 2023 | 281 | [SEALED] Letter to the Honorable Gregory B. Williams from Nippon Shinyaku Co. and NS Pharma, Inc. regarding Sarepta's Motion for Leave to File a Second Amended Answer - re 273 Letter,. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Dudash, Amy) (Entered: 07/26/2023) (0) |
| Jul 24, 2023 | 277 | NOTICE to Take Deposition of Dr. Frank Schnell on July 26, 2023 filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 07/24/2023) (3) |
| Jul 20, 2023 | 276 | ORAL ORDER: Having reviewed Plaintiff/Counter-Defendants' Motion for Expedited Briefing (D.I. 275) related to the pending Motion for Issuance of Letters Rogatory (D.I. 274), IT IS HEREBY ORDERED that Plaintiff/Counter-Defendants Motion for Expedited Briefing (D.I. 275) is GRANTED. Any response to Plaintiff/Counter-Defendants' Motion for Issuance of Letters Rogatory (D.I. 274) shall be filed within seven (7) days from the entry of this Order. Any reply must be filed within three (3) days thereafter. ORDERED by Judge Gregory B. Williams on 7/20/23. (ntl) (Entered: 07/20/2023) (0) |
| Jul 19, 2023 | 270 | NOTICE OF SERVICE of Sarepta Therapeutics, Inc.'s Second Supplemental Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) and Paragraph 3 of the Default Standard for Discovery filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 07/19/2023) (4) |
| Jul 19, 2023 | 271 | REDACTED VERSION of 263 [SEALED] SPECIAL MASTER ORDER #3. (etg) (Entered: 07/19/2023) (2) |
| Jul 19, 2023 | 272 | [SEALED] MOTION for Leave to File a Second Amended Answer, Defenses, and Counterclaims to Hippon Shinyaku Co., Ltd.'s Second Amended Complaint - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibit 1 - Second Amended Answer and Counterclaims, # 2 Exhibits A-C to Second Amended Answer, # 3 Vol. 1 - Exs. AA-AC, # 4 Vol. 1 - Ex. AD, # 5 Vol. 1 - Exs. AE-AF, # 6 Vol. 1 - Exs. AG-AK, # 7 Vol. 2 - Exs. AL-AR, # 8 Vol. 2 - Exs. AS-AW, # 9 Vol. 2 - Exs. AX-BG, # 10 Vol. 3 - Exs. BH-BN, # 11 Vol. 3 - Exs. BO-BT, # 12 Exhibit 2 - REDLINE)(Dellinger, Megan) (Entered: 07/19/2023) (0) |
| Jul 19, 2023 | 273 | [SEALED] Letter to The Honorable Gregory B. Williams from Megan E. Dellinger regarding motion for leave to amend - re 272 MOTION for Leave to File a Second Amended Answer, Defenses, and Counterclaims to Hippon Shinyaku Co., Ltd.'s Second Amended Complaint. (Dellinger, Megan) (Entered: 07/19/2023) (0) |
| Jul 19, 2023 | 274 | [SEALED] MOTION for Issuance of Letters Rogatory - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Text of Proposed Order)(Dudash, Amy) (Entered: 07/19/2023) (0) |
| Jul 19, 2023 | 275 | [SEALED] MOTION to Expedite Briefing - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Text of Proposed Order)(Dudash, Amy) (Entered: 07/19/2023) (0) |
| Jul 18, 2023 | 269 | STIPULATION and [Proposed] Order to Extend Time for Certain Case Deadlines re 143 Scheduling Order, by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 07/18/2023) (3) |
| Jul 17, 2023 | 268 | MOTION for Pro Hac Vice Appearance of Attorney Eric J. Lee - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 07/17/2023) (4) |
| Jul 14, 2023 | 260 | NOTICE to Take Deposition of Patrick O'Malley on July 20, 2023 filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 07/14/2023) (3) |
| Jul 14, 2023 | 261 | NOTICE to Take Deposition of Stephen Sudovar on July 18, 2023 filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 07/14/2023) (4) |
| Jul 14, 2023 | 262 | NOTICE to Take Deposition of Leslie Magnus on July 20, 2023 filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 07/14/2023) (4) |
| Jul 14, 2023 | 263 | [SEALED] SPECIAL MASTER ORDER #3. Signed by Special Master Monte T. Squire on 7/14/2023.This order has been emailed to local counsel. (etg) (Entered: 07/14/2023) (0) |
| Jul 14, 2023 | 264 | REDACTED VERSION of 254 [SEALED] MEMORANDUM OPINION AND SPECIAL MASTER ORDER #2. (etg) (Entered: 07/14/2023) (13) |
| Jul 14, 2023 | 265 | NOTICE OF SERVICE of (1) Sarepta Therapeutics, Inc.'s Supplemental Responses and Objections to Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s First Set of Requests for Admission (Nos. 2 & 3); and (2) The University of Western Australia's Responses and Objections to Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s Rule 30(b)(6) Notice of Deposition filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 07/14/2023) (4) |
| Jul 14, 2023 | 266 | NOTICE to Take Deposition of Joe Zenkus on July 25, 2023 filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 07/14/2023) (3) |
| Jul 14, 2023 | 267 | NOTICE to Take Deposition of Ihor Sehinovych on July 28, 2023 filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 07/14/2023) (3) |
| Jul 11, 2023 | 256 | NOTICE to Take Deposition of Ryan Wong on July 13, 2023 filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 07/11/2023) (3) |
| Jul 11, 2023 | 257 | NOTICE to Take Deposition of Dr. Jurjus Jurayj on July 18, 2023 filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 07/11/2023) (3) |
| Jul 11, 2023 | 258 | NOTICE OF SERVICE of Nippon Shinyaku Co. Ltd.'s Finali Validity Contentions and Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Noninfringement Contentions filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 07/11/2023) (3) |
| Jul 11, 2023 | 259 | NOTICE OF SERVICE of (1) Sarepta Therapeutics, Inc.'s Non-Infringement Contentions and (2) Sarepta Therapeutics, Inc.'s Final Invalidity Contentions filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 07/11/2023) (4) |
| Jul 10, 2023 | 255 | MOTION for Pro Hac Vice Appearance of Attorney Kaitlyn S. Pehrson - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 07/10/2023) (4) |
| Jul 7, 2023 | 253 | NOTICE of Subpoena to Zhengyu Feng by Sarepta Therapeutics, Inc., The University of Western Australia (Attachments: # 1 Exhibit 1)(Dellinger, Megan) (Entered: 07/07/2023) (0) |
| Jul 7, 2023 | 254 | [SEALED] MEMORANDUM OPINION AND SPECIAL MASTER ORDER #2. Signed by Special Master Monte T. Squire, Esq. on 7/6/23. (ntl) (Entered: 07/07/2023) (0) |
| Jul 6, 2023 | 251 | NOTICE to Take Deposition of Gardner Gendron on July 11, 2023 filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 07/06/2023) (4) |
| Jul 6, 2023 | 252 | NOTICE to Take Deposition of Angela Melia on July 13, 2023 filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 07/06/2023) (4) |
| Jul 5, 2023 | 250 | NOTICE OF SERVICE of (1) Sarepta's Objections to NS Pharma's Third-Party Subpoena to Amy Mandragouras for Deposition Testimony; and (2) Sarepta's Objections to NS Pharma's Third-Party Subpoenas to Dr. Diane Frank Seeking Documents and Things (Nos. 1-3) and Deposition Testimony filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 07/05/2023) (4) |
| Jul 3, 2023 | 248 | MEMORANDUM OPINION re claim construction. Signed by Judge Gregory B. Williams on 7/3/23. (ntl) (Entered: 07/03/2023) (38) |
| Jul 3, 2023 | 249 | ORDER re 248 Memorandum Opinion regarding claim construction. Signed by Judge Gregory B. Williams on 7/3/23. (ntl) (Entered: 07/03/2023) (2) |
| Jun 30, 2023 | 245 | NOTICE OF SERVICE of Sarepta's Objections to NS Pharma's Third-Party Subpoena to Bachem Americas, Inc. Seeking Documents and Things (Nos. 1-23) and Deposition (Topic Nos. 1-17) filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 06/30/2023) (4) |
| Jun 30, 2023 | 246 | MOTION to Compel Deposition of Dr. Takeda in the United States - filed by Sarepta Therapeutics, Inc.(A Delaware Corporation). (etg) (Entered: 06/30/2023) (2) |
| Jun 30, 2023 | 247 | MOTION to Compel - filed by Nippon Shinyaku Co.,Ltd.. (etg) (Entered: 06/30/2023) (2) |
| Jun 29, 2023 | 244 | NOTICE OF SERVICE of Sarepta's Objections to NS Pharma's Third-Party Subpoenas to Dr. Ryszard Kole Seeking Documents and Things (Nos. 1-3) and Deposition Testimony filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 06/29/2023) (4) |
| Jun 28, 2023 | 243 | NOTICE to Take Deposition of Toshihiro Ueda on July 11, 2023 filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 06/28/2023) (3) |
| Jun 27, 2023 | 240 | NOTICE OF SERVICE of (1) Sarepta Therapeutic, Inc.'s Sixth Set of Interrogatories to Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. (Nos. 30-35), (2) Sarepta Therapeutic, Inc.'s Second Set of Requests for Admission to Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. (Nos. 38-48) and (3) Sarepta Therapeutic, Inc.'s Fifth Set of Requests for the Production of Documents and Things (Nos. 95-100) - filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 06/27/2023) (4) |
| Jun 27, 2023 | 241 | REDACTED VERSION of 233 Answering Brief in Opposition, by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Ex. 1, # 2 Ex. 2, # 3 Ex. 3)(Dellinger, Megan) (Entered: 06/27/2023) (0) |
| Jun 27, 2023 | 242 | NOTICE OF SERVICE of Nippon Shinyaku and NS Pharmas Second Set of Request for Admission to Sarepta (Nos. 11-56) and Nippon Shinyakus and NS Pharmas Third Set of Interrogatories to Sarepta and UWA (Nos. 22-35) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 06/27/2023) (3) |
| Jun 26, 2023 | 239 | [SEALED] ORDER re 215 [SEALED] Motion for Issuance of Letters Rogatory. Signed by Judge Gregory B. Williams on 6/26/2023. (Attachments: # 1 Request for International Judicial Assistance) Documents are available for pickup at Clerk's Office by local counsel. (etg) (Entered: 06/26/2023) (0) |
| Jun 23, 2023 | 238 | NOTICE OF SERVICE of Sarepta's Objections to NS Pharma's Third-Party Subpoenas to Dr. Peter Sazani Seeking Documents and Things (Nos. 1-3) and Deposition Testimony filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 06/23/2023) (4) |
| Jun 22, 2023 | 236 | NOTICE OF SERVICE of Sarepta Therapeutics, Inc.'s Final Infringement Contentions filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 06/22/2023) (4) |
| Jun 22, 2023 | 237 | NOTICE OF SERVICE of Nippon Shinyaku Co., Ltd.'s Final Infringement Contentions filed by Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 06/22/2023) (3) |
| Jun 21, 2023 | 235 | NOTICE OF SERVICE of Nippon Shinyaku and NS Pharma Incs First Supplemental Responses and Objections to Sareptas First Set of Interrogatories (Nos. 1-3, 5 and 6) and First Supplemental Responses and Objections to Sareptas Second Set of Interrogatories (No. 12) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 06/21/2023) (3) |
| Jun 20, 2023 | 231 | NOTICE to Take Deposition of Emily Naughton on July 12, 2023 filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 06/20/2023) (3) |
| Jun 20, 2023 | 232 | NOTICE OF SERVICE of Notice of Intent to Serve Subpoena to Amy Mandragouras filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 06/20/2023) (3) |
| Jun 20, 2023 | 233 | [SEALED] ANSWERING BRIEF in Opposition re 215 MOTION for Issuance of Letters Rogatory filed by Sarepta Therapeutics, Inc., The University of Western Australia.Reply Brief due date per Local Rules is 6/27/2023. (Attachments: # 1 Ex. 1, # 2 Ex. 2, # 3 Ex. 3)(Dellinger, Megan) (Entered: 06/20/2023) (0) |
| Jun 20, 2023 | 234 | NOTICE to Take Deposition of Ethan Jacoby on June 22, 2023 filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 06/20/2023) (3) |
| Jun 16, 2023 | 228 | NOTICE to Take Deposition of Youhei Satou on June 30, 2023 filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 06/16/2023) (3) |
| Jun 16, 2023 | 229 | NOTICE to Take Deposition of Masaya Toda on June 27, 2023 filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 06/16/2023) (3) |
| Jun 16, 2023 | 230 | NOTICE to Take Deposition of Naoki Watanabe on June 26, 2023 filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 06/16/2023) (3) |
| Jun 15, 2023 | 227 | NOTICE OF SERVICE of Sarepta's Objections to NS Pharma's Third-Party Subpoenas to Dr. Richard Bestwick Seeking Documents and Things (Nos. 1-3) and Deposition Testimony filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 06/15/2023) (4) |
| Jun 14, 2023 | 226 | SPECIAL MASTER ORDER #1. Signed by Special Master Monte T. Squire, Esquire on 6/14/2023. (etg) (Entered: 06/14/2023) (2) |
| Jun 13, 2023 | 225 | MOTION for Pro Hac Vice Appearance of Attorney John M. Williamson - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 06/13/2023) (4) |
| Jun 12, 2023 | 223 | NOTICE to Take Deposition of Brian Forsa and Steve Wilton on June 14, 2023 and June 15, 2023 filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 06/12/2023) (3) |
| Jun 12, 2023 | 224 | REDACTED VERSION of 215 MOTION for Issuance of Letters Rogatory by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A)(Dudash, Amy) (Entered: 06/12/2023) (0) |
| Jun 9, 2023 | 221 | MOTION for Pro Hac Vice Appearance of Attorney L. Scott Burwell - filed by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 06/09/2023) (4) |
| Jun 9, 2023 | 222 | NOTICE OF SERVICE of Sarepta's and UWA's Supplemental Responses and Objections to NS's Interrogatories (Nos. 6-9 and 15) filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 06/09/2023) (4) |
| Jun 8, 2023 | 220 | Letter to Judge Williams and Special Master Squire from Amy M. Dudash regarding Discovery Dispute [Joint]. (Dudash, Amy) (Entered: 06/08/2023) (2) |
| Jun 7, 2023 | 219 | ORDER appointing Special Master: Monte T. Squire, Esq. appointed. Signed by Judge Gregory B. Williams on 6/7/23. (ntl) (Entered: 06/07/2023) (4) |
| Jun 6, 2023 | 217 | NOTICE OF SERVICE of UWA's Responses to Nippon Shinyaku's Previously Served Discovery Requests filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 06/06/2023) (4) |
| Jun 6, 2023 | 218 | STIPULATION and [Proposed] Order Adding UWA to Protective Order re 117 Protective Order by Sarepta Therapeutics, Inc., The University of Western Australia. (Dellinger, Megan) (Entered: 06/06/2023) (2) |
| Jun 5, 2023 | 213 | NOTICE to Take Deposition of Kazuchika Takagaki on June 13, 2023 filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 06/05/2023) (3) |
| Jun 5, 2023 | 214 | NOTICE OF SERVICE of Nippon Shinyakus NS Pharmas Responses and Objections to Sareptas First Set of Requests for Admission (Nos. 1-37) and Fifth Set of Interrogatories (Nos. 23-29) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 06/05/2023) (3) |
| Jun 5, 2023 | 215 | [SEALED] MOTION for Issuance of Letters Rogatory - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A, # 2 Text of Proposed Order, # 3 Certificate of Service)(Dudash, Amy) (Entered: 06/05/2023) (0) |
| Jun 5, 2023 | 216 | NOTICE OF SERVICE of The University of Western Australia's Responses and Objections to Topics from Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s Rule 30(b)(6) Notice of Deposition for Which Dr. Wilton Will Be Designated filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 06/05/2023) (4) |
| Jun 2, 2023 | 212 | MOTION for Pro Hac Vice Appearance of Attorney Alison P. Patitucci - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) (Entered: 06/02/2023) (0) |
| May 31, 2023 | 207 | NOTICE OF SERVICE of Plaintiff Nippon Shinyaku Co., Ltd.'s Second Supplemental Rule 26(a)(1) Initial Disclosures filed by Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 05/31/2023) (3) |
| May 31, 2023 | 208 | NOTICE OF SERVICE of Notice of Intent to Serve subpoenas to Baechem Americas, Inc. and Diane Frank filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 05/31/2023) (3) |
| May 31, 2023 | 209 | ORAL ORDER: Having reviewed the parties' joint discovery dispute letter (see D.I. 202), IT IS HEREBY ORDERED that the Court will be appointing a special master to handle this discovery dispute (D.I. 202) and all future discovery disputes, with costs to be shared equally by both sides. ORDERED by Judge Gregory B. Williams on 5/31/23. (ntl) (Entered: 05/31/2023) (0) |
| May 31, 2023 | 210 | ORDER REFERRING CASE to Clerk for assignment of a Special Master. Signed by Judge Gregory B. Williams on 5/31/23. (ntl) (Entered: 05/31/2023) (1) |
| May 31, 2023 | 211 | NOTICE OF SERVICE of Notice of Intent to Serve Subpoenas to Peter Sazani, Richard Bestwick, and Ryszard Kole filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 05/31/2023) (4) |
| May 30, 2023 | 206 | NOTICE OF SERVICE of The University of Western Australia's Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) and Paragraph 3 of the Default Standard for Discovery - filed by The University of Western Australia.(Dellinger, Megan) (Entered: 05/30/2023) (4) |
| May 26, 2023 | 204 | NOTICE OF SERVICE of Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.s Responses and Objections to Sarepta Therapeutics, Inc.s Notice of Deposition (Topics 1-73) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 05/26/2023) (3) |
| May 26, 2023 | 205 | NOTICE OF SERVICE of Responses and Objections to Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s Rule 30(b)(6) Notice of Deposition of Sarepta Therapeutics, Inc. filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 05/26/2023) (4) |
| May 24, 2023 | 203 | NOTICE OF SERVICE of Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.s Notice of Deposition of University of Western Australia Pursuant to Fed. R. Civ. P. 30(b)(6) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 05/24/2023) (3) |
| May 22, 2023 | 202 | Letter to the Honorable Gregory B. Williams from Amy M. Dudash regarding Discovery Dispute [Joint]. (Dudash, Amy) (Entered: 05/22/2023) (1) |
| May 5, 2023 | 200 | ANSWER to 195 Amended Answer to Complaint, Counterclaim by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 05/05/2023) (30) |
| May 5, 2023 | 201 | NOTICE OF SERVICE of Sarepta Therapeutics, Inc.'s First Set of Requests for Admissions to Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. (Nos. 1-37) filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 05/05/2023) (4) |
| May 1, 2023 | 199 | NOTICE OF SERVICE of Notice of Deposition of Plaintiffs Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 05/01/2023) (4) |
| Apr 27, 2023 | 198 | NOTICE OF SERVICE of Counter-Plaintiffs' Fifth Set of Interrogatories to Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. (Nos. 23-29) filed by Sarepta Therapeutics, Inc., The University of Western Australia.(Dellinger, Megan) (Entered: 04/27/2023) (4) |
| Apr 26, 2023 | 197 | NOTICE of Claim Construction Proceedings by The University of Western Australia (Dellinger, Megan) (Entered: 04/26/2023) (3) |
| Apr 21, 2023 | 194 | ORAL ORDER: Having reviewed Defendant Sarepta Therapeutics, Inc.'s ("Sarepta") Motion to Amend its Answer, Counterclaims, and Defenses (D.I. 175), and having since been notified by Plaintiffs Nippon Shinyaku Co. and NS Pharma, Inc. that they withdraw their opposition to Sarepta's Motion (see D.I. 188), IT IS HEREBY ORDERED that Sarepta's Motion to Amend its Answer, Counterclaims, and Defenses (D.I. 175) is GRANTED. ORDERED by Judge Gregory B. Williams on 4/21/23. (ntl) (Entered: 04/21/2023) (0) |
| Apr 21, 2023 | 195 | AMENDED ANSWER to 86 Amended Complaint, COUNTERCLAIM against NS Pharma, Inc., Nippon Shinyaku Co.,Ltd. by Sarepta Therapeutics, Inc., The University of Western Australia. (Attachments: # 1 Exhibits A-C)(Dellinger, Megan) (Entered: 04/21/2023) (0) |
| Apr 17, 2023 | 193 | NOTICE OF SERVICE of Nippon Shinyaku and NS Pharma Responses and Objections to Sarepta Therapeutics, Inc.'s Fourth Set of Interrogatories (Nos. 18-22) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 04/17/2023) (2) |
| Apr 12, 2023 | 192 | NOTICE OF SERVICE of Nippon Shinyaku Co., Ltd.s and NS Pharma, Inc.s Notice of Deposition of Sarepta Therapeutics, Inc. pursuant to Fed. R. Civ. P. 30(b)(6) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 04/12/2023) (2) |
| Apr 10, 2023 | 191 | REDACTED VERSION of 186 Letter, regarding Request for Leave to File an Amended Answer to Sarepta's Counterclaim by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 04/10/2023) (4) |
| Apr 6, 2023 | 190 | REDACTED VERSION of 183 Letter, by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 04/06/2023) (8) |
| Apr 3, 2023 | 186 | [SEALED] Letter to Honorable Gregory B. Williams from Amy M. Dudash regarding Nippon Shinyaku Co. and NS Pharma, Inc.'s Reply In Support of Motion to Amend - re 183 Letter, 178 Letter, 177 MOTION to Amend/Correct 96 Answer to Counterclaim and New Counterclaim. (Attachments: # 1 Certificate of Service)(Dudash, Amy) (Entered: 04/03/2023) (0) |
| Apr 3, 2023 | 187 | Letter to Honorable Gregory B. Williams from Amy M. Dudash regarding Requesting Teleconference Regarding Nippon Shinyaku Co. and NS Pharma, Inc.'s Motion to Amend - re 177 MOTION to Amend/Correct 96 Answer to Counterclaim and New Counterclaim. (Dudash, Amy) (Entered: 04/03/2023) (1) |
| Apr 3, 2023 | 188 | Letter to Honorable Gregory B. Williams from Amy M. Dudash regarding Withdrawing Opposition to Sarepta's Motion to Amend - re 179 Letter, 175 MOTION to Amend/Correct 89 Answer to Amended Complaint, Counterclaim . (Dudash, Amy) (Entered: 04/03/2023) (1) |
| Apr 3, 2023 | 189 | NOTICE OF SERVICE of (1) Sarepta Therapeutics, Inc.'s Responses to Nippon Shinyaku Co., Ltd. and NS Pharma, Inc.'s First Set of Requests for Admission (Nos. 1-10); and (2) Sarepta's Responses and Objections to NS's Second Set of Interrogatories (Nos. 14-21) filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 04/03/2023) (4) |
| Mar 31, 2023 | 184 | Letter to The Honorable Gregory B. Williams from Megan E. Dellinger regarding reply to Nippon's opposition to Sarepta's motion to amend - re 179 Letter. (Dellinger, Megan) (Entered: 03/31/2023) (2) |
| Mar 31, 2023 | 185 | Letter to The Honorable Gregory B. Williams from Megan E. Dellinger regarding request for the scheduling of a teleconference - re 175 MOTION to Amend/Correct 89 Answer to Amended Complaint, Counterclaim . (Dellinger, Megan) (Entered: 03/31/2023) (1) |
| Mar 30, 2023 | 183 | [SEALED] Letter to The Honorable Gregory B. Williams from Megan E. Dellinger regarding Nippon Shinyaku's Request for Leave to File an Amended Answer to Sarepta's Counterclaims - re 177 MOTION to Amend/Correct 96 Answer to Counterclaim and New Counterclaim. (Dellinger, Megan) (Entered: 03/30/2023) (0) |
| Mar 29, 2023 | 180 | ORAL ORDER: IT IS HEREBY ORDERED that the Markman hearing scheduled for April 19, 2023 at 10:00 a.m. is rescheduled to May 3, 2023 at 10:00 a.m. Additionally, the Court has reviewed the parties' joint letter (D.I. 172) and has allotted three (3) hours for the Markman Hearing, which is to be split evenly between the parties. Any slide presentations the parties wish to use during the hearing shall be emailed (in PDF format) to gbw_civil@ded.uscourts.gov no later than 72 hours prior to the hearing with hard copies delivered to the Clerk's office within one hour thereafter. ORDERED by Judge Gregory B. Williams on 3/29/23. (ntl) (Entered: 03/29/2023) (0) |
| Mar 29, 2023 | 181 | REDACTED VERSION of 177 MOTION to Amend/Correct 96 Answer to Counterclaim and New Counterclaim by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit 1 - Amended Answer, # 2 Exhibit A to Amended Answer, # 3 Exhibit 2 - Redline)(Dudash, Amy) (Entered: 03/29/2023) (0) |
| Mar 29, 2023 | 182 | REDACTED VERSION of 178 Letter, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 03/29/2023) (5) |
| Mar 28, 2023 | 179 | Letter to the Honorable Gregory B. Williams from Nippon Shinyaku Co. and NS Pharma, Inc. regarding Opposition to Sarepta Therapeutics, Inc.'s Motion to Amend. (Attachments: # 1 Exhibit A)(Dudash, Amy) (Entered: 03/28/2023) (0) |
| Mar 23, 2023 | 177 | [SEALED] MOTION to Amend/Correct 96 Answer to Counterclaim and New Counterclaim - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit 1 - Amended Answer, # 2 Exhibit A to Amended Answer, # 3 Exhibit 2 - Redline, # 4 Certificate of Service)(Dudash, Amy) (Entered: 03/23/2023) (0) |
| Mar 23, 2023 | 178 | [SEALED] Letter to the Honorable Gregory B. Williams from Nippon Shinyaku Ltd. Co. and NS Pharma, Inc. regarding Request for Leave to File an Amended Answer to Sarepta's Counterclaims - re 177 MOTION to Amend/Correct 96 Answer to Counterclaim and New Counterclaim. (Attachments: # 1 Certificate of Service)(Dudash, Amy) (Entered: 03/23/2023) (0) |
| Mar 21, 2023 | 175 | MOTION to Amend/Correct 89 Answer to Amended Complaint, Counterclaim - filed by Sarepta Therapeutics, Inc.. (Attachments: # 1 Exhibit 1 - First Amended Answer, # 2 Exhibits A-C to First Amended Answer, # 3 Exhibit 2 - Redline)(Dellinger, Megan) (Entered: 03/21/2023) (0) |
| Mar 21, 2023 | 176 | Letter to The Honorable Gregory B. Williams from Megan E. Dellinger regarding motion to amend - re 175 MOTION to Amend/Correct 89 Answer to Amended Complaint, Counterclaim . (Dellinger, Megan) (Entered: 03/21/2023) (4) |
| Mar 20, 2023 | 166 | JOINT CLAIM CONSTRUCTION BRIEF filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 03/20/2023) (30) |
| Mar 20, 2023 | 167 | APPENDIX re 166 Joint Claim Construction Brief (Volume 1 - Part 1) by Sarepta Therapeutics, Inc.. (Attachments: # 1 Exhibits 1-4)(Dellinger, Megan) (Entered: 03/20/2023) (0) |
| Mar 20, 2023 | 168 | APPENDIX re 166 Joint Claim Construction Brief (Volume 1 - Part 2) (Exhibits 5-12) by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 03/20/2023) (30) |
| Mar 20, 2023 | 169 | APPENDIX re 166 Joint Claim Construction Brief (Volume 2 - Part 1) (Exhibits 13-28) by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 03/20/2023) (30) |
| Mar 20, 2023 | 170 | APPENDIX re 166 Joint Claim Construction Brief (Volume 2 - Part 2) (Exhibits 29-33) by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 03/20/2023) (30) |
| Mar 20, 2023 | 171 | APPENDIX re 166 Joint Claim Construction Brief (Volume 3) (Exhibits 34-53) by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 03/20/2023) (30) |
| Mar 20, 2023 | 172 | Letter to Honorable Gregory B. Williams from Amy M. Dudash regarding Claim Construction Hearing. (Dudash, Amy) (Entered: 03/20/2023) (1) |
| Mar 20, 2023 | 173 | JOINT CLAIM CONSTRUCTION BRIEF for the NS Patents filed by Nippon Shinyaku Co.,Ltd., NS Pharma, Inc.. (Dudash, Amy) (Entered: 03/20/2023) (30) |
| Mar 20, 2023 | 174 | APPENDIX re 173 Joint Claim Construction Brief for NS Patents by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Vol. 1 (Ex. 1-6), # 2 Vol. 2 (Ex. 7-20), # 3 Vol. 3 (Ex. 21-25))(Dudash, Amy) (Entered: 03/20/2023) (0) |
| Mar 17, 2023 | 165 | NOTICE OF SERVICE of Fourth Set of Interrogatories to Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. (Nos. 18-22) filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 03/17/2023) (4) |
| Mar 16, 2023 | 164 | NOTICE OF SERVICE of Nippon Shinyaku Co. Ltd.'s and NS Pharma, Inc.'s Responses and Objections to Sarepta Therapeutics, Inc.'s Third Set of Interrogatories (Nos. 13-17) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 03/16/2023) (2) |
| Mar 13, 2023 | 162 | NOTICE OF SERVICE of Nippon Shinyaku Co. Ltd.'s and NS Pharma, Inc.'s Claim Construction Surreply filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 03/13/2023) (2) |
| Mar 13, 2023 | 163 | NOTICE OF SERVICE of Sur-Reply Claim Construction Brief filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 03/13/2023) (4) |
| Mar 6, 2023 | 161 | MOTION for Pro Hac Vice Appearance of Attorney Wan-Shon Lo - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) (Entered: 03/06/2023) (0) |
| Mar 3, 2023 | 160 | NOTICE OF SERVICE of Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s Second Set of Interrogatories (Nos. 14-21) and First Set of Requests for Admission (Nos. 1-10) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 03/03/2023) (2) |
| Feb 27, 2023 | 158 | NOTICE OF SERVICE of Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s Reply Claim Construction Brief filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 02/27/2023) (2) |
| Feb 27, 2023 | 159 | NOTICE OF SERVICE of Reply Claim Construction Brief filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 02/27/2023) (4) |
| Feb 23, 2023 | 157 | Letter to Honorable Gregory B. Williams from Amy M. Dudsh regarding Joint Status Letter. (Dudash, Amy) (Entered: 02/23/2023) (2) |
| Feb 14, 2023 | 156 | NOTICE OF SERVICE of Third Set of Interrogatories to Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. (Nos. 13-17) filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 02/14/2023) (4) |
| Feb 8, 2023 | 154 | MOTION for Pro Hac Vice Appearance of Attorney Ryan P. O'Quinn and Yoonhee Kim - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 02/08/2023) (5) |
| Feb 8, 2023 | 155 | NOTICE requesting Clerk to remove Aaron G. Clay as co-counsel.. (Dellinger, Megan) (Entered: 02/08/2023) (3) |
| Feb 6, 2023 | 152 | NOTICE OF SERVICE of Answering Claim Construction Brief filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 02/06/2023) (4) |
| Feb 6, 2023 | 153 | NOTICE OF SERVICE of Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s Responsive Claim Construction Brief filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 02/06/2023) (2) |
| Jan 26, 2023 | 151 | MULTI MEDIA DOCUMENT filed by Nippon Shinyaku Co.,Ltd., Sarepta Therapeutics, Inc. in the form of a disk re joint technology tutorial. Filing related to 150 Letter. (Media on file in Clerk's Office). (ntl) (Entered: 01/26/2023) (0) |
| Jan 24, 2023 | 150 | Letter to Honorable Gregory B. Williams from Amy M. Dudash regarding joint technology tutorial presentation. (Dudash, Amy) (Entered: 01/24/2023) (1) |
| Jan 13, 2023 | 149 | STIPULATION TO EXTEND TIME for Submission of Joint Technology Tutorial to January 24, 2023 - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 01/13/2023) (2) |
| Jan 6, 2023 | 147 | NOTICE OF SERVICE of Opening Claim Construction Brief filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 01/06/2023) (4) |
| Jan 6, 2023 | 148 | NOTICE OF SERVICE of Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s Opening Claim Construction Brief filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 01/06/2023) (2) |
| Jan 3, 2023 | 146 | MOTION for Pro Hac Vice Appearance of Attorney Yoonjin Lee - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) (Entered: 01/03/2023) (5) |
| Dec 30, 2022 | 145 | NOTICE OF SERVICE of Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.s Responses and Objections to Sarepta Therapeutics, Inc.s Fourth Request for the Production of Documents and Things (Nos. 91-94) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 12/30/2022) (2) |
| Dec 15, 2022 | 144 | CLAIM Construction Chart by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Exhibit L, # 13 Exhibit M, # 14 Exhibit N, # 15 Exhibit O, # 16 Exhibit P, # 17 Exhibit Q, # 18 Exhibit R, # 19 Exhibit S)(Dudash, Amy) (Entered: 12/15/2022) (0) |
| Dec 12, 2022 | 143 | SCHEDULING ORDER: Fact Discovery completed by 7/27/2023. Status Report due by 2/23/2023. Joint Claim Construction Brief due by 3/20/2023. A Markman Hearing is set for 4/19/2023 at 10:00 AM in Courtroom 6B before Judge Gregory B. Williams. A 7-day jury trial is scheduled for 5/13/24. Signed by Judge Gregory B. Williams on 12/12/22. (ntl) (Entered: 12/12/2022) (18) |
| Dec 9, 2022 | 142 | Joint PROPOSED ORDER Proposed Joint Scheduling Order re 141 Order,,,,,,,,,,, by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Entered: 12/09/2022) (18) |
| Dec 2, 2022 | 140 | NOTICE OF SERVICE of First Supplemental Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) and Paragraph 3 of the Default Standard for Discovery filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 12/02/2022) (4) |
| Dec 2, 2022 | 141 | ORAL ORDER: The Court has reviewed the parties' proposed amended scheduling order and accompanying letter. D.I. 132; D.I. 132-1. Consistent with the Court's ruling in the Rule 16 scheduling teleconference held on December 2, 2022, the parties shall submit, no later than December 9, 2022, a revised proposed scheduling order that contains the following dates decided by the Court: in paragraph 3(e): By June 22, 2023, Plaintiff and Counterclaim-Plaintiff shall provide final infringement contentions; in paragraph 3(f): By July 11, 2023, Defendant and Counterclaim-Defendants shall provide final invalidity contentions; in paragraph 3(g): By July 11, 2023, Defendant and Counterclaim-Defendants shall provide final non-infringement contentions; in paragraph 3(h): By July 20, 2023, Plaintiff and Counterclaim-Plaintiff shall provide final invalidity contentions; in paragraph 4(a): All fact discovery will be completed on or before July 27, 2023; in paragraph 4(f)(i): Disclosure of expert testimony is due on or before August 14, 2023, disclosure to contradict or rebut evidence is due on or before September 11, 2023, and reply expert reports are due on or before October 2, 2023; in paragraph 4(f)(iii): Expert discovery cut-off is on or before October 30, 2023; in paragraph 8: The parties' Joint Claim Construction Chart shall be filed no later than December 15, 2022; in paragraph 9: Plaintiff and Counterclaim-Plaintiff shall serve their opening claim construction brief on January 5, 2023, Defendant and Counterclaim-Defendants shall serve their answering brief on February 6, 2023, Plaintiff and Counterclaim-Plaintiff shall serve their reply brief on February 27, 2023, and Defendant and Counterclaim-Defendants shall serve their sur-reply brief no later than March 13, 2023. The parties shall file their Joint Claim Construction Brief no later than March 20, 2023; in paragraph 10: A Claim Construction Hearing will be scheduled for April 19, 2023, beginning at 10:00 a.m. in Courtroom 6B; in paragraph 12(a): The patentees must finally supplement the identification of all accused products and serve final infringement contentions no later than June 22, 2023; in paragraph 12(b): The accused infringers must finally supplement the identification of all invalidity references and serve final invalidity contentions no later than July 11, 2023; in paragraph 19: A pretrial conference will be held on May 6, 2024 at 4:30 p.m.; and, in paragraph 21, there shall be a 7-day trial beginning on May 13, 2024 at 9:30 a.m. Further, while the parties may file separate joint claim construction briefs for terms applicable to the patents asserted by Plaintiff and by Counterclaim-Plaintiff, the parties shall meet and confer to ensure that the parties request that the Court construe no more than twelve (12) terms across the two joint claim construction briefs. ORDERED by Judge Gregory B. Williams on 12/2/22. (ntl) (Entered: 12/02/2022) (0) |
| Nov 30, 2022 | 139 | NOTICE OF SERVICE of Fourth Set of Requests for the Production of Documents and Things (Nos. 91-94) filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 11/30/2022) (4) |
| Nov 28, 2022 | 138 | ORAL ORDER: IT IS HEREBY ORDERED that the telephonic status conference scheduled for Friday, December 2, 2022 at 11:00 a.m. is rescheduled for Friday, December 2, 2022 at 1:00 p.m. The parties shall arrange for the teleconference and shall provide chambers with the call-in information. ORDERED by Judge Gregory B. Williams on 11/28/22. (ntl) (Entered: 11/28/2022) (0) |
| Nov 22, 2022 | 136 | NOTICE OF SERVICE of Proposed Counter-Constructions filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) (Entered: 11/22/2022) (4) |
| Nov 22, 2022 | 137 | NOTICE OF SERVICE of Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s First Supplemental Rule 26(a)(1) Initial Disclosures and Proposed Constructions for Terms Identified by Sarepta Therapeutics, Inc. filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 11/22/2022) (2) |
| Nov 21, 2022 | 135 | NOTICE OF SERVICE of Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s Responses and Objections to Sarepta Therapeutics, Inc.'s Third Request for the Production of Documents and Things (Nos. 78-90) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) (Entered: 11/21/2022) (2) |
| Nov 15, 2022 | N/A | Order Setting Teleconference (0) Docket Text: ORAL ORDER: Having reviewed the parties' proposed amended scheduling order and accompanying letter, D.I. 132, a telephonic status conference will be held on Friday, December 2, 2022 at 11:00 a.m. The parties shall arrange for the teleconference and shall provide chambers with the call-in information. ORDERED by Judge Gregory B. Williams on 11/15/22. (ntl) |
| Nov 15, 2022 | 134 | ORAL ORDER: Having reviewed the parties' proposed amended scheduling order and accompanying letter, D.I. 132, a telephonic status conference will be held on Friday, December 2, 2022 at 11:00 a.m. The parties shall arrange for the teleconference and shall provide chambers with the call-in information. ORDERED by Judge Gregory B. Williams on 11/15/22. (ntl) (Entered: 11/15/2022) (0) |
| Nov 10, 2022 | 133 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Nippon Shinyaku and NS Pharma Responses and Objections to Sareptas Second Set of Requests for Production (Nos. 71-77) and Responses and Objections to Sareptas Second Set of Interrogatories (No. 12) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) |
| Nov 8, 2022 | 132 | Letter (Main Document) (1) Docket Text: Letter to Honorable Gregory B. Williams from Amy M. Dudash regarding Proposed Scheduling Order. (Attachments: # (1) Proposed Scheduling Order)(Dudash, Amy) |
| Nov 8, 2022 | 132 | Letter (Proposed Scheduling Order) (19) Docket Text: Letter to Honorable Gregory B. Williams from Amy M. Dudash regarding Proposed Scheduling Order. (Attachments: # (1) Proposed Scheduling Order)(Dudash, Amy) |
| Oct 26, 2022 | 130 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Claim Construction Issue Identification filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) |
| Oct 26, 2022 | 131 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Initial Disclosure of Claim Terms and Proposed Constructions filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) |
| Oct 25, 2022 | N/A | Order (0) Docket Text: ORAL ORDER IT IS HEREBY ORDERED that, not later than fourteen (14) days from the date of this Order, the parties shall meet and confer and file a joint amended proposed Scheduling Order in this action consistent with the applicable form Scheduling Order of Judge Williams, which is posted at http://www/ded/uscourts.gov (see Chambers, Judge Williams, Forms), along with a cover letter requesting the Court to enter the joint amended proposed Scheduling Order (if there are no disputes or other issues concerning scheduling in the joint amended proposed Scheduling Order that the Court needs to address) or to schedule a status conference. If there are disputes or other issues the Court needs to address in the joint amended proposed Scheduling Order, in the cover letter, the parties shall direct the Court to the paragraph numbers in the joint amended proposed Scheduling Order which those appear. ORDERED by Judge Gregory B. Williams on 10/25/22. (ntl) |
| Oct 21, 2022 | 128 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Third Set of Requests for the Production of Documents and Things (Nos. 78-90) filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) |
| Oct 11, 2022 | 127 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of (1) Second Set of Requests for the Production of Documents and Things (Nos. 71-77); and (2) Second Set of Interrogatories to Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. (No. 12) filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) |
| Sep 7, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Gregory B Williams. Please include the initials of the Judge (GBW) after the case number on all documents filed. (apk) |
| Aug 30, 2022 | 125 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) and Paragraph 3 of the Default Standard for Discovery filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) |
| Aug 30, 2022 | 126 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Nippon Shinyaku Co., Ltd.'s Rule 26(a)(1) Initial Disclosures filed by Nippon Shinyaku Co.,Ltd..(Dudash, Amy) |
| Aug 16, 2022 | 124 | Scheduling Order (15) Docket Text: SCHEDULING ORDER: Joinder of Parties due by 3/23/2023. Amended Pleadings due by 3/23/2023. Fact Discovery completed by 5/25/2023. Opening Expert Reports due by 8/14/2023. Rebuttal Expert Reports due by 9/11/2023. Reply Expert Reports due by 10/2/2023. Expert Discovery due by 10/2/2023. Dispositive Motions due by 11/20/2023. Answering Brief due 12/15/2023. Reply Brief due 1/10/2024. Claim Construction Opening Brief served by 3/31/2023. Claim Construction Answering Brief served by 4/18/2023. Claim Construction Reply Brief served by 5/5/2023. Claim Construction Surreply Brief served by 5/15/2023. Joint Claim Construction Brief filed by 5/22/2023. A Markman Hearing is set for 6/29/2023 at 10:00 AM in Courtroom 4A before Judge Maryellen Noreika. A Pretrial Conference is set for 5/6/2024 at 04:30 PM in Courtroom 4A before Judge Maryellen Noreika. A 10-day Jury Trial is set for 5/13/2024 at 09:30 AM in Courtroom 4A before Judge Maryellen Noreika. Signed by Judge Maryellen Noreika on 8/16/2022. (dlw) |
| Aug 12, 2022 | 123 | Proposed Order (15) Docket Text: PROPOSED ORDER -- [Proposed] Scheduling Order -- by Sarepta Therapeutics, Inc.. (Dellinger, Megan) |
| Jul 29, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re [121] MOTION for Pro Hac Vice Appearance of Attorney William B. Raich filed by Sarepta Therapeutics, Inc. ORDERED by Judge Maryellen Noreika on 7/29/2022. (dlw) |
| Jul 29, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney William B. Raich for Sarepta Therapeutics, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Jul 29, 2022 | 121 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney William B. Raich - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) |
| Jul 29, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER - Having reviewed the parties' [120] letter and updated proposed Scheduling Order, IT IS HEREBY ORDERED that the Court adopts Sarepta's proposal as it is more consistent with this Court's practices. On or before 8/12/2022, the parties shall submit a further updated proposed Scheduling Order. IT IS FURTHER ORDERED that today's 4:00 p.m. teleconference is CANCELLED. ORDERED by Judge Maryellen Noreika on 7/29/2022. (dlw) |
| Jul 27, 2022 | 120 | Letter (Main Document) (2) Docket Text: Letter to Honorable Maryellen Noreika from Amy M. Dudash regarding Proposed Scheduling Order. (Attachments: # (1) Exhibit A, # (2) Exhibit B)(Dudash, Amy) |
| Jul 27, 2022 | 120 | Letter (Exhibit A) (19) Docket Text: Letter to Honorable Maryellen Noreika from Amy M. Dudash regarding Proposed Scheduling Order. (Attachments: # (1) Exhibit A, # (2) Exhibit B)(Dudash, Amy) |
| Jul 27, 2022 | 120 | Letter (Exhibit B) (19) Docket Text: Letter to Honorable Maryellen Noreika from Amy M. Dudash regarding Proposed Scheduling Order. (Attachments: # (1) Exhibit A, # (2) Exhibit B)(Dudash, Amy) |
| Jul 18, 2022 | 118 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Nippon Shinyaku Co., Ltd.'s Initial Invalidity Contentions filed by Nippon Shinyaku Co.,Ltd..(Dudash, Amy) |
| Jul 18, 2022 | 119 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Sarepta Therapeutics, Inc.'s Initial Invalidity Contentions filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) |
| Jun 22, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Alissa K. Lipton for Sarepta Therapeutics, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Jun 21, 2022 | 116 | Proposed Order (23) Docket Text: PROPOSED ORDER // Proposed Stipulated Protective Order by NS Pharma, Inc., Nippon Shinyaku Co., Ltd. (Dudash, Amy) Modified on 6/21/2022 (dlw). |
| Jun 21, 2022 | 117 | Protective Order (23) Docket Text: STIPULATED PROTECTIVE ORDER. Signed by Judge Maryellen Noreika on 6/21/2022. (dlw) |
| Jun 17, 2022 | 114 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Nippon Shinyaku Co., Ltd.'s Initial Infringement Contentions and Appendices filed by Nippon Shinyaku Co.,Ltd..(Dudash, Amy) |
| Jun 17, 2022 | 115 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Initial Infringement Contentions filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) |
| Jun 8, 2022 | N/A | Order Setting Scheduling Conference (0) Docket Text: ORAL ORDER Setting Telephonic Scheduling Conference: IT IS HEREBY ORDERED that a telephonic Scheduling Conference is set for 7/29/2022 at 04:00 PM before Judge Maryellen Noreika. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 6/8/2022. (dlw) |
| May 16, 2022 | 111 | Order (3) Docket Text: ORDER - IT IS HEREBY ORDERED that: 1. Nippon Shinyaku's Motion for Preliminary Injunction (D.I. 4) is GRANTED; 2. Sarepta Therapeutics, Inc. shall withdraw its previously-filed IPR petitions for U.S. Patent Nos. 9,708,361; 10,385,092; 10,407,461; 10,487,106; 10,647,741; 10,662,217; and 10,683,322; 3. Within five (5) days of this Order, to effectuate withdrawal of the IPR petitions, the parties shall jointly submit an email to the Patent Trial and Appeal Board requesting a conference call to facilitate the withdrawal of the IPR petitions by requesting leave to file motions to terminate the IPR petitions. If the PTAB grants leave to file the motions to terminate the IPR petitions, Sarepta shall move to terminate the IPR petitions according to the schedule set by the PTAB; and 4. Sarepta shall take no further action in the IPR proceedings aside from effectuating withdrawal of the aforementioned petitions. Signed by Judge Maryellen Noreika on 5/16/2022. (dlw) |
| May 16, 2022 | 112 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.s Responses and Objections to Sarepta Therapeutics, Inc.s First Set of Interrogatories (Nos. 1-11) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) |
| May 11, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Aaron Gleaton Clay for Sarepta Therapeutics, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| May 10, 2022 | 110 | Letter (Main Document) (4) Docket Text: Letter to Honorable Maryellen Noreika from Amy M. Dudash regarding form of preliminary injunction order. (Attachments: # (1) Exhibit A, # (2) Exhibit B)(Dudash, Amy) |
| May 10, 2022 | 110 | Letter (Exhibit A) (3) Docket Text: Letter to Honorable Maryellen Noreika from Amy M. Dudash regarding form of preliminary injunction order. (Attachments: # (1) Exhibit A, # (2) Exhibit B)(Dudash, Amy) |
| May 10, 2022 | 110 | Letter (Exhibit B) (3) Docket Text: Letter to Honorable Maryellen Noreika from Amy M. Dudash regarding form of preliminary injunction order. (Attachments: # (1) Exhibit A, # (2) Exhibit B)(Dudash, Amy) |
| May 5, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re [106] MOTION for Pro Hac Vice Appearance of Attorney Eric Kraeutler filed by NS Pharma, Inc., Nippon Shinyaku Co., Ltd. ORDERED by Judge Maryellen Noreika on 5/5/2022. (dlw) |
| May 5, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Eric Kraeutler for NS Pharma, Inc. and Nippon Shinyaku Co.,Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| May 5, 2022 | 107 | USCA Mandate (1) Docket Text: MANDATE of USCA as to [55] Notice of Appeal (Federal Circuit) filed by Nippon Shinyaku Co.,Ltd.. USCA Decision: Reversed and remanded, the petition for panel rehearing is denied. The petition for rehearing en banc is denied. (See [92], [105]). (mdb) |
| May 5, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER - The Federal Circuit has concluded that "Nippon Shinyaku has shown that all four preliminary injunction factors weigh in its favor" and remanded the case "for entry of a preliminary injunction." THREFORE, IT IS HEREBY ORDERED that, on or before May 10, 2022, the parties shall meet and confer and jointly submit a form of preliminary injunction to the Court. ORDERED by Judge Maryellen Noreika on 5/5/2022. (dlw) |
| May 5, 2022 | 109 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Nippon Shinyaku Co., Ltd. and NS Pharma, Inc.'s Responses and Objections to Sarepta Therapeutics, Inc.'s First Request for the Production of Documents and Things (Nos. 1-70) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) |
| May 4, 2022 | 106 | Motion for Leave to Appear Pro Hac Vice (Main Document) (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Eric Kraeutler - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Certification of Eric Kraeutler)(Dudash, Amy) |
| May 4, 2022 | 106 | Motion for Leave to Appear Pro Hac Vice (Certification of Eric Kraeutler) (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Eric Kraeutler - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Certification of Eric Kraeutler)(Dudash, Amy) |
| May 3, 2022 | 105 | USCA Order (2) Docket Text: ORDER of USCA as to [55] Notice of Appeal (Federal Circuit) filed by Nippon Shinyaku Co., Ltd. Decision of USCA: The petition for panel rehearing is denied. The petition for rehearing en banc is denied. (ntl) |
| Apr 19, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Guylaine Hache, PhD for NS Pharma, Inc., Nippon Shinyaku Co.,Ltd., and Nippon Shinyaku Co.,Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 18, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re [102] MOTION for Pro Hac Vice Appearance of Attorney Guylaine Hache, Ph.D. filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd. ORDERED by Judge Maryellen Noreika on 4/18/2022. (dlw) |
| Apr 18, 2022 | 102 | Motion for Leave to Appear Pro Hac Vice (Main Document) (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Guylaine Hache, Ph.D. - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) |
| Apr 18, 2022 | 102 | Motion for Leave to Appear Pro Hac Vice (Certification by Counsel to be Admitted Pro Hac Vice) (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Guylaine Hache, Ph.D. - filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) |
| Apr 18, 2022 | 103 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Initial Identification of Asserted Patents, Accused Product, and Damages Model filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) |
| Apr 18, 2022 | 104 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Nippon Shinyaku Co., Ltd.'s Initial Identification of Asserted Patents, Accused Product, and Damages Model filed by Nippon Shinyaku Co.,Ltd..(Dudash, Amy) |
| Apr 15, 2022 | 101 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of First Set of Interrogatories to Nippon Shinyaku Co., Ltd. And NS Pharma, Inc. (Nos. 1-11) filed by Sarepta Therapeutics, Inc..(Blumenfeld, Jack) |
| Apr 12, 2022 | 100 | Letter (Main Document) (1) Docket Text: Letter to Honorable Maryellen Noreika from Amy Dudash regarding Proposed Scheduling Order Disputes. (Attachments: # (1) Proposed Scheduling Order)(Dudash, Amy) |
| Apr 12, 2022 | 100 | Letter (Proposed Scheduling Order) (18) Docket Text: Letter to Honorable Maryellen Noreika from Amy Dudash regarding Proposed Scheduling Order Disputes. (Attachments: # (1) Proposed Scheduling Order)(Dudash, Amy) |
| Apr 11, 2022 | 99 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of (1) Sarepta's Responses and Objections to NS's First Set of Interrogatories (Nos. 1-13) and (2) Sarepta's Responses and Objections to NS's First Set of Requests for Production to Sarepta (Nos. 1-149) filed by Sarepta Therapeutics, Inc..(Dellinger, Megan) |
| Apr 5, 2022 | 98 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of First Set of Requests for the Production of Documents and Things (Nos. 1-70) filed by Sarepta Therapeutics, Inc..(Blumenfeld, Jack) |
| Mar 11, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb) |
| Mar 11, 2022 | 97 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Plaintiff-Counterclaim Defendant Nippon Shinyaku Co., Ltd.s and Counterclaim Defendant NS Pharma, Inc.s First Set of Requests for Production to Defendant Sarepta Therapeutics, Inc. (Nos. 1-149) and First Set of Interrogatories to Defendant Sarepta Therapeutics, Inc. (Nos. 1-13) filed by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) |
| Feb 18, 2022 | 96 | Answer to Counterclaim (30) Docket Text: ANSWER to [89] Answer to Amended Complaint, Counterclaim by NS Pharma, Inc., Nippon Shinyaku Co.,Ltd..(Dudash, Amy) |
| Feb 14, 2022 | N/A | Order (0) Docket Text: ORAL ORDER: Having reviewed the parties' joint status report (D.I. 94), IT IS HEREBY ORDERED that Nippon Shinyaku's request to set an expedited letter briefing schedule on the scope of a preliminary injunction is DENIED. The Court does not currently have jurisdiction over Nippon Shinyaku's motion for a preliminary injunction. See generally Griggs v. Provident Consumer Discount Co., 459 U.S. 56, 58 (1982) ("The filing of a notice of appeal is an event of jurisdictional significance - it confers jurisdiction on the court of appeals and divests the district court of its control over those aspects of the case involved in the appeal."); Wright & Miller, 16AA Federal Practice and Procedure § 3987 (5th ed. 2021) ("Until the mandate issues... the case ordinarily remains within the jurisdiction of the court of appeals and the district court lacks power to proceed further with respect to the matters involved with the appeal.") (footnote omitted). Moreover, even if the Court did have jurisdiction over the preliminary injunction issues, the Court would exercise its discretion to defer further letter briefing until the Federal Circuit issues its mandate. Sarepta is still considering whether it will file a rehearing petition. (D.I. 94 at 2) Until any such petition is resolved and the Federal Circuit's mandate issues, "the three judge panel, or the Federal Circuit sitting en banc, may rehear the matter, alter or amend the opinion, or otherwise change the scope of issues that must be addressed on remand." Apple, Inc. v. Samsung Elecs. Co., 2012 WL 1987042, at *3 (N.D. Cal. June 4, 2012). Thus, continuing with preliminary injunction proceedings before this Court at this time risks creating substantial confusion. See id. Once the Federal Circuit issues its mandate, assuming that its instructions to this Court remain unchanged, this Court will act promptly (with the parties' assistance) to enter a preliminary injunction. IT IS FURTHER ORDERED that, as the parties have agreed, they shall participate in a Rule 26(f) conference within seven days of the close of the pleadings. ORDERED by Judge Leonard P. Stark on 2/14/22. (ntl) |
| Feb 10, 2022 | 94 | Status Report (4) Docket Text: Joint STATUS REPORT Pursuant to the Court's February 8, 2022 Oral Order (D.I. 93) by Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) |
| Feb 8, 2022 | 92 | USCA Order (Main Document) (1) Docket Text: ORDER of USCA as to [55] Notice of Appeal (Federal Circuit) filed by Nippon Shinyaku Co.,Ltd. Decision of USCA: Reversed and Remanded. (Attachment: # (1) Opinion) (ntl) |
| Feb 8, 2022 | 92 | USCA Order (Opinion) (16) Docket Text: ORDER of USCA as to [55] Notice of Appeal (Federal Circuit) filed by Nippon Shinyaku Co.,Ltd. Decision of USCA: Reversed and Remanded. (Attachment: # (1) Opinion) (ntl) |
| Feb 8, 2022 | N/A | Order (0) Docket Text: ORAL ORDER: Having considered the parties' joint status report (D.I. 88), and in light of the Federal Circuit's opinion regarding Nippon Shinyaku's motion for a preliminary injunction (see D.I. 92), IT IS HEREBY ORDERED that the parties shall meet and confer and, no later than February 10, submit a joint status report regarding: (i) the scheduling of a Rule 26(f) conference, and (ii) any other matters the parties would like to address at this time. ORDERED by Judge Leonard P. Stark on 2/8/22. (ntl) |
| Feb 1, 2022 | 91 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Sarepta Therapeutics, Inc.. NS Pharma, Inc. served on 1/31/2022, answer due 2/22/2022. (Dellinger, Megan) |
| Jan 28, 2022 | 89 | Answer to Amended Complaint (Main Document) (30) Docket Text: ANSWER to Amended Complaint, re: [86] Amended Complaint with Jury Demand , COUNTERCLAIM against Nippon Shinyaku Co.,Ltd., NS Pharma, Inc. by Sarepta Therapeutics, Inc.. (Attachments: # (1) Exhibits A-C)(Dellinger, Megan) |
| Jan 28, 2022 | 89 | Answer to Amended Complaint (Exhibits A-C) (30) Docket Text: ANSWER to Amended Complaint, re: [86] Amended Complaint with Jury Demand , COUNTERCLAIM against Nippon Shinyaku Co.,Ltd., NS Pharma, Inc. by Sarepta Therapeutics, Inc.. (Attachments: # (1) Exhibits A-C)(Dellinger, Megan) |
| Jan 28, 2022 | 90 | Disclosure Statement (3) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) |
| Jan 20, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [87] STIPULATION TO EXTEND TIME for the parties to file a Joint Status Report to January 20, 2022 filed by Sarepta Therapeutics, Inc. Signed by Judge Leonard P. Stark on 1/20/22. (ntl) |
| Jan 20, 2022 | 88 | Status Report (4) Docket Text: Joint STATUS REPORT Pursuant to the Court's December 10, 2021 Oral Order (D.I. 81) by Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) |
| Jan 18, 2022 | 87 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME for the parties to file a Joint Status Report to January 20, 2022 - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) |
| Jan 14, 2022 | 86 | Amended Complaint* (1) |
| Jan 14, 2022 | 86 | Amended Complaint (30) Docket Text: Second AMENDED COMPLAINT against Sarepta Therapeutics, Inc.- filed by Nippon Shinyaku Co.,Ltd..(Dudash, Amy) |
| Dec 27, 2021 | N/A | Order (0) Docket Text: ORAL ORDER: For the reasons stated at the end of the teleconference on December 20, 2021, IT IS HEREBY ORDERED that: (i) Sarepta's motion to dismiss Claims II and III and to strike portions of the First Amended Complaint (D.I. 53) is GRANTED IN PART and DENIED IN PART, and (ii) Nippon Shinyaku shall file its Second Amended Complaint no later than January 20, 2022. IT IS FURTHER ORDERED that Sarepta's earlier-filed motion to dismiss and to strike (D.I. 32) is DENIED AS MOOT. ORDERED by Judge Leonard P. Stark on 12/27/21. (ntl) |
| Dec 27, 2021 | 85 | Transcript (39) Docket Text: Official Transcript of Telephonic Oral Argument held on December 20, 2021 before Judge Leonard P. Stark. Court Reporter Brian Gaffigan, email: gaffigan@verizon.net. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 1/18/2022. Redacted Transcript Deadline set for 1/27/2022. Release of Transcript Restriction set for 3/28/2022. (bpg) |
| Dec 20, 2021 | N/A | Telephone Conference (0) Docket Text: Minute Entry for proceedings held before Judge Leonard P. Stark - Telephone Conference held on 12/20/2021. (Court Reporter B. Gaffigan.) (ntl) |
| Dec 17, 2021 | N/A | Oral Order (0) Docket Text: ORAL ORDER: IT IS HEREBY ORDERED that the teleconference hearing on Monday, December 20 will begin at 3:00 p.m. Each side will be allocated twenty (20) minutes for its presentation. The parties and any interested members of the public can access the teleconference by dialing 877-336-1829 and using the access code 1408971. Ordered by Judge Leonard P. Stark on 12/17/2021. (etg) |
| Dec 17, 2021 | N/A | Oral Order (0) Docket Text: ORAL ORDER: IT IS HEREBY ORDERED that the teleconference hearing on Monday, December 20 will begin at 04:15 p.m. Each side will be allocated twenty (20) minutes for its presentation. The parties and any interested members of the public can access the teleconference by dialing 877-336-1829 and using the access code 1408971. Ordered by Judge Leonard P. Stark on 12/17/2021. (etg) |
| Dec 10, 2021 | N/A | Oral Order (0) Docket Text: ORAL ORDER: Having considered the parties' letters (D.I. 77, 79, 80), IT IS HEREBY ORDERED that Nippon Shinyaku's request to compel Sarepta to participate in an immediate Rule 26(f) conference is DENIED. Nippon Shinyaku is correct that "no statute, Federal Rule, or Local Rule provides that a party may unilaterally delay a Rule 26(f) conference." (D.I. 79 at 1) Sarepta is also correct, however, that Nippon Shinyaku "overstates" Sarepta's position. (D.I. 80 at 1) Under the totality of circumstances presented in this case, including the Court's upcoming consideration of Sarepta's motion to dismiss and motion to strike, the upcoming Federal Circuit argument on Nippon Shinyaku's interlocutory appeal, and the upcoming institution decisions by the PTAB on Sarepta's inter partes review petitions -- all within the next month -- the Court agrees with Sarepta that the appropriate course of action is to reconsider this issue during the latter half of January 2022. IT IS FURTHER ORDERED that the parties shall meet and confer and file a joint status report of no more than two single-spaced pages by no later than January 18, 2022 to provide the Court with any updated positions on this issue. IT IS FURTHER ORDERED that the teleconference set for Monday, December 13 at 4:45 p.m. is CANCELLED, and (ii) the Court will hear argument on Sarepta's motion to dismiss and motion to strike (D.I. 53) by teleconference on Monday, December 20 at 4:45 p.m. Ordered by Judge Leonard P. Stark on 12/10/2021. (etg) |
| Dec 9, 2021 | 80 | Letter (3) Docket Text: Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding Response to Plaintiff's Request to Compel a Rule 26(f) Conference - re [79] Letter. (Blumenfeld, Jack) |
| Dec 8, 2021 | 79 | Letter (3) Docket Text: Letter to Honorable Leonard P. Stark from Counsel for Plaintiff regarding Regarding Motion to Compel Rule 26(f) Conference - re [77] Letter, [78] Order Setting Teleconference,,,,. (Dudash, Amy) |
| Dec 6, 2021 | N/A | Order Setting Teleconference (0) Docket Text: ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for December 13, 2021 at 4:45 p.m. The Court will also hear argument on the pending motion to dismiss and to strike (D.I. 53). The parties and any interested members of the public can access the teleconference by dialing 877-336-1829 and using the access code 1408971. IT IS FURTHER ORDERED that not later than December 8, 2021 any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than December 9, 2021, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 12/6/2021. (ntl) |
| Nov 23, 2021 | 77 | Letter (1) Docket Text: Letter to Honorable Leonard P. Stark from Counsel for Plaintiff regarding Requesting Discovery Dispute Teleconference. (Dudash, Amy) |
| Oct 29, 2021 | 75 | Redacted Document (4) Docket Text: REDACTED VERSION of [70] MOTION to Seal (Unopposed) by Sarepta Therapeutics, Inc.. (Dellinger, Megan) |
| Oct 29, 2021 | 76 | Redacted Document (15) Docket Text: REDACTED VERSION of [71] Reply Brief, by Sarepta Therapeutics, Inc.. (Dellinger, Megan) |
| Oct 27, 2021 | N/A | Document Unsealed (0) Docket Text: Document Unsealed -- [72] Memorandum Order. (ntl) |
| Oct 26, 2021 | 73 | Request for Oral Argument (1) Docket Text: REQUEST for Oral Argument by Nippon Shinyaku Co.,Ltd. re [53] MOTION to Dismiss for Failure to State a Claim MOTION to Strike -- Defendant Sarepta Therapeutics, Inc.'s Motion to Dismiss Claims II-III of Nippon Shinyaku's First Amended Complaint and to Strike Portions of the First Amended Complaint --. (Dudash, Amy) |
| Oct 26, 2021 | 74 | Order (1) Docket Text: ORDER re [70] MOTION to Seal (Unopposed) filed by Sarepta Therapeutics, Inc. Signed by Judge Leonard P. Stark on 10/26/21. (ntl) |
| Oct 25, 2021 | 72 | Memorandum and Order (8) Docket Text: MEMORANDUM ORDER re [47] Memorandum Order, [4] MOTION for Preliminary Injunction. Signed by Judge Leonard P. Stark on 10/25/21. This order has been emailed to local counsel. (ntl) (Main Document 72 replaced and UNSEALED on 10/27/2021) (ntl). Modified on 10/27/2021 (ntl). |
| Oct 15, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [66] Joint STIPULATION TO EXTEND TIME for Defendant to file its Reply Brief in support of its Motion to Dismiss and to Strike [D.I. 53] to October 22, 2021 filed by Sarepta Therapeutics, Inc. Signed by Judge Leonard P. Stark on 10/15/21. (ntl) |
| Oct 15, 2021 | 68 | Redacted Document (3) Docket Text: REDACTED VERSION of [63] MOTION to Seal [Unopposed] by Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) |
| Oct 15, 2021 | 69 | Redacted Document (26) Docket Text: REDACTED VERSION of [64] Answering Brief in Opposition, by Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) |
| Oct 13, 2021 | 67 | Order (1) Docket Text: ORDER re [63] MOTION to Seal [Unopposed] filed by Nippon Shinyaku Co.,Ltd. Signed by Judge Leonard P. Stark on 10/12/21. (ntl) |
| Oct 12, 2021 | 66 | Stipulation to EXTEND Time (1) Docket Text: Joint STIPULATION TO EXTEND TIME for Defendant to file its Reply Brief in support of its Motion to Dismiss and to Strike [D.I. 53] to October 22, 2021 - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) |
| Oct 8, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Zachary D. Miller for Nippon Shinyaku Co.,Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
| Oct 8, 2021 | 65 | Notice (Other) (30) Docket Text: NOTICE of Subsequent Authority by Sarepta Therapeutics, Inc. re [47] Memorandum and Order, [55] Notice of Appeal (Federal Circuit) , [4] MOTION for Preliminary Injunction (Blumenfeld, Jack) |
| Oct 7, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [62] MOTION for Pro Hac Vice Appearance of Attorney Zachary Miller filed by Nippon Shinyaku Co., Ltd. Signed by Judge Leonard P. Stark on 10/7/21. (ntl) |
| Oct 7, 2021 | 62 | Motion for Leave to Appear Pro Hac Vice (Main Document) (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Zachary Miller - filed by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) |
| Oct 7, 2021 | 62 | Motion for Leave to Appear Pro Hac Vice (Certification by Counsel to be Admitted Pro Hac Vice) (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Zachary Miller - filed by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) |
| Oct 1, 2021 | 58 | Redacted Document (3) Docket Text: REDACTED VERSION of [43] MOTION to Seal (Unopposed) by Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) |
| Oct 1, 2021 | 59 | Redacted Document (12) Docket Text: REDACTED VERSION of [44] Answering Brief in Opposition, by Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) |
| Oct 1, 2021 | 60 | Redacted Document (5) Docket Text: REDACTED VERSION of [52] MOTION for Leave to File Under Seal by Sarepta Therapeutics, Inc.. (Dellinger, Megan) |
| Oct 1, 2021 | 61 | Redacted Document (30) Docket Text: REDACTED VERSION of [54] Opening Brief in Support, by Sarepta Therapeutics, Inc.. (Dellinger, Megan) |
| Sep 29, 2021 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: Corrected main documents added to D.I. 11 and D.I. 12 per request of counsel. (ntl) |
| Sep 29, 2021 | 57 | USCA Notice of Docketing ROA (4) Docket Text: NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re [55] Notice of Appeal (Federal Circuit) filed by Nippon Shinyaku Co., Ltd. USCA Case Number 2021-2369. (ntl) |
| Sep 28, 2021 | 55 | Notice of Appeal* (1) |
| Sep 28, 2021 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: Entry previously filed at D.I. 55 was improperly filed and will be re-docketed using the correct code. (nmg) |
| Sep 28, 2021 | N/A | APPEAL - Credit Card Payment (0) Docket Text: APPEAL - Credit Card Payment of $505.00 received re [55] Notice of Appeal (Federal Circuit) filed by Nippon Shinyaku Co.,Ltd.. ( Filing fee $505, receipt number ADEDC-3708791.) (Dudash, Amy) |
| Sep 28, 2021 | N/A | Notice of Appeal and Docket Sheet to USCA (0) Docket Text: Notice of Appeal and Docket Sheet to US Court of Appeals for the Federal Circuit re [55] Notice of Appeal (Federal Circuit). (nmg) |
| Sep 28, 2021 | 55 | Notice of Appeal (Federal Circuit) (1) Docket Text: NOTICE OF APPEAL to the Federal Circuit of [47] Memorandum and Order . Appeal filed by Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) |
| Sep 28, 2021 | 56 | Order (1) Docket Text: ORDER re [52] MOTION for Leave to File Under Seal filed by Sarepta Therapeutics, Inc. Signed by Judge Leonard P. Stark on 9/28/21. (ntl) |
| Sep 24, 2021 | 50 | Amended Complaint* (1) |
| Sep 24, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [48] STIPULATION TO EXTEND TIME for plaintiff to file redacted versions of its motion to seal and its answering brief in opposition to motion to dismiss and strike (D.I. Nos. 43-44) to October 1, 2021 filed by Sarepta Therapeutics, Inc. Signed by Judge Leonard P. Stark on 9/24/21. (ntl) |
| Sep 24, 2021 | 47 | Memorandum and Order (2) Docket Text: MEMORANDUM ORDER re [4] MOTION for Preliminary Injunction is DENIED; requests for oral argument and expedited scheduling of oral argument are DENIED. Signed by Judge Leonard P. Stark on 9/24/21. (ntl) |
| Sep 24, 2021 | 48 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME for plaintiff to file redacted versions of its motion to seal and its answering brief in opposition to motion to dismiss and strike (D.I. Nos. 43-44) to October 1, 2021 - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) |
| Sep 24, 2021 | 49 | Redacted Document (3) Docket Text: REDACTED VERSION of [38] MOTION to Seal Unopposed by Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) |
| Sep 24, 2021 | 50 | Redacted Document (Main Document) (30) Docket Text: REDACTED VERSION of [39] Amended Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5)(Dudash, Amy) |
| Sep 24, 2021 | 50 | Redacted Document (Exhibit 1) (30) Docket Text: REDACTED VERSION of [39] Amended Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5)(Dudash, Amy) |
| Sep 24, 2021 | 50 | Redacted Document (Exhibit 2) (30) Docket Text: REDACTED VERSION of [39] Amended Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5)(Dudash, Amy) |
| Sep 24, 2021 | 50 | Redacted Document (Exhibit 3) (4) Docket Text: REDACTED VERSION of [39] Amended Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5)(Dudash, Amy) |
| Sep 24, 2021 | 50 | Redacted Document (Exhibit 4) (1) Docket Text: REDACTED VERSION of [39] Amended Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5)(Dudash, Amy) |
| Sep 24, 2021 | 50 | Redacted Document (Exhibit 5) (1) Docket Text: REDACTED VERSION of [39] Amended Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit 1, # (2) Exhibit 2, # (3) Exhibit 3, # (4) Exhibit 4, # (5) Exhibit 5)(Dudash, Amy) |
| Sep 24, 2021 | 51 | Reply Brief (3) Docket Text: REPLY BRIEF re [32] MOTION to Dismiss MOTION to Strike [2] Complaint, -- Motion to Dismiss Claims II-X of Complaint and to Strike Paragraphs 11, 66 and 69 of the Complaint -- - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) |
| Sep 24, 2021 | 53 | Motion to Dismiss for Failure to State a Claim (4) Docket Text: MOTION to Dismiss for Failure to State a Claim , MOTION to Strike -- Defendant Sarepta Therapeutics, Inc.'s Motion to Dismiss Claims II-III of Nippon Shinyaku's First Amended Complaint and to Strike Portions of the First Amended Complaint -- - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) |
| Sep 23, 2021 | 46 | Letter (2) Docket Text: Letter to Leonard P. Stark from Counsel for Plaintiff regarding Request for Expedited Scheduling of Oral Argument Regarding Plaintiff's Motion for Preliminary Injunction - re [26] Request for Oral Argument, [4] MOTION for Preliminary Injunction, [27] Letter. (Dudash, Amy) |
| Sep 21, 2021 | 45 | Order (1) Docket Text: ORDER re [43] MOTION to Seal (Unopposed) filed by Nippon Shinyaku Co., Ltd. Signed by Judge Leonard P. Stark on 9/21/21. (ntl) |
| Sep 20, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [42] STIPULATION TO EXTEND TIME to file redacted versions of the First Amended Complaint (D.I. 39) and Motion to Seal (D.I. 38) to September 24, 2021 filed by Nippon Shinyaku Co.,Ltd. Signed by Judge Leonard P. Stark on 9/20/21. (ntl) |
| Sep 16, 2021 | 42 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME to file redacted versions of the First Amended Complaint (D.I. 39) and Motion to Seal (D.I. 38) to September 24, 2021 - filed by Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) |
| Sep 13, 2021 | 40 | Order (1) Docket Text: ORDER re [38] MOTION to Seal Unopposed filed by Nippon Shinyaku Co., Ltd. Signed by Judge Leonard P. Stark on 9/13/21. (ntl) |
| Sep 10, 2021 | 36 | Redacted Document (5) Docket Text: REDACTED VERSION of [31] MOTION to Seal Opening Brief by Sarepta Therapeutics, Inc.. (Dellinger, Megan) |
| Sep 10, 2021 | 37 | Redacted Document (28) Docket Text: REDACTED VERSION of [33] Opening Brief in Support, by Sarepta Therapeutics, Inc.. (Dellinger, Megan) |
| Sep 9, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [34] MOTION for Pro Hac Vice Appearance of Attorney Jitsuro Morishita filed by Nippon Shinyaku Co.,Ltd. Signed by Judge Leonard P. Stark on 9/9/21. (ntl) |
| Sep 9, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Jitsuro Morishita for Nippon Shinyaku Co.,Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
| Sep 9, 2021 | 35 | Order (1) Docket Text: ORDER re [31] MOTION to Seal Opening Brief filed by Sarepta Therapeutics, Inc. Signed by Judge Leonard P. Stark on 9/8/21. (ntl) |
| Sep 8, 2021 | 34 | Motion for Leave to Appear Pro Hac Vice (Main Document) (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Jitsuro Morishita - filed by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) |
| Sep 8, 2021 | 34 | Motion for Leave to Appear Pro Hac Vice (Certification by Counsel to be Admitted Pro Hac Vice) (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Jitsuro Morishita - filed by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) |
| Sep 3, 2021 | 32 | Motion to Dismiss (4) Docket Text: MOTION to Dismiss, MOTION to Strike [2] Complaint, -- Motion to Dismiss Claims II-X of Complaint and to Strike Paragraphs 11, 66 and 69 of the Complaint -- - filed by Sarepta Therapeutics, Inc.. (Blumenfeld, Jack) |
| Sep 1, 2021 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: Corrected document added to D.I. [14] per request of counsel. (ntl) |
| Sep 1, 2021 | 29 | Redacted Document (4) Docket Text: REDACTED VERSION of [24] MOTION to Seal [Unopposed] by Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) |
| Sep 1, 2021 | 30 | Redacted Document (14) Docket Text: REDACTED VERSION of [25] Reply Brief by Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) |
| Aug 27, 2021 | 27 | Letter (1) Docket Text: Letter to The Honorable Leonard P. Stark from Jack B. Blumenfeld regarding request for oral argument - re [4] MOTION for Preliminary Injunction. (Blumenfeld, Jack) |
| Aug 27, 2021 | 28 | Order (1) Docket Text: ORDER re [24] MOTION for Leave to file under Seal [Unopposed] filed by Nippon Shinyaku Co., Ltd. Signed by Judge Leonard P. Stark on 8/27/21. (ntl) |
| Aug 25, 2021 | 26 | Request for Oral Argument (1) Docket Text: REQUEST for Oral Argument by Nippon Shinyaku Co.,Ltd. re [4] MOTION for Preliminary Injunction. (Dudash, Amy) |
| Aug 18, 2021 | 22 | Redacted Document (5) Docket Text: REDACTED VERSION of [17] MOTION to Seal (Unopposed) - by Sarepta Therapeutics, Inc.. (Dellinger, Megan) |
| Aug 18, 2021 | 23 | Redacted Document (Main Document) (27) Docket Text: REDACTED VERSION of [18] Answering Brief in Opposition - by Sarepta Therapeutics, Inc.. (Attachments: # (1) Exhibits 1-3)(Dellinger, Megan) |
| Aug 18, 2021 | 23 | Redacted Document (Exhibits 1-3) (30) Docket Text: REDACTED VERSION of [18] Answering Brief in Opposition - by Sarepta Therapeutics, Inc.. (Attachments: # (1) Exhibits 1-3)(Dellinger, Megan) |
| Aug 17, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [21] STIPULATION TO EXTEND TIME Deadline for Plaintiff to File Its Reply Brief in Support of Motion for Preliminary Injunction (D.I. 4) to August 25, 2021 filed by Nippon Shinyaku Co., Ltd. Signed by Judge Leonard P. Stark on 8/17/21. (ntl) |
| Aug 16, 2021 | 20 | Order (1) Docket Text: ORDER re [17] MOTION for Leave to Seal (Unopposed) filed by Sarepta Therapeutics, Inc. Signed by Judge Leonard P. Stark on 8/16/21. (ntl) |
| Aug 16, 2021 | 21 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME Deadline for Plaintiff to File Its Reply Brief in Support of Motion for Preliminary Injunction (D.I. 4) to August 25, 2021 - filed by Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) |
| Aug 13, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [19] MOTION for Pro Hac Vice Appearance of Attorney Alissa K. Lipton, Charles E. Lipsey, Michael J. Flibbert, J. Derek McCorquindale, and Aaron Gleaton Clay filed by Sarepta Therapeutics, Inc. Signed by Judge Leonard P. Stark on 8/13/21. (ntl) |
| Aug 12, 2021 | 19 | Motion for Leave to Appear Pro Hac Vice (8) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Alissa K. Lipton, Charles E. Lipsey, Michael J. Flibbert, J. Derek McCorquindale, and Aaron Gleaton Clay - filed by Sarepta Therapeutics, Inc.. (Dellinger, Megan) |
| Jul 28, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [16] MOTION for Pro Hac Vice Appearance of Attorney Amanda Williamson, Christopher Betti, Krista Vink Venegas, Maria Doukas, and Michael Sikora filed by Nippon Shinyaku Co.,Ltd. Signed by Judge Leonard P. Stark on 7/28/21. (ntl) |
| Jul 28, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Amanda S. Williamson, Christopher J Betti, Krista Vink Venegas, Michael T. Sikora, and Maria E. Doukas for Nippon Shinyaku Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
| Jul 28, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [15] STIPULATION TO EXTEND TIME for the defendant to file its answering brief and its answer to the complaint to August 11, 2021 and September 3, 2021, respectively filed by Sarepta Therapeutics, Inc. Signed by Judge Leonard P. Stark on 7/28/21. (ntl) |
| Jul 27, 2021 | 16 | Motion for Leave to Appear Pro Hac Vice (Main Document) (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Amanda Williamson, Christopher Betti, Krista Vink Venegas, Maria Doukas, and Michael Sikora - filed by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Amanda Williamson Certification by Counsel to be Admitted Pro Hac Vice, # (2) Christopher Betti Certification by Counsel to be Admitted Pro Hac Vice, # (3) Krista Venegas Certification by Counsel to be Admitted Pro Hac Vice, # (4) Maria Doukas Certification by Counsel to be Admitted Pro Hac Vice, # (5) Michael Sikora Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) |
| Jul 27, 2021 | 16 | Motion for Leave to Appear Pro Hac Vice (Amanda Williamson Certification by Counsel to be Admitted Pro Hac Vice) (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Amanda Williamson, Christopher Betti, Krista Vink Venegas, Maria Doukas, and Michael Sikora - filed by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Amanda Williamson Certification by Counsel to be Admitted Pro Hac Vice, # (2) Christopher Betti Certification by Counsel to be Admitted Pro Hac Vice, # (3) Krista Venegas Certification by Counsel to be Admitted Pro Hac Vice, # (4) Maria Doukas Certification by Counsel to be Admitted Pro Hac Vice, # (5) Michael Sikora Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) |
| Jul 27, 2021 | 16 | Motion for Leave to Appear Pro Hac Vice (Christopher Betti Certification by Counsel to be Admitted Pro Hac Vice) (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Amanda Williamson, Christopher Betti, Krista Vink Venegas, Maria Doukas, and Michael Sikora - filed by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Amanda Williamson Certification by Counsel to be Admitted Pro Hac Vice, # (2) Christopher Betti Certification by Counsel to be Admitted Pro Hac Vice, # (3) Krista Venegas Certification by Counsel to be Admitted Pro Hac Vice, # (4) Maria Doukas Certification by Counsel to be Admitted Pro Hac Vice, # (5) Michael Sikora Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) |
| Jul 27, 2021 | 16 | Motion for Leave to Appear Pro Hac Vice (Krista Venegas Certification by Counsel to be Admitted Pro Hac Vice) (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Amanda Williamson, Christopher Betti, Krista Vink Venegas, Maria Doukas, and Michael Sikora - filed by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Amanda Williamson Certification by Counsel to be Admitted Pro Hac Vice, # (2) Christopher Betti Certification by Counsel to be Admitted Pro Hac Vice, # (3) Krista Venegas Certification by Counsel to be Admitted Pro Hac Vice, # (4) Maria Doukas Certification by Counsel to be Admitted Pro Hac Vice, # (5) Michael Sikora Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) |
| Jul 27, 2021 | 16 | Motion for Leave to Appear Pro Hac Vice (Maria Doukas Certification by Counsel to be Admitted Pro Hac Vice) (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Amanda Williamson, Christopher Betti, Krista Vink Venegas, Maria Doukas, and Michael Sikora - filed by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Amanda Williamson Certification by Counsel to be Admitted Pro Hac Vice, # (2) Christopher Betti Certification by Counsel to be Admitted Pro Hac Vice, # (3) Krista Venegas Certification by Counsel to be Admitted Pro Hac Vice, # (4) Maria Doukas Certification by Counsel to be Admitted Pro Hac Vice, # (5) Michael Sikora Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) |
| Jul 27, 2021 | 16 | Motion for Leave to Appear Pro Hac Vice (Michael Sikora Certification by Counsel to be Admitted Pro Hac Vice) (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Amanda Williamson, Christopher Betti, Krista Vink Venegas, Maria Doukas, and Michael Sikora - filed by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Amanda Williamson Certification by Counsel to be Admitted Pro Hac Vice, # (2) Christopher Betti Certification by Counsel to be Admitted Pro Hac Vice, # (3) Krista Venegas Certification by Counsel to be Admitted Pro Hac Vice, # (4) Maria Doukas Certification by Counsel to be Admitted Pro Hac Vice, # (5) Michael Sikora Certification by Counsel to be Admitted Pro Hac Vice)(Dudash, Amy) |
| Jul 26, 2021 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: Corrected document added to D.I. 5 per request of counsel. (ntl) |
| Jul 26, 2021 | 15 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME for the defendant to file its answering brief and its answer to the complaint to August 11, 2021 and September 3, 2021, respectively - filed by Sarepta Therapeutics, Inc.. (Blumenfeld, Jack) |
| Jul 21, 2021 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (rjb) |
| Jul 20, 2021 | 12 | Complaint* (1) |
| Jul 20, 2021 | 11 | Redacted Document (Main Document) (4) Docket Text: REDACTED VERSION of [1] MOTION to Seal by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Text of Proposed Order)(Dudash, Amy) (Main Document 11 replaced on 9/29/2021) (ntl). |
| Jul 20, 2021 | 11 | Redacted Document (Text of Proposed Order) (1) Docket Text: REDACTED VERSION of [1] MOTION to Seal by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Text of Proposed Order)(Dudash, Amy) (Main Document 11 replaced on 9/29/2021) (ntl). |
| Jul 20, 2021 | 12 | Redacted Document (Main Document) (30) Docket Text: REDACTED VERSION of [2] Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G, # (8) Exhibit H, # (9) Exhibit I, # (10) Exhibit J, # (11) Exhibit K, # (12) Civil Cover Sheet)(Dudash, Amy) (Main Document 12 replaced on 9/29/2021) (ntl). |
| Jul 20, 2021 | 12 | Redacted Document (Exhibit A) (2) Docket Text: REDACTED VERSION of [2] Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G, # (8) Exhibit H, # (9) Exhibit I, # (10) Exhibit J, # (11) Exhibit K, # (12) Civil Cover Sheet)(Dudash, Amy) (Main Document 12 replaced on 9/29/2021) (ntl). |
| Jul 20, 2021 | 12 | Redacted Document (Exhibit B) (30) Docket Text: REDACTED VERSION of [2] Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G, # (8) Exhibit H, # (9) Exhibit I, # (10) Exhibit J, # (11) Exhibit K, # (12) Civil Cover Sheet)(Dudash, Amy) (Main Document 12 replaced on 9/29/2021) (ntl). |
| Jul 20, 2021 | 12 | Redacted Document (Exhibit C) (30) Docket Text: REDACTED VERSION of [2] Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G, # (8) Exhibit H, # (9) Exhibit I, # (10) Exhibit J, # (11) Exhibit K, # (12) Civil Cover Sheet)(Dudash, Amy) (Main Document 12 replaced on 9/29/2021) (ntl). |
| Jul 20, 2021 | 12 | Redacted Document (Exhibit D) (30) Docket Text: REDACTED VERSION of [2] Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G, # (8) Exhibit H, # (9) Exhibit I, # (10) Exhibit J, # (11) Exhibit K, # (12) Civil Cover Sheet)(Dudash, Amy) (Main Document 12 replaced on 9/29/2021) (ntl). |
| Jul 20, 2021 | 12 | Redacted Document (Exhibit E) (30) Docket Text: REDACTED VERSION of [2] Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G, # (8) Exhibit H, # (9) Exhibit I, # (10) Exhibit J, # (11) Exhibit K, # (12) Civil Cover Sheet)(Dudash, Amy) (Main Document 12 replaced on 9/29/2021) (ntl). |
| Jul 20, 2021 | 12 | Redacted Document (Exhibit F) (30) Docket Text: REDACTED VERSION of [2] Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G, # (8) Exhibit H, # (9) Exhibit I, # (10) Exhibit J, # (11) Exhibit K, # (12) Civil Cover Sheet)(Dudash, Amy) (Main Document 12 replaced on 9/29/2021) (ntl). |
| Jul 20, 2021 | 12 | Redacted Document (Exhibit G) (30) Docket Text: REDACTED VERSION of [2] Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G, # (8) Exhibit H, # (9) Exhibit I, # (10) Exhibit J, # (11) Exhibit K, # (12) Civil Cover Sheet)(Dudash, Amy) (Main Document 12 replaced on 9/29/2021) (ntl). |
| Jul 20, 2021 | 12 | Redacted Document (Exhibit H) (30) Docket Text: REDACTED VERSION of [2] Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G, # (8) Exhibit H, # (9) Exhibit I, # (10) Exhibit J, # (11) Exhibit K, # (12) Civil Cover Sheet)(Dudash, Amy) (Main Document 12 replaced on 9/29/2021) (ntl). |
| Jul 20, 2021 | 12 | Redacted Document (Exhibit I) (30) Docket Text: REDACTED VERSION of [2] Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G, # (8) Exhibit H, # (9) Exhibit I, # (10) Exhibit J, # (11) Exhibit K, # (12) Civil Cover Sheet)(Dudash, Amy) (Main Document 12 replaced on 9/29/2021) (ntl). |
| Jul 20, 2021 | 12 | Redacted Document (Exhibit J) (30) Docket Text: REDACTED VERSION of [2] Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G, # (8) Exhibit H, # (9) Exhibit I, # (10) Exhibit J, # (11) Exhibit K, # (12) Civil Cover Sheet)(Dudash, Amy) (Main Document 12 replaced on 9/29/2021) (ntl). |
| Jul 20, 2021 | 12 | Redacted Document (Exhibit K) (30) Docket Text: REDACTED VERSION of [2] Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G, # (8) Exhibit H, # (9) Exhibit I, # (10) Exhibit J, # (11) Exhibit K, # (12) Civil Cover Sheet)(Dudash, Amy) (Main Document 12 replaced on 9/29/2021) (ntl). |
| Jul 20, 2021 | 12 | Redacted Document (Civil Cover Sheet) (2) Docket Text: REDACTED VERSION of [2] Complaint, by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Exhibit D, # (5) Exhibit E, # (6) Exhibit F, # (7) Exhibit G, # (8) Exhibit H, # (9) Exhibit I, # (10) Exhibit J, # (11) Exhibit K, # (12) Civil Cover Sheet)(Dudash, Amy) (Main Document 12 replaced on 9/29/2021) (ntl). |
| Jul 20, 2021 | 13 | Redacted Document (Main Document) (2) Docket Text: REDACTED VERSION of [4] MOTION for Preliminary Injunction by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Text of Proposed Order)(Dudash, Amy) |
| Jul 20, 2021 | 13 | Redacted Document (Text of Proposed Order) (1) Docket Text: REDACTED VERSION of [4] MOTION for Preliminary Injunction by Nippon Shinyaku Co.,Ltd.. (Attachments: # (1) Text of Proposed Order)(Dudash, Amy) |
| Jul 20, 2021 | 14 | Redacted Document (14) Docket Text: REDACTED VERSION of [5] MEMORANDUM in Support by Nippon Shinyaku Co.,Ltd.. (Dudash, Amy) (Main Document 14 replaced on 9/1/2021) (ntl). |
| Jul 15, 2021 | N/A | Remark (0) Docket Text: Remark: Case Submitted for Routine Judicial Assignment (apk) |
| Jul 15, 2021 | 10 | Order on Motion to Seal (1) Docket Text: ORDER granting [1] Motion to Seal. Signed by Judge Maryellen Noreika on 07/15/2021. (apk) |
| Jul 14, 2021 | 9 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Nippon Shinyaku Co.,Ltd.. Sarepta Therapeutics, Inc. served on 7/14/2021, answer due 8/4/2021. (Dudash, Amy) |
| Jul 13, 2021 | N/A | Remark (0) Docket Text: Remark: Exit Electronic Copies to Duty Judge (MN) (apk) |
| Jul 13, 2021 | 3 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (apk) |
| Jul 13, 2021 | 6 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s)(SEE PATENT REPORT). (apk) |
| Jul 13, 2021 | 7 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Nippon Shinyaku Co.,Ltd. (apk) |
| Jul 13, 2021 | 8 | Summons Issued - Electronic (2) Docket Text: Summonses Issued (please complete the top portion of the form and print out for use/service). (apk) |
